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Abstract 
 
Current synthetic vascular grafts for the reconstructive bypass 
surgeries face the problem of post-surgery restenosis. Localised sustained 
release of nitric oxide (NO) is a promising strategy to prevent restenotic events 
such as vascular smooth muscle cells (vSMCs) over-proliferation, and 
promote the healing of injured endothelial layer. In this project, a composite 
controlled release system of NO was developed as a potential material for 
synthetic vascular grafts via the integration of NO-releasing nanoparticle, 
hydrogel and polymeric film. A new NO-releasing gelatin-siloxane 
nanoparticle (GS-NO NP) was developed via S-nitrosothiol modification with 
good NO-releasing property and excellent cytocompatibility. The potential of 
freeze-thawed poly(vinyl alcohol) (FT-PVA) hydrogels as carriers for GS-NO 
NP was evaluated from their property changes with nanoparticle addition, 
suggesting single FT-PVA hydrogel system might be suitable for applications 
with moderate addition of GS-NO NPs to maintain their hydrogel properties. 
GS-NO NP-doped PVA hydrogels were further integrated with biaxial 
stretched poly(ε-caprolactone) films (µPCL) using electrospinning and 
freezing-thawing (F/T) technique. The integrated composite release system of 
NO (PCL/PVA/GS-NO) exhibited prolonged NO release for up to 40 days, 
and enhanced mechanical properties as compared to single FT-PVA hydrogel 
system, demonstrating the potential to be used for restenosis prevention and as 
materials for synthetic vascular graft construction. 
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Cardiovascular diseases (CVDs) are a group of disorders for the heart 
and blood vessels. It has been the leading cause of mortality globally. In 2008, 
17.3 million deaths were caused by CVDs, accounting for 30 % of all global 
deaths [1]. By 2030, an estimated 23.3 million deaths will result from 
CVDs annually [1, 2]. In Singapore, 15 people die from CVDs daily, and 
CVDs accounted for 30.4 % of all deaths in 2011 [3]. Among all the types of 
CVDs, coronary heart disease (CHD) is the most common type and is 
responsible for almost half of the total deaths from CVDs [4]. In CHD, 
coronary arteries are narrowed or blocked, usually by the slow build-up of 
plaques (cholesterol and fatty deposits) on their inner walls (atherosclerosis). 
The resultant reduced blood circulation fails to supply enough oxygen to the 
cardiac muscles, and thus leads to heart deficiency and death.  
Conventional therapeutic strategies for CHD include angioplasty with 
or without stent application. When the occlusion condition of the vessel is 
more severe, reconstructive surgery such as coronary artery bypass graft 
surgery (CABG) is applied to substitute the diseased vessels or generate 
bypass to improve the blood supply downstream of the stenosed vessels. [5] 
Every year, more than half a million coronary artery bypass grafts are 
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implanted [6]. Autologous vascular grafts such as mammary artery and 
saphenous vein segments harvested from the patient, are considered as the first 
choice of substitutes for coronary and peripheral bypass procedures [5, 7-9]. 
However, the supply of autologous grafts is not readily available due to size 
mismatch, previous surgical intervention or the pre-existence of pathological 
conditions [6, 10, 11]. When a venous graft is used in the arterial circulation, it 
often undergoes vessel remodelling with neointimal thickening, leading to 
vessel stenosis or aneurysm formation [5, 12]. Elderly patients are especially 
prone to this problem when the graft from their saphenous vein is transplanted 
into high-pressure arterial sites [8, 13]. Moreover, the necessity of two 
surgeries on the same patient increases the risk of infection and costs. 
To supplement the limited supply of autologous graft, synthetic 
vascular prostheses such as expanded polytetrafluoroethylene (ePTFE) and 
Dacron™ fabric grafts have been developed and used conventionally [5-8]. 
Although they perform satisfactorily in high-flow, low-resistance conditions 
such as the large peripheral arteries, they have low patency for small diameter 
(<6 mm) arterial reconstruction [14, 15]. A major problem with synthetic 
vascular grafts is early and mid-term restenosis. Restenosis refers to the 
narrowing of the graft characterised by the early formation of thrombosis, 
which is the aggregation of platelets and fibrin, and neointimal hyperplasia 
developed at longer time, which is the abnormal migration and proliferation of 
vascular smooth muscle cells (vSMCs) with associated deposition of 
extracellular connective tissue matrix [16, 17]. Pathological studies of 
restenosis showed that the removal or mechanical injury of endothelial cells 
(ECs) of the blood vessel either by surgical operation or flow turbulence 
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generated due to compliance mismatch between the graft and native artery, is 
a major trigger for the thrombotic events and hyperplasia formation [18, 19]. 
A mismatch of mechanical compliance between the graft and host tissue also 
induces vSMCs at the anastomotic sites to hyperproliferates and secretes 
excessive extracellular matrix (ECM) [20]. 
Conventional treatment to prevent post-surgery restenosis requires 
extensive anticoagulant/antithrombotic control, which however, can result in 
further hemorrhagic complications such as bleeding [8, 21]. In order to 
improve the function and patency of the vascular grafts, the concept of 
vascular tissue engineering (VTE) that involves the principles of engineering 
and life sciences in the development of vascular substitutes has been 
introduced [22]. While progress has been made in the development of in vitro 
tissue engineered blood vessel (TEBV) through cell-scaffold hybrid and cell 
self-assembly TEBV, a lot of researches in VTE focus on the generation of 
multifunctional materials used for synthetic vascular grafts with release and 
presentation of bioactive molecules to guide in situ vascular regeneration [23]. 
To address restenosis problem, anticoagulant, anti-vSMC proliferation agents 
and bioactive drugs have been used to modify the synthetic graft materials by 
means such as coating and polymer chain modification [17, 24]. This can be a 
promising approach in the development of synthetic vascular grafts as the 
incorporated agents can be delivered to specific site with high local 
concentrations and low systemic effects [25, 26].  
Among the physiologic agents for restenosis prevention, a gas 
molecule, nitric oxide (NO), may be particularly effective as it is a natural 
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product produced by healthy ECs and is involved in limiting the molecular and 
cellular events underlying the restenotic response [27]. It has been proven that 
NO can inhibit platelet adhesion and aggregation, vSMC proliferation and 
intimal migration, and ECM formation [28-30], which are the key processes in 
thrombosis and neointimal formation. Moreover, NO can promote EC growth 
and maintain the endothelial integrity.  
Due to the damage of ECs during surgery and poor endothelialisation 
of the synthetic grafts post-surgery, there is no or not enough NO production 
to inhibit restenosis by the blood vessel itself. Therefore, it is desirable to 
introduce local release of NO in a controlled and sustained manner from the 
synthetic vascular graft. Conventional strategies to achieve controlled NO 
release include mixing NO donors with polymer solutions to make a 
polymeric film or attaching NO-releasing moieties to polymer backbones via 
covalent chemical bonding [31, 32]. Recently, along with the quick 
development in nanotechnologies, there is a trend to make use of nanoparticles 
in controlled release of NO. Fumed silica nanoparticles and gold nanoparticles 
have been modified to release NO through derivatisation of the particle’s 
surface with functional groups [33-35]. A unique advantage of this approach is 
that these particles can be blended into a wide variety of biomedical polymers 
without altering the fundamental chemistry of the polymer backbone. 
Therefore, it is possible to control NO-releasing properties by changing the 
amount of blended particles and changing the specific identity of the polymer 
[36]. 
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Although a lot of studies have been reported on the development of 
NO-releasing nanoparticles, most of the studies focused on the properties of 
the nanoparticles, and very few demonstrated how to apply these nanoparticles 
in the modification of synthetic vascular grafts. In light of this, this report 
details the development of a composite controlled release system of NO as an 
improved material for synthetic vascular graft construction, which is capable 
of releasing NO in a slow and sustained manner to prevent restenotic events 
such as vSMC over-proliferation. A novel NO-releasing gelatin-siloxane 
nanoparticle (GS-NO NP) is synthesised and incorporated into a composite 
architecture formed by poly(vinyl alcohol) (PVA) hydrogel and poly(ε-
caprolactone) (PCL) film. The integrated composite system is expected to 
show not only the ability of controlled release of NO, but also improved 
mechanical properties as compared to single hydrogel release system, and the 
potential to be used as a material for synthetic vascular graft construction. As 
NO plays various physiologic roles in the biological system, the successful 
construction of the composite system also implies potential solutions to other 
biomedical problems related to NO. This study demonstrates the feasibility of 
assembling components with superior properties in different fields to improve 
the systematic performance, which may provide some inspirations in 
engineering design of biomedical devices such as synthetic vascular grafts.  
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1.2 Objectives and Hypotheses 
The schematic illustration of the proposed composite controlled release 
system of NO is depicted in Figure 1-1. There are three main parts in the 
composite system: supportive film, NO donor, and host of NO donor. 
Biodegradable biaxial stretched PCL films (μPCL) with electrospun PCL fibre 
matrix on its surface will be fabricated and served as the supportive base for 
the composite system. NO-releasing nanoparticles (GS-NO NPs) will be 
synthesised from modified gelatin-siloxane nanoparticles (GS NPs) and then 
uniformly mixed with PVA aqueous solution. The mixture will be adsorbed by 
PCL fibrous matrix with the aid of a vacuum. The composite will then be 
subjected to freezing-thawing (F/T) cycles to crosslink the hydrogel as the 
host of GS-NO NPs.  
 
Figure 1-1 Schematic illustration of the proposed work 
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The primary goal of this study is therefore to construct a composite 
controlled release system of NO using nanoparticles, tailored PVA hydrogel 
and biodegradable PCL films through different fabrication techniques in order 
to achieve improved mechanical and NO release properties. The hypotheses 
made in the study include: 
1. Gelatin-siloxane nanoparticles can be converted into NO carriers 
through S-nitrosothiol modification; 
2. PVA hydrogels can be used as the host material of NO-releasing 
nanoparticles with physical crosslinked induced by F/T method; 
3. Assembly of two incompatible materials, PCL and PVA, can be 
achieved with electrospun PCL fibres as intermediate; and 
4. The integrated composite controlled release system of NO consisting 
of NO-releasing nanoparticles, PVA hydrogel and supporting PCL film 
has improved systematic properties and performance than each single 
component. 
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1.3 Scope 
This dissertation includes seven chapters. Chapter 1 gives the 
background information to the field of research and the research proposal, 
objectives and hypotheses. Chapter 2 provides the relevant literature reviews 
on the pathology of restenosis, the biology and role of NO in cardiovascular 
system, current therapeutic applications of NO, and approaches for controlled 
release of NO. Literature reviews on gelatin-siloxane nanoparticles (GS NPs), 
PVA and PCL materials and the relevant fabrication techniques are also 
included. Chapter 3 presents the synthesis and properties of the novel NO-
releasing gelatin-siloxane nanoparticles (GS-NO NPs) and their effects on 
vSMCs and ECs. Chapter 4 focus on the investigation of property changes of 
physically crosslinked PVA hydrogels with GS NP addition to explore their 
potential as GS-NO NP carriers. Chapter 5 is on the development and 
evaluation of the composite controlled release system of NO constructed by 
assembling components with different functions. Chapter 6 provides the 
conclusions of the research work and Chapter 7 gives the recommendations 
for future work. 
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Chapter 2  
Literature Review 
 
2.1 Vascular System 
The vascular system is a network of blood vessels. It is one of the most 
important and complex organs in the mammalian body. As part of the 
circulatory system, the vascular system is responsible for blood circulation 
throughout the body [37]. The oxygen and nutrients in the blood diffuse across 
the blood vessel walls to the interstitial fluid and then to the target cells, while 
carbon dioxide and wastes from the target cells diffuse in the opposite 
direction and are sent back to the heart.  
In the vascular system, there are three major types of blood vessels: (1) 
the arteries which transport the blood away from the heart, (2) the capillaries 
which realise the exchange of gas and chemicals between the blood and the 
tissues, and (3) the veins which return the blood from the capillaries back to 
the heart [38].  
2.2 Coronary Arteries 
In human vascular system, the arteries that deliver oxygen-rich blood 
to the myocardium are called coronary arteries. They originate from the left 
side of the heart at the root of the aorta, and are divided into right and left 
coronary arteries on the surface of the heart, which further branch into 
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segments and capillary networks that penetrate into the tissue (Figure 2-1). 
Generally, the right coronary artery supplies the right ventricle and atrium, 
while the left coronary artery supplies the left ventricle and atrium as well as 
the intraventricular septum. Coronary arteries are very important in vascular 
system as they participate in the coronary circulation, and are the only source 
of blood supply to the myocardium. They are subjected to cyclic pulsatile 
force from the heart, and the blood flow through coronary arteries depends on 
both the perfusion pressure in the aorta and the extravascular compression 
from the myocardial contraction [39, 40]. 
 
Figure 2-1 Anatomy of the coronary arteries of the heart [41] 
2.2.1 Structure and Composition 
Same as the other arteries, coronary arteries are composed of three 
histologically distinct layers (Figure 2-2) [42]. The innermost layer in contact 
with the blood stream is called the intima, which is a monolayer of vascular 
endothelial cells (ECs) mounted on a basement membrane (or basal lamina) 
composed of laminin, fibronectin, type IV collagen and some other 
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extracellular matrix (ECM) constituents [43]. Separated by the internal elastic 
membrane from the intima, the middle layer named as tunic media, is 
composed of vascular smooth muscle cells (vSMCs) and elastin fibres. This 
layer is located between the internal and external elastic membranes. The 
outermost layer, the adventitia consists almost entirely of connective tissue 
with nerve fibres, small blood vessels, and fat in loose interstitial matrix [44].  
  
Figure 2-2 Layered structure of a coronary artery [45] 
For a coronary artery, the elastic components such as elastin and 
collagen determine the mechanical characteristics including elasticity and 
strength, while the cells play active and regulatory roles in physiology, local 
responses to injury and the pathogenesis of vascular diseases. The principal 
cells of the coronary artery wall are ECs and vSMCs. Their characteristics and 
functions are introduced in Sections 2.2.1.1 and 2.2.1.2. 
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2.2.1.1 Endothelial Cells (ECs) 
ECs are the cells that form the endothelium, which is the thin layer that 
lines the entire vascular system, from the heart to the smallest capillary [46]. 
These cells usually have a characteristic squamous morphology in situ [47]. A 
fundamental ability of vascular ECs is to proliferate and form a network of 
capillaries, which is known as “angiogenesis” [48]. They are also involved in 
various physiological processes of the blood vessels via cell-cell interaction 
and the release of vasoactive or growth regulating agents. ECs can regulate the 
growth and development of the vSMCs and connective tissue cells through 
signalling. As ECs are in direct contact with the blood, they perform a critical 
role in all aspects of tissue homeostasis [38]. Quiescent ECs can generate an 
active antithrombotic and anti-platelet surface to facilitate the transit of plasma 
and cellular constituents throughout the vasculature by secreting factors such 
as tissue plasminogen activator and expressing membrane thrombomodulin 
[49, 50]. In inflammatory and immunological processes, ECs are induced by 
the perturbations to create a prothrombotic and antifibrinolytic 
microenvironment [51]. ECs can also mediate vascular tone in a paracrine 
manner through rapid response to the signal from the peripheral nervous 
system and the release of endothelium-derived relaxing or contracting factors 
such as nitric oxide (NO), prostanoids and endothelin to make smooth muscle 
relax or contract in the vessel wall [52].  
In addition, ECs can regulate the flow of nutrient substances, 
biologically active molecules, and the blood cells through the presence of 
membrane-bound receptors on their surface. For instance, ECs can sense the 
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shear stress from the blood flow via the mechanoreceptors on their surface, 
and signal the surrounding cells to adapt the vascular diameter and wall 
thickness to suit the blood flow [42]. The EC surface also consists of a layer of 
surface glycoprotein (glycocalyx), which not only provides a local charged 
barrier to the trans-endothelial migration of blood cells and plasma proteins 
under normal physiological conditions but is also very metabolically active 
[53]. Because of the numerous functions of ECs, the integrity of endothelium 
is significant in maintaining the structure and functions of the blood vessels. 
2.2.1.2 Vascular Smooth Muscle Cells (vSMCs) 
In typical normal blood vessels, the vSMCs of the tunica media are 
elongated bipolar cells containing both thin actin filaments and thick myosin 
filaments [54]. They are highly oriented in a circumferential direction of the 
blood vessel wall [55]. There is a marked heterogeneity in vSMCs in different 
types or locations of blood vessels due to their different embryonic origins 
[56]. In large elastic (or conducting) arteries such as the aorta, layers of 
vSMCs are sandwiched between lamellae of connective tissue in a highly 
organised structure so that they can tolerate the pressure coming from the heart. 
In muscular (or distributing) arteries such as the coronary arteries, the layers 
of vSMCs are less demarcated and overlapping [42, 57]. The vSMC layers 
near the vessel lumen receive oxygen and nutrients via direct diffusion from 
the vessel lumen through the holes in the internal elastic membrane, while the 
outer portions of vSMC layers in medium and large sized arteries are 
nourished by small arterioles arising from outside the vessel coursing into the 
outer one half to two thirds of the media [58].  
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vSMCs are very important for the maintenance of vascular tone and 
the regulation of blood circulation due to their contractile characteristics. They 
also participate in the morphogenesis and maintenance of the normal 
architecture of the blood vessel wall [59]. vSMCs can secrete ECM proteins 
that are major components of the vascular media [60], and synthesise type I 
and III collagens that are components of the vascular interstitial matrix [61]. 
They can also synthesise elastin that provides mechanical properties for the 
normal function of the elastic arteries [62].  
2.2.2 Response to Injuries 
For a healthy coronary artery, the EC and vSMCs are in a quiescent 
state that both types of cells seldom divide [59, 63]. The ECs maintain 
themselves as a highly ordered monolayer at all times for the tissue 
homeostasis. The growth of vSMCs are controlled by both the growth factors 
and inhibitors released from blood cells, ECs and fibroblasts (FBs) of the 
vessel wall [64]. However, the EC lining may be injured by mechanical 
stimuli evoked mainly by non-physiological high blood pressure or 
biochemical stimuli such as diabetes mellitus and dyslipidemia [58, 65]. This 
damage of EC layer disrupts the endothelial integrity and leads to dysfunction 
of ECs, which will further result in compensatory responses that alter the 
normal homeostatic properties of the endothelium.  
The initial responses of ECs to the injury include decreased production 
of NO and increased permeability to lipoprotein and other plasma constituents 
that do not occur inside the vessel under physiological conditions [56]. The 
ECs become procoagulant instead of anticoagulant and form vasoactive 
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substances, cytokines and growth factors. Moreover, the adhesiveness of the 
ECs is also increased with respect to the cells of immune system such as 
leukocytes (or platelets) [66]. The platelets aggregating and degranulating at 
the lumen surface release platelet-derived growth factor (PDGF) that is 
chemotactic and mitogenic for vSMCs and FBs [42, 67]. Inflammatory cells 
penetrating into the vessel wall also release proteolytic enzymes that can 
disrupt and oxidise the ECM, and thus activate the migration and growth of 
vSMCs [68]. In addition, the ECs, inflammatory cells or even vSMCs 
themselves produce growth factors and cytokines similar as PDGF, which 
induce the phenotypic change of vSMCs from the quiescent contractile state to 
the active synthetic state [58]. The phenotypically changed vSMCs are prone 
to hyperplastic and hypertrophic cell growth and migration from the media 
into the intima, and increased production of ECM proteins [65, 69], which can 
further result in many adverse changes that promote thrombosis, 
atherosclerosis and hypertension [50, 63]. The abnormal migration and 
proliferation of vSMC become intermixed with the area of injury and form 
lesion and the basis for the complicated atherosclerotic plaque [42, 58]. The 
accumulation of ECM material participates in the fibrogenesis in vascular 
pathology, and in the fixed structural alterations of the blood vessel that 
accompany hypertension and arteriosclerosis [70].  
On the other hand, it is found that the endothelial cell growth ceases 
when they are in contact with vSMCs in co-culture system due to the 
activation of transforming growth factor beta 1 (TGF-β1) [71]. The study 
using a rat aorta injury model also showed that the regeneration of endothelial 
layer after a scratch injury occurs by movement without cell replication unless 
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the distance between the wound edges requires sufficiently long period of 
movement [72]. Direct injury of the blood vessel also triggers sequential 
events involving adventitial FBs, which begin with apoptosis and lead to 
proliferation and differentiation of adventitial FBs into myofibroblasts that 
migrate to the site of injury [73, 74]. 
2.2.3 Restenosis of Coronary Artery 
The term ‘restenosis’ usually refers to the recurrence of stenosis, which 
is an abnormal narrowing of the blood vessel. In this thesis, ‘restenosis’ is 
defined as an occlusive vascular response to arterial injury and inflammation 
characterised by lumen narrowing that particularly appears after coronary 
artery bypass graft surgery (CABG) or percutaneous coronary intervention 
(PCI) such as angioplasty [75]. It usually evolves over several months after the 
surgery [75]. Statistics has shown that 15 to 25 % of the patients develop graft 
closure within one year following the CABG with saphenous vein graft [76]. 
The immediate injuries caused by the surgical procedure include intimal 
tearing, endothelial cell damage, and exposure of subendothelial connective 
tissue to blood components [75, 77], which trigger a series of intravascular 
changes. 
2.2.3.1 Pathophysiology of Restenosis 
The most widely held theory in literature is that the pathophysiology of 
restenosis bears many relations to the process of wound healing [78]. The 
vascular wall responds to the injury acutely with exuberant activation of the 
sealing mechanisms [79]. The platelets, fibrin, and red blood cells accumulate 
at the site of injury and form thrombus, which is usually responsible for 
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immediate occlusion of the graft. The process of neointima formation also 
starts from the thrombotic phase, followed by the cellular recruitment 
(migration) and proliferation phases [80]. After the thrombotic phase, ECs are 
recruited together with monocytes and lymphocytes infiltration, causing an 
inflammatory response with re-endothelialisation [81]. In the proliferative 
phase, actin-positive cells from the lumen side forms a “cap” on the lumen 
surface and gradually replace the deeper thrombotic material. The ECM 
secretion and additional recruitment also likely add to neointimal volume 
during this phase [81]. As the three phases in neointima formation are usually 
exaggerated, the formation process ends up as neointimal hyperplasia. In 
addition, vSMCs play a pivotal role in causing restenosis, and are involved in 
all the above phases [82]. The platelets, ECs, and inflammatory cells produce 
large amount of mitogens that stimulate the migration and proliferation of 
vSMCs from the media into the intima, followed by the formation of 
fibrocellular tissue with an abundant proteoglycan matrix [82]. The failure of 
secreting inhibitors for vSMC proliferation such as NO and heparin sulphate 
from the injured endothelium aggravates the vSMC proliferation [78]. The 
thrombus formed also provide an absorbable matrix for vSMC infiltration and 
proliferation [81]. Moreover, the mismatch of mechanical compliance between 
the graft and host tissue induces vSMCs at the anastomotic sites to 
hyperproliferates and secretes excessive ECM [20]. As a result, the neointima 
is further thickened by excessive cells and ECM deposition. Recently, it has 
been found that a number of cell types such as the stem or progenitor cells in 
circulation and the FBs/myofibroblasts and progenitor cells located within the 
adventitial layer of the damaged vessel, can also exhibit the potential to 
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differentiate into a vSMC phenotype and show the potential to partially 
contribute to the neointimal hyperplasia [83]. Since neointimal hyperplastic 
lesions result from the healing of injury, the distribution pattern may be 
diffused throughout the vessel, focal at the anastomotic sites or within the 
body of the vessel [84]. 
Besides the tissue responses to the injury, which is considered 
biological, the restenosis also depends on mechanical processes that result in a 
geometric change in the circumference of the damaged vessel, especially for 
the coronary arteries after angioplasty. The mechanical processes involve both 
an acute and a chronic phase [85]. In the acute phase, elastic recoil due to the 
elastic properties of the arterial wall contributes to the vessel closure [86]. In 
the chronic phase (3-6 months), negative arterial remodelling resulting from 
the mechanical stretch damage to the vessel wall leads to the shrinkage of the 
arterial wall diameter. The remodelling is largely an adventitia-based process 
that is restricted to dilation injury and involves the adventitial myofibroblasts 
and ECM [86-88]. The adventitial FBs undergo phenotypic conversion to 
myofibroblasts, which in turn produce large amount of ECM materials that 
contributes most to the stiffness of the arterial wall. They also secrete pro-
inflammatory factors that result in an alteration of the tensile force of the 
artery. In addition, the endothelial dysfunction due to the injury diminishes the 
endothelium-dependent relaxation, which may also lead to vasoconstriction 
and eventually, the remodelling [88]. It is interesting to note that the 
neointimal hyperplasia increases along with restricted remodelling by stents, 
which is explained by the theory that neointimal hyperplasia and geometric 
remodelling compete to re-narrow the artery [88].  
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Taking into account all those proposed theories, the restenosis 
probably reflects a complex equilibrium of vessel recoil, neointimal 
hyperplasia and geometric remodelling of the vessel [89]. The understanding 
of these factors involved in the pathophysiology of restenosis would be much 
helpful to determine the effective therapeutic control of restenosis. 
2.2.3.2 Therapeutic Control of Restenosis 
In clinical treatment, the most commonly strategy to treat restenosis is 
repeated angioplasty, which however, causes recurrent restenosis for a 
significant percentage of patients [90]. Alternatively, CABG is considered for 
the patients whose are at high risk for angioplasty or with likelihood of 
recurrent restenosis. Rather than surgical treatment, more attempted solutions 
have been made on pharmacologic interventions and improved mechanical 
devices [75]. Diverse pharmacological agents have been evaluated as 
restenosis inhibitors [75, 78, 84, 88]. Heparin has been routinely used post-
surgery to reduce acute complications like thrombosis due to its anticoagulant 
and antithrombotic properties. However, extended heparin therapy results in 
more bleeding complications [78, 91]. Vitamins E and C have been found to 
directly control the ECM synthesis and subsequently promote favourable 
vascular remodelling after injury [92]. Antimetabolite agents and growth 
inhibitors such as methotrexate and somatostatin analogues have been studied 
to prevent vSMC proliferation. However, their effects on vSMC proliferation 
and neointimal hyperplasia development are still controversial [93-95]. As 
each pharmacologic intervention usually targets one specific process 
implicated in restenosis, it may not sufficiently modify the complex 
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underlying pathology for clinical benefits. Studies have shown that NO is an 
important determinant of vascular homeostasis and a natural modulator of 
several contributors to restenosis. These properties make NO a unique and 
potentially powerful candidate to help control restenosis [87, 96]. Details on 
NO functions and its applications will be reviewed in Section 2.4. 
For device approach, coronary stenting technology is effective in 
preventing acute vessel re-occlusion and reduced post-angioplasty restenosis 
by sealing the dissection flaps and preventing vessel recoil [96]. Unfortunately, 
they fail to eliminate in-stent restenosis as neointimal hyperplasia is 
accelerated by restricted remodelling [88, 97]. Seeding EC on the prosthetic 
vascular grafts and the angioplasty sites has been proposed as a solution, yet 
the efficacy of EC seeding is often low with a rapid loss of the seeded cells [98, 
99]. Drug-eluting stents and prosthetic grafts have been developed to deliver 
selective antiproliferative drugs at the site of neointima formation [6, 96]. 
Sirolimus- or paclitaxel-eluting stents have been applied in clinical trials and 
shown reduced rates of restenosis and associated clinical events [100-102]. 
Heparin-coated or paclitaxel-eluting synthetic vascular grafts have also shown 
the effects on reducing thrombosis and neointima formation in vitro and in 
vivo [103, 104]. Nonetheless, the risk of late restenosis and the associated 
endothelium-dependent vasomotor dysfunction remain the concerns for these 
devices [105]. Besides the candidate drugs, extensive efforts have also been 
made in finding the optimal material for the device since coronary restenosis 
may be partially attributed to the material-induced cellular responses. In 
addition to the above attempts, there is an increasing interest in applying gene 
therapy such as locally delivering antisense oligonucleotide or a class of 
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endogenous, small and noncoding RNAs to down-regulate gene expression 
and prevent vSMC proliferation and neointimal hyperplasia [84, 106].  
2.3 Vascular Tissue Engineering (VTE) 
Vascular tissue engineering (VTE) is an interdisciplinary field 
involving the principles of engineering and life sciences to develop biological 
substitutes in order to restore, maintain, or improve the function of human 
blood vessels [22]. Different approaches and strategies have been studied to 
improve the performance of the vascular graft or promote vascular 
regeneration mainly including acellular approach, in vitro tissue engineered 
blood vessel (TEBV) through cell-scaffold hybrid and cell self-assembly 
TEBV. 
2.3.1 Acellular Approach  
Acellular approach started from directly implanting the vascular 
prostheses made from synthetic material such as expanded 
polytetrafluoroethylene (ePTFE) and Dacron™. However, the performance of 
these synthetic grafts was only satisfactory in large diameter applications. In 
small diameter (<5 mm) applications, the prosthesis is prone to 
thrombogenesis and results in stenosis and poor patency rates [14, 15]. The 
approach of seeding an EC monolayer on the synthetic surface prior to 
implantation was adopted, and it appeared to improve the antithrombogenic 
property of the graft [107]. Various surface modifications have been 
investigated to improve the EC attachment and survival on the synthetic 
surface such as coating with a recombinant fibronectin-like adhesion factor, or 
 Chapter 2 Literature Review 
- 22 - 
treatment with ammonia plasma on the surface [108, 109]. Nonetheless, the 
limitations of EC-seeded synthetic grafts are also obvious. The mismatches of 
the mechanical properties between the non-biodegradable synthetic graft and 
the surrounding host tissue result in a hindered remodelling response of the 
vascular system. Due to the complete loss of the vasoactive component, the 
synthetic grafts could not regulate vasotone and eventually cause occlusion by 
intimal hyperplasia [110]. Consequently, the aim of acellular approach was 
shifted to use acellular graft as a conduit to induce appropriate cellular 
response and promote tissue in-growth in vivo [111]. Biological grafts made 
from decellularised porcine carotid artery with heparin linkage were reported 
to be capable to promote growth and remodelling of the graft by the host 
organism cells while retaining its natural mechanical properties [6, 112]. 
Synthetic grafts made from biodegradable materials such as polyglycolic acid 
(PGA) were also reported to facilitate the infiltration and proliferation of 
vascular cells in vivo [113]. However, the exact control of the remodelling 
process is limited by the in situ regeneration rates via polymer degradation. 
2.3.2 In vitro Tissue Engineered Blood Vessel (TEBV) 
In vitro construction of a cell-scaffold hybrid is the most common 
approach in VTE. One example is the collagen-based blood vessel construct, 
in which vascular cells are embedded in the reconstructive collagen matrix 
[114]. It allowed the cell-mediated remodelling of the graft and made the 
functional vasoactivity possible [110]. However, the construct alone could not 
withstand the physiological pressures without additional supporting material 
such as Dacron™ [114]. Efforts have been made in improving the culturing 
 Chapter 2 Literature Review 
- 23 - 
technique, optimising the composition of culture medium as well as 
introducing dynamic mechanical stimulation, to enhance the mechanical 
properties of the collagen-based construct [115-119]. However, the resultant 
constructs still suffered from poor mechanical integrity of the reconstituted 
collagen gel. On the other hand, studies have been done on the in vitro TEBV 
based on synthetic biodegradable scaffolds. Biodegradable synthetic polymers 
such as PGA [120, 121] and fibrin-polylactide [122] have been used for the 
scaffold. During the in vitro development process, the cultured vascular cells 
produce large amount of matrix proteins while the polymer scaffold undergoes 
degradation. To promote the synthesis of ECM proteins, biochemicals like 
growth factors and chemical supplements have been added into culture 
medium to give proper biochemical signalling and provide protein building 
blocks [120]. Mechanical stimuli such as pulsatile radial stress have also been 
introduced via bioreactor to enhance the mechanical strength and vasoactivity 
of the construct [120-122]. It has been proven clinically that the in vitro TEBV 
could achieve good long-term result in large diameter applications such as 
pulmonary artery replacement in paediatric patients [123, 124]. However, the 
in vitro TEBV still faces some problems including the mismatch of the 
scaffold degradation rate and the cell proliferation rate, the long culture time 
required for the desired characteristics of the construct, and the incapability of 
inducing cellular orientation due to the preformed isotropic scaffolds. 
2.3.3 Cell Self-Assembled TEBV 
Cell self-assembled TEBV is a completely biological approach based 
exclusively on the cultured human cells without synthetic or exogenous 
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biological material [125]. A unique advantage of this approach is that 
immunological mismatch can be eliminated by using autologous cells. 
Different combinations of cells such as vSMCs, ECs and FBs, or ECs and FBs 
have been used to construct cell self-assembled TEBVs [125, 126]. The cells 
were first cultured in medium to secrete ECM and form cell sheets, and the 
cell sheets were then wrapped around a temporary inert tubular support and 
allowed for maturation for some time to form a cylinder composed of 
concentric sheet layers [125]. The resulting TEBV showed adequate 
mechanical strength for arterial implantation (>2000 mmHg). Despite the 
satisfactory properties of cell self-assembled TEBV, the culture time required 
for the vascular construct was up to three months [125], which also makes the 
development process quite expensive. The procedure to take tissue from the 
patient for cell isolation may also be an issue to be addressed. 
2.3.4 Limitations of Current VTE Approaches 
Current VTE research shows a favour of in vitro and cell self-
assembled approaches since acellular approach has more limitations in 
biocompliance and remodelling ability. Some success of TEBV has also been 
achieved in large diameter applications. However, current TEBVs still suffer 
from thrombotic events and neointimal hyperplasia, which will result in early 
and mid-term restenosis [17]. As reviewed in Section 2.2.3.1, the damage of 
EC layer, platelet adhesion and over-proliferation of vSMCs contribute a lot to 
these problems. It has been suggested that the ideal vascular grafts should 
have a selective antiproliferative effect on vSMCs while being inert toward 
ECs or even promoting their growth [96]. Therefore, how to regulate vSMC 
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proliferation, promote EC proliferation, improve the blood compatibility of the 
graft surface and match the mechanical compliance with host tissue are 
important issues to be addressed in VTE. 
2.3.5 Composite Vascular Grafts 
As one possible solution to address the problems in current VTE 
approaches, the construction of composite vascular grafts have been proposed, 
which involves several components with superior properties in certain area 
and techniques that can achieve the integration of these components. It is 
expected that the integration can combine the superior properties of each 
component and achieve improved systematic performance for the resultant 
construct. Composite vascular graft constructions have been attempted in 
different approaches. Acellular composite vascular grafts have been 
constructed by integrating different biocompatible materials with appropriate 
techniques. Composite vascular grafts consisting of collagen/chitosan inner 
and out layers and a poly(l-lactide-co-caprolactone) (P(LLA-CL)) middle 
layer have been constructed via electrospinning technique by Huang et al. 
[127]. The resultant composite scaffolds could provide better strength and 
flexibility due to the P(LLA-CL) layer and meanwhile, supported prompt 
adhesion and proliferation of ECs as the collagen and chitosan content were 
bioactive. In order to prevent neointimal hyperplasia of ePTFE vascular grafts, 
Lim et al. [128] transferred paclitaxel-loaded poly(lactic-co-glycolic acid) 
(PLGA) nanoparticles (NPs) to the luminal surface and inner part of the 
vascular grafts through micro-tube pumping followed by spin penetration 
technique. The modified ePTFE vascular grafts could achieve controlled 
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delivery of paclitaxel with a reduced initial burst release. To induce 
appropriate cellular response, Hsu et al. [129] mixed gold nanoparticles 
(AuNPs) with polyurethane (PU) and cast composite films for vascular graft 
construction. It was found that small amount doping of AuNPs could change 
the surface morphology significantly and induce better FB proliferation, low 
platelet activation and reduced bacterial adhesion on the composite material.  
The in vitro TEBV approach has also adopted the composite concept to 
construct biomimetic vascular grafts. Fayol et al. [130] reported a pluricellular 
and organized vascular grafts created using a porous tubular scaffold and 
magnetically labelled ECs or endothelial progenitors. While the porous bulk 
structure of the scaffold made cell ingrowth possible, the magnetically labelled 
cells with iron oxide NPs enabled cell patterning by different magnets and the 
monitoring of endothelialisation with 3D magnetic resonance imaging. In 
addition to the above approaches, ex vivo vascular grafts have also been 
modified with functional components for improved functionality and 
therapeutic benefits. Zou et al. [131] coated rapamycin-loaded PLGA NPs to 
the lumen of excised rat jugular veins via dipping method, and the treated 
grafts could inhibit the graft thickening without affecting the re-
endothelialisation. Kimura et al. [132] also reported modified excised rabbit 
jugulars vein grafts with imatinib mesylate-incorporated NP coating prepared 
using dipping method, which showed reduced neointima formation. 
Although the composite vascular grafts have showed promising 
improvements in their properties against problems such as restenosis, there are 
still some limitations in their construction. The integration techniques such as 
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dipping can only achieve limited doping amount of the functional components 
like drug-loaded NPs. Spin penetration and covalent bonding techniques also 
have specific requirement for the structural or chemical properties of the 
components. Therefore, choices of appropriate materials and techniques with 
fewer limitations are crucial for the development of composite vascular grafts. 
2.4 Nitric Oxide 
Nitric oxide (NO) is a unique cell-cell signalling messenger that can be 
found in almost all tissues of the body and throughout the central nervous 
system [133]. It was first identified as an endothelium-derived relaxing factor 
(EDRF) in 1980 [134]. In 1992, it was titled as “Molecule of the Year” by 
Science [135], and was the subject of the Nobel Prize in 1998. NO has been in 
the limelight for many therapeutic activities due to its critical roles in 
physiological processes such as neurotransmission [136], cardiovascular 
homeostasis [137], immune regulation [138], and inhibition of platelet 
aggregation [139]. In this section, an introduction on the properties of NO and 
its role in cardiovascular system will be given. Different types of NO donors 
will be reviewed briefly. Different approaches for the controlled release of NO 
will also be discussed. 
2.4.1 Properties of NO  
NO is a diatomic radical molecule that is known as one of the smallest 
biologically active messenger molecules. It is a colourless gas with good water 
solubility at room temperature [140]. As one of the simplest odd-electron 
species, NO is uncharged with an unpaired electron. The presence of the 
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unpaired electron makes NO paramagnetic, reluctant to dimerise, and highly 
reactive (with a half-life of 2-30 s) with a myriad of atoms and free radicals 
[133, 140, 141]. NO can also diffuse freely across the cell membranes due to 
its small size and uncharged characteristics. 
In mammalian cells, NO is produced endogenously from a 5-elelctron 
oxidation of the terminal guanidine nitrogen of the amino acid L-arginine, 
which forms L-citrulline and the NO free radical. Molecular oxygen [142] and 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) [143] are also 
involved in the reaction as the co-substrates. The reaction is catalysed by NO 
synthases (NOS), which can be broadly divided into two main isoform classes 
with different regulation and activities [133, 144]. One main class is the 
constitutive class, which is made up of the neuronal isoform (nNOS) and the 
endothelial isoform (eNOS). The constitutive isoforms are regulated by 
calcium (Ca2+) and calmodulin. The other main class is the inducible class, 
which contains the inducible isoforms (iNOS) found in macrophages, 
neutrophils, fibroblasts and hepatocytes [144]. These isoforms are activated 
immunologically by exposure to bacterial endotoxin or cytokines [145, 146], 
and therefore not affected by intracellular Ca2+ levels. It has been 
demonstrated that the production of NO is regulated not only by the 
intracellular Ca2+ concentration and the subcellular localisation of NOS, but 
also affected by the presence of agonists and stimuli like fluid shear stress and 
pathogens [147, 148]. 
Once NO is produced and released, it diffuses across the cell 
membranes to neighbouring cells and approaches its target – the soluble 
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guanylate cyclase (sGC). NO activates sGC by binding to its heme moiety and 
subsequently, induces an accumulation of cyclic guanylate monophosphate 
(cGMP) [147]. As a signalling messenger, cGMP further activates GMP-
dependent pathways and results in a variety of downstream cellular processes 
such as the vasodilation and antidepressant effect [149]. In addition to sGC, 
NO also targets sulfhydryl-containing proteins [150] and certain protein 
kinases [151] through c-GMP-independent mechanisms. 
The cellular effects of NO are dose-dependent. Quantitative research 
with modelling and biosensors suggests that the physiological NO 
concentration range should be 100 pM to 5 nM [152]. It has been 
demonstrated in vitro that low NO concentrations (10 nM to 1 μM) result in 
anti-apoptotic effects whereas high concentrations induce cell death [153]. 
High NO levels also induce chemical reactions specifically with molecular 
oxygen, generating nitrosating species capable of mediating protein 
modifications and subsequent cell function [154]. 
2.4.2 NO in Cardiovascular System 
In the cardiovascular system, NO is continuously generated by ECs 
from L-arginine oxidation catalysed by eNOS. It is implicated as a mediator in 
several physiological roles (Figure 2-3) [75, 144, 155]. NO is involved in the 
regulation of vascular tone by diffusing into sub-adjacent vSMCs and 
activating sGC that can produce cGMP. The increase in cGMP level activates 
a GMP-dependent pathway that results in a basal level of relaxation of the 
smooth muscle. By this signal-transduction route, NO acts as the most potent 
endogenous vasodilator yet known [156]. NO also reduces myocardial 
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contraction via a cGMP-dependent mechanism. Moreover, NO acts as a potent 
inhibitor of platelet and leukocyte responses including adhesion, aggregation 
and recruitment to maintain the integrity of vascular endothelium [75, 157]. 
The inactivation mechanism includes an increase of cGMP level, which 
consequently results in the impairment of shape change and granule secretion 
of the platelets. An attenuation of intracellular calcium flux is also associated, 
resulting in the inactivation of the receptors for adhesion on the platelet 
surface [27]. 
Another important role of NO is to regulate vSMC mitogenesis and 
proliferation. It helps maintain the quiescent status of vSMCs by acting 
together with other mediators like TGF-β1 and counteracting proliferative 
agents such as PDGF and fibroblast growth factors [158]. Besides the direct 
inhibitive effect on vSMC proliferation, NO also indirectly influences vSMC 
proliferation through effects on other cell types such as ECs, which generally 
suppress vSMC proliferation [159]. 
 
Figure 2-3 Schematic of the basic physiological functions of nitric oxide in 
the cardiovascular system (Blue arrows: inhibitive actions; red arrow: 
promotive actions) 
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2.4.3 NO and Restenosis 
As reviewed in Section 2.2.3.1, the restenosis development involves 
vessel recoil, thrombotic events, neointimal hyperplasia and geometric 
remodelling. It has been found that the damage of endothelial lining of the 
blood vessel leads to a decrease in the local production of NO. This is 
probably due to the loss of the eNOS-containing ECs, which are the prime 
source of vasoactive NO [160]. Evidence from numerous studies has 
suggested that NO deficiency may affect virtually every point in the process: 
vessel recoil and remodelling, thrombus formation, and neointimal hyperplasia 
[27, 75, 161]. NO deficiency leads to the diminishment of vasodilation, which 
triggers the vessel remodelling. NO deficiency also causes the loss of 
antiplatelet and anti-inflammatory properties of the endothelial layer, making 
the vessel lumen prone to thrombotic events [162]. In addition, NO deficiency 
impairs the inhibitive regulation of vSMC proliferation and migration. The 
increased release of growth factors from activated platelet and leukocytes also 
stimulates the proliferation, migration and ECM production of vSMCs [161]. 
Since NO deficiency facilitates restenosis development, local and systemic 
supplementation of NO at the injury sites may serve as an effective measure to 
prevent restenosis. 
2.4.4 NO Donors 
As NO plays a vital role in many physiological activities, extensive 
research has been done for its biomedical applications over the last two 
decades. Because NO gas is difficult to manipulate, a variety of chemical NO 
donors have been explored. Chemical NO donors normally belong to one of 
 Chapter 2 Literature Review 
- 32 - 
the following categories: organic nitrate/nitrites, iron-nitrosyl complexes, 
sydnonimines, C-nitroso compounds, diazeniumdiolates (NONOates), and S-
nitrosothiols (RSNOs) [163]. For each category of NO donor, NO is produced 
through a different reaction mechanism. 
2.4.4.1 Organic Nitrate/Nitrites  
Organic nitrate and nitrite esters have been used as classic 
nitrovasodilators for over a century. The general formulae for organic 
nitrates/nitrites are RONO2 and RONO, respectively, where R is an aryl or 
alkyl group. Organic nitrates/nitrites are used primarily for the treatment of 
angina symptoms because they can produce NO from the metabolism within 
the endothelium [163]. Commonly used organic nitrates/nitrites include amyl 
nitrite, glyceryl trinitrate (GTN), isosorbide dinitrate, and isosorbide 5-
mononitrate [164]. Amyl nitrite was initially used as a therapeutic agent in the 
treatment of angina, but was superseded a decade later by organic nitrates such 
as GTN due to their ease of administration and longer duration of action [165]. 
Since then, organic nitrates have been used extensively in the treatment of 
numerous conditions ranging from heart failure to anal fissures [166, 167]. 
Rapid-acting nitrates such as GTN are used to treat acute attacks like angina as 
they can relieve the symptoms within minutes, while intermediate- to long-
term nitrates like isosorbide dinitrate are preferred for the prevention of 
exercise angina [165, 168]. 
Despite of the extensive usage over a long period, organic 
nitrates/nitrites are considerably limited in prolonged continuous treatment by 
the development of pharmacologic tolerance and endothelial dysfunction [164, 
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169]. In vivo studies have shown that endothelial dysfunction and oxidative 
stress probably aggravate the tolerance, and increase the risk in cardiac events 
[170, 171]. Other side effects include headache, vomiting, and increased 
ischaemia-reperfusion injury [165]. To prevent the development of tolerance, 
scheduled nitrate-free breaks are required. It has been suggested that co-
administration of organic nitrates with other vasodilators such as captopril and 
hydralazine may avoid the development of nitrate tolerance [172]. The 
sustained-release tablets of isosorbide 5-mononitrate have also been reported 
to be effective with long-term use without inducing tolerance. [168] 
2.4.4.2 Iron-Nitrosyl Complexes 
Iron-nitrosyl complexes are inorganic complexes containing NO, 
which is bonded to an iron atom. In this group, sodium nitroprusside (SNP) is 
the most commonly used vasodilator in clinic to treat hypertensive crises. It is 
also recognised as the gold standard NO-dependent, but endothelium-
independent vasodilator [173]. SNP does not spontaneously liberate in the 
physiological setting, and requires either light activation or tissue-specific 
release mechanism [163, 174]. As a result, it is often used as a slow release 
agent for NO. However, a main concern with SNP is the potential release of 
the cyanide groups incorporated in its structure [175]. Cases of cyanidosis 
with long-term use of SNP have also been reported [176]. Other limitations of 
SNP include the restriction to intravenous delivery, the photolability in 
solution and the difficulty in dose titration [177]. 
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2.4.4.3 Sydnonimines 
Sydnonimines are heterocyclic compounds derived from morpholine 
[163]. They liberate NO via decomposition, which requires both alkaline pH 
and the presence of oxygen [163, 178]. Linsidomine (3-
morpholinosydnonimine or SIN-1) is a common vasodilator and anti-
aggregator in this group, which is a metabolite of the anti-anginal drug 
molsidomine. SIN-1 releases NO via a two-step process that occurs 
spontaneously in the blood [178]. Molsidomine is also an orally active, long 
acting vasodilator. It is metabolised and converted to SIN-1 in liver, which 
then releases NO. As a possible tolerance-free alternative to organic nitrates, 
sydnonimines have received a lot of attention in angina, heart failure and 
coronary vasospasm [179]. However, one problem with sydnonimines is the 
stoichiometric production of superoxide radicals (ONOO-), which is a highly 
toxic agent [180]. 
2.4.4.4 C-Nitroso Compounds 
C-nitroso compounds are alkyl, aryl or acyl compounds containing a 
nitroso group (–N=O) directly attached to an aliphatic, aromatic or carbonyl 
carbon, with the general formula R-N=O [181]. Upon exposure to light, C-
nitroso compounds may undergo a first-order hemolytic cleavage of the C-NO 
bond and generate NO [163]. Therefore, C-nitroso compounds are considered 
as the sources of biologically active neutral NO that can display potent NO 
bioactivity. It has been reported that appropriately substituted C-nitroso 
compounds can release neutral NO with up to 88 % efficiency [182]. A major 
problem with C-nitroso compounds is their preparation due to the high 
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reactivity of these compounds, particularly with regard to the yield of the 
desired product [183]. However, it has been shown that C-nitroso compounds 
can exist as stable dimers in pure form for significant period of time, which 
makes them with great potential in therapeutic treatment as a NO donor [182]. 
2.4.4.5 Diazeniumdiolates (NONOates) 
Diazeniumdiolates (NONOates) are chemical species that contain a 
diolate [N(O)NO]- group bound to a nucleophile adduct, which is usually an 
amine [184, 185]. They are generally synthesised by exposing the nucleophiles 
to several atmospheres of NO under anaerobic conditions. NONOates are 
usually stable in solid form when stored at 4 °C under argon or dry nitrogen. 
They have excellent aqueous solubility, and produce NO spontaneously 
without requirements of redox or light activation [184]. The decomposition 
rate of NONOates depends on pH, temperature and chemical nature of the 
nucleophile, ranging from 1 min to 1 day under normal physiological 
conditions [185, 186]. NONOates have received attention for their clinically 
relevant NO donor properties since 1990s [187]. They are favoured because of 
their stability in solid form and prolonged release of NO. The lack of 
tachyphylaxis is another advantage of NONOates as compared to organic 
nitrates, which is probably due to their tissue-independent decomposition 
mechanism. 
Though numerous studies have demonstrated that NONOates can be a 
reliable source of NO for therapeutic applications, no diazeniumdiolates 
compounds have been clinically approved to-date. One concern with 
NONOates is that they are powerful mutagens [163]. The subsequent reactions 
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between the decomposition by-products may also lead to the formation of 
carcinogenic nitrosamines [187]. It has been suggested that the incorporation 
of NONOates into polymers may prevent the leaching of the by-products and 
improve the long-term safety of NONOates [32]. 
2.4.4.6 S-Nitrosothiols (RSNOs) 
S-nitrosothiols (RSNOs) are organic compounds or functional groups 
containing a nitroso group bound to the sulphur atom of a thiol, with the 
general formula RS-N=O [141]. It has been generally assumed that RSNOs 
liberate NO from its thermal or photochemical decomposition via a homolytic 
cleavage of the S-N bond, generating a thiyl radical together with NO [163, 
188]. The presence of transition metal ions (Cu2+) or reducing agents can 
greatly accelerate the reaction [188, 189]. In addition, decomposition of 
RSNOs relies on their direct reaction with nucleophilic species whereby NO+ 
is transferred to the nucleophile. The biological activity of RSNOs is also 
highly influenced by the molecular environment of the parent thiol [190]. 
Some of the RSNOs naturally exist in tissues and blood, including S-
nitrosoglutathione (GSNO), S-nitrosoalbumin and S-nitrosocystein [147]. 
They act as the transporter of NO within the biological system, and take part 
in several physiological and pathophysiological processes [141]. The 
endogenous occurrence of the biological RSNOs may probably explain the 
limited cytotoxicity shown by RSNOs such as GSNO at pharmacologically 
relevant concentrations as compared to other NO donors. 
Although no RSNOs have been used in clinic yet, there are numerous 
animal and clinical studies demonstrating their advantageous features. Ex vivo 
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studies with rat thoracic aorta rings have shown that RSNOs have a low 
incidence of inducing tolerance or cross-tolerance with long-term usage as 
compared to organic nitrates [191, 192]. In vivo study has revealed a 
significant antiplatelet effect of certain RSNOs with only a small decrease in 
blood pressure [193]. Moreover, the rates of NO production from RSNOs can 
be varied within a wide range by simple chemical modifications of the R 
group [163]. Enhanced tissue selectivity has also been reported for some S-
nitrosated dipeptides [194]. Since RSNO can be easily obtained by treating 
thiols with a variety of nitrosating agents [195], various types of materials 
such as polymers [196, 197] and nanoparticles [35, 198] can be modified to 
have RSNO functionalities for different applications. In view of these, RSNOs 
may be a promising NO donor for therapeutic applications. 
2.4.5 Approaches for the Controlled Release of NO 
Due to the high reactivity and concentration-dependent effects of NO, 
appropriate delivery methods are crucial to control the effects of NO treatment 
to specific disease. Increasing attention has been put on the localised drug 
delivery to avoid drug loss and systematic effects. Therefore, different NO-
releasing materials have been developed to achieve a controlled and 
sustainable release of NO. Generally, there are two main approaches for the 
material development. One approach is to use the NO donors as additives and 
incorporate them into a host material. The NO release profile depends on the 
type of the NO donor [199, 200], the characteristics of the polymer (e.g. the 
water uptake rate) [201], and the interaction between the additive and the host 
materials [202]. The incorporation techniques such as melting also affect the 
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decomposition of the NO donor [203]. A concern with this approach is that 
there is a risk of leaching of the NO donors or by-products from their 
decomposition, which may be toxic or potentially carcinogenic (e.g. N-
nitrosamine by-products) [204].  
The other approach is to immobilise the functional groups capable to 
liberate NO on the host material via covalent bonding. This approach may 
provide a solution to the concern of potential leaching of harmful by-products. 
A slow and localised release of NO can also be achieved depending on the 
type of functional group immobilised and the properties of the host material 
[197, 205]. In this section, a variety of NO-releasing materials will be 
summarised according to the forms of the materials. 
2.4.5.1 NO-Releasing Polymeric Membranes 
NO-releasing polymeric membranes account for a significant portion 
in the development of NO-releasing materials as polymeric membranes are 
widely used in the development of biomedical devices such as synthetic 
vascular grafts and wound dressings. Numerous biocompatible polymers have 
been utilised as the host material. Saavedra et al. [203] made PU membranes 
using solvent cast method with a NONOate adduct (PROLI/NO) as the 
additive. The resultant PU membrane could steadily generate NO for 7 weeks 
under physiological conditions (pH 7.4 at 37 °C) at a rate of 0.2-0.7 
pmol/(min·mg). Mowery et al. [32] reported poly(vinyl chloride) (PVC) 
membranes with the addition of another NONOate adduct (N,N’-dimethyl-1,6-
hexanediamine or DMHD/NO), a plasticiser and ion-sensing additives. The 
NO-releasing PVC membranes could release NO for up to 72 h, and showed a 
 Chapter 2 Literature Review 
- 39 - 
significant improvement in thromboresistivity to platelet adhesion. However, a 
leaching of a toxic degradation by-product was also detected. 
Smith et al. [205] incorporated low molecular weight NONOate 
adducts into molten poly(ε-caprolactone) (PCL) or poly(ethylene glycol) 
(PEG), and made into solid membranes. The PCL membranes showed gradual 
release of NO for 7 days at physiological conditions. The PEG membranes 
could store NO for over 5 weeks as the solid under ambient conditions with 
the addition of zwitterionic as an inhibitor for acid-catalysed decomposition. 
However, the PEG membranes dissolved instantly in physiological fluids. 
There was also a concern of the technique for NO donor incorporation as the 
polymer melt may accelerate the thermal decomposition of the NO donor, and 
result in decreased total NO release. 
Seabra et al. [206] prepared solid polymeric membranes (PVA/PVP-
GSNO) from the blend of poly(vinyl alcohol)/poly(vinyl pyrrolidone) 
(PVA/PVP) with GSNO addition. The PVA/PVP-GSNO membranes showed 
a great stabilisation effect on the thermal decomposition of GSNO. The 1st-
order rate constants of the NO release profile for PVA/PVP-GSNO were 8-16-
fold less than those for the aqueous GSNO solutions. The NO release under 
physiological conditions could last for 24 h, with 90 % of the total 
incorporated NO released. In a later study, they found that both NO and 
GSNO were released from PVA/PVP-GSNO to aqueous solution through 
diffusion [31]. 
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In addition to using NO donors as additives in polymers, many 
polymers have been covalently modified with NO-releasing functional groups. 
Saavedra et al. [207] modified PVC with O2-methoxymethylated piperazine 
diazeniumdiolates. 1-2 % of the chloride in the polymer was replaced by the 
NONOate piperazine analogues. In a later study, the membranes made from 
diazeniumdiolated PVC blended with plasticisers and ionophores were proven 
to be thromboresistant and have a potential as a coating for blood-contacting 
devices [32]. Smith et al. [205] crosslinked poly(ethylenimine) (PEI) with 1,4-
butanediol diglycidyl ether, and treated it with pressurised NO for 3-6 days. 
The resultant crosslinked diazeniumdiolated PEI could release NO at a 
relatively constant rate for 5 weeks before exhaustion under physiological 
conditions. It could also provide a flexible film coating on the PTFE vascular 
graft that reduced platelet adhesion and vSMC proliferation.  
de Oliveira et al. [208] reported the synthesis of polynitrosated 
polyesters (PNPE) via the polycondensation of diols with mercaptosuccinic 
acid and subsequent nitrosation. They blended PNPE with poly(methyl 
methacrylate) (PMMA) to form membranes, and the membranes showed 
significant effect in decreasing platelet adhesion. Li and Lee [209] modified 
poly(vinyl methyl ether-co-maleic anhydride) (PVMMA) with GSNO, and 
blended it with PVP to form interpolymer complexes through intermolecular 
hydrogen bonding. The obtained membranes exhibited enhanced stability in 
the solid state than free GSNO, and could release NO for more than 10 days. 
As the membranes were designed to aid in diabetic wound healing, in vivo 
study with diabetic rats revealed that the membranes could accelerate the 
diabetic wound healing. 
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2.4.5.2 NO-Releasing Hydrogels/Xerogels 
Hydrogels are a network of hydrophilic polymer chains dispersed in 
water that are sometimes colloidal whereas xerogels are solids formed from a 
gel by drying with unhindered shrinkage. Both hydrogels and xerogels allow 
exchange of solvent and small solute molecules due to the complex porous 
network within the matrix, which makes them good candidates for localised 
drug delivery. Shishido et al. [210] incorporated the NO donors GSNO and S-
nitroso-N-acetylcysteine (SNAC) into F127 hydrogels, which are fluidic at 
refrigerator temperature (~5 °C) and become rigid semi-solid clear gels at 
body temperature (~37 °C). The resultant hydrogels could release NO via 
thermal and photochemical decomposition. The F127 hydrogel matrices 
exhibited a stabilising effect on the initial rates of the thermal and 
photochemical NO release in the first 2 h, which ranged from 2 to 45 µmol·l-
1·min-1 depending on the NO donor type and irradiation condition. This effect 
was attributed to a cage recombination mechanism. The study suggested that 
F127 hydrogels may be used as the storage and controlled release material for 
RSNOs. A similar study was done by Seabra et al. [211], in which GSNO and 
SNAC were incorporated into Synperonic F-127 hydrogels (a triblock 
copolymer of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO)) 
for topical applications. When applied on human forearm skin, both GSNO- 
and SNAC-containing hydrogels induced increased blood flows throughout 
the 3-h study. The dermal nitrite concentration was measured simultaneously 
and found directly correlated with blood flow. In contrast, high levels of blood 
flow led to a reduction in dermal nitrite due to the increased blood scavenging. 
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In a recent study done by Simoes and de Oliveira [212], PVA 
hydrogels with GSNO addition were prepared using the freezing-thawing (F/T) 
technique. It was found that the pore size of PVA hydrogels decreased with 
increasing F/T cycles, whereas the crystallinity increased. The diffusion 
coefficient of NO depended not only on the pore size of the hydrogels but also 
on the interconnectivity of the pores. The vasodilating effect of NO-releasing 
PVA hydrogels were also confirmed with tests on human forearm skin. 
In addition, there are also many studies reported to produce NO-
releasing hydrogels/xerogels via covalent modification. Masters et al. [213] 
developed a NO-releasing PVA hydrogel dressings via amination of PVA and 
subsequent diazeniumdiolation. The diazeniumdiolated PVA (PVA-NO) was 
photocrosslinked with Irgacure initiator to form hydrogel sheets. The PVA-
NO hydrogels could release almost 80% of the total incorporated NO over 48 
h at pH 6.0, which is the pH level of most wound environment. In vivo test 
with a diabetic mouse dorsal wound model showed that the PVA-NO 
hydrogels could promote the formation of granulation and scar tissues, which 
is important for stable wound healing. 
In order to prevent neointima hyperplasia, Lipke and West [214] 
developed a NO-releasing PEG-based hydrogel (PEG-Cys-NO) via covalent 
binding cysteine to a PEG-based copolymer and subsequent nitrosation. The 
PEG-Cys-NO hydrogels could undergo rapid photopolymerisation in situ, and 
generated NO for up to 50 days. In vitro test of the PEG-Cys-NO hydrogels 
proved that the hydrogels could effectively inhibit vSMC proliferation and 
platelet adhesion, and increase EC proliferation. In vivo test with a rat carotid 
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balloon-injury model revealed that the perivascular application of PEG-Cys-
NO hydrogels could inhibit intimal thickening and slightly enhance re-
endothelialisation, leading to approximately 80 % reduced neointima 
formation 2 weeks post-injury compared to the controls. Similar studies done 
by Bohl et al. [197, 215] showed that the neointima formation in a rat balloon-
injury model could be reduced by approximately 75 % at 14 days post-injury. 
Another study done by Taite and West [216] achieved approximately 90 % 
decrease in intimal thickening at 28 days post-injury in a rat balloon-injury 
model with NO-releasing PEG hydrogels. 
In a recent study done by Kim et al. [217], they developed a NO-
conjugated gel system (F127-BPEI-NONOates) through the coupling of the 
thermosensitive Pluronic F127 to branched PEI (BPEI) and subsequent 
conjugation of NONOates. The cage recombination effect of F127 reduced the 
diffusion of NO in the gel, resulting in a much longer half-life of NO release 
from F127-BPEI-NONOates (1.68-2.0 h) compared to the control group 
without F127 (<1 min). The longevity of NO release for F127-BPEI-
NONOates ranged from 32 to 54 h depending on the composition. F127-BPEI-
NONOates also showed inhibitive and promotive effect on in vitro vSMC and 
EC proliferation, respectively. 
Besides hydrogels, Schoenfisch et al. [218, 219] reported the method 
to incorporate NO donors within a crosslinked silica xerogel matrix. Highly 
crosslinked amine-containing networks could be produced using sol-gel 
chemistry with amine-functionalised alkoxysilanes (aminosilanes) and 
alkyltrimethoxysilanes (alkylsilanes). Upon diazeniumdiolation, the xerogels 
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could release NO from several hours to 20 days under physiological 
conditions depending on the type and amount of the aminosilane precursor. 
For a 50 µm thick xerogel matrix, the average NO fluxes over the first 10 h 
were between 8.0×10-6 and 5.6×10-5 µmol·s-1·cm-2 [219]. In vitro study 
showed a flux-dependent platelet adhesion on the xerogels, suggesting the 
NO-releasing xerogels might be useful for short-term applications. 
2.4.5.3 NO-Releasing Particles 
The idea of using particles for NO release was first attempted by 
Forslund and Sundqvist in 1997 [220]. They simply incubated the heat-killed 
yeast particles in a hydrophobic NO-releasing substance for some time to 
absorb the agent, and used them to study the effect of NO on neutrophil 
functions in vitro. Along with the extensive applications of 
micro/nanoparticles in different research fields, a variety of NO-releasing 
particles have been developed either by entrapping NO donors or derivatising 
the particle surface with NO-releasing functional groups. NO-releasing 
particles are usually used as fillers. They can be blended into a variety of 
biocompatible polymers without altering the fundamental polymer chemistry. 
The NO release can be modulated by changing the amount of particle blended 
or changing the specific identity of the polymer [36]. In addition, for 
derivatised NO-releasing particles, the risk of by-product leaching from NO 
donor decomposition can be eliminated as they are covalently modified and 
mechanically entrapped in the polymer matrix [198]. 
The first NO-releasing particles with covalent modification was 
reported by Zhang et al. [33]. Nontoxic amorphous fumed silica particles 
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(200-300 nm in diameter) were tethered with amine-containing silylation 
reagents followed by diazeniumdiolation. The diazeniumdiolated fumed silica 
particles released NO under physiological conditions via primarily the proton-
driven dissociation associated with negligible thermal dissociation. The fumed 
silica particles also exhibited a stabilising effect on the NONOate groups 
anchored on the surface characterised by a longer half-life (43 min) than that 
of the solution phase analogue NONOate compound (2.8 min). The NO-
releasing particles bended into PU matrices were coated on the inner wall of 
an extracorporeal PVC tubing and evaluated in a rabbit extracorporeal 
circulation (ECC) model. Prolonged NO release was detected for at least 4 h, 
with NO flux comparable to that from stimulated endothelial cells (4.1 × 10-10 
mol·cm-2·min-1) [221]. Fewer thrombi and much lower platelet activation and 
consumption for NO-releasing particle coating were observed compared to the 
control surfaces, suggesting a good potential of the NO-releasing fumed silica 
particles in the development of more blood-compatible devices.  
A similar study was carried out by Carpenter et al. [222] for 
bactericidal application. The NO-releasing silica nanoparticles (NPs) were 
prepared from diazeniumdiolation of amine-functionalised silica NPs of 
distinct sizes (50, 100, and 200 nm). The diazeniumdiolated silica NPs could 
release NO instantaneously characterised by an initial burst of NO with the 
maximum concentration of NO ranging from 43.5 to 49.7 ppm·mg-1. The 
bactericidal activity of NO-releasing silica NPs was enhanced with decreased 
particle size because the faster diffusion rate of smaller NPs allowed for more 
rapid association with bacteria. In another study done by Shin et al. [223], 
aminosilanes were first diazeniumdiolated and then mixed with 
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tetraethoxysilane or tetramethoxysilane (TEOS or TMOS) to form 
organic/inorganic hybrid silica NPs via a sol-gel process. The NO-releasing 
silica NPs were reported to have remarkably improved NO storage and release 
properties than the macromolecular NO donors. The NO payload could reach 
11.26 µmol·mg-1, and the release could last for 101 h with a half-life of 253 
min. 
Besides silica particles, AuNPs have also been modified as NO-
releasing materials. Rothrock et al. [34] functionalised monolayer-protected 
cluster AuNPs (MPCs) with amino groups followed by diazeniumdiolation 
with pressurised NO. The NONOate-modified MPCs were with an average 
core diameter of 2 nm. The total amount of NO released was found tuneable 
by varying the number and/or chemical structure of the substituted amino 
ligands. Increased amount of amino ligands or increased length of the alkyl 
chain could result in more NO released, ranging from 9750 to 87000 pmol·mg-
1 with NO release duration from 200 to 300 min. In another study done by the 
same research group, water-soluble NO-releasing AuNPs were synthesised 
from Tiopronin-protected MPCs (Tio-MPCs) via similar modifications [224]. 
Despite the water solubility, the NO-releasing Tio-MPCs could only release 
modest amount of NO (<0.023 µmol·mg-1) for short durations (<1.5 h). In the 
same study, they also demonstrated that the NO storage capacity and release 
stability could be improved by using polyamine-stabilised MPCs, which could 
release 0.386 µmol·mg-1 NO within up to 16 h after modifications. A concern 
with AuNPs is that AuNPs with small sizes (<2 nm) or certain surface 
chemistry (e.g. cationic AuNPs) may be cytotoxic [225]. Therefore, more 
cautions should be taken in using AuNPs as NO-releasing particles. 
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Compared to silica and gold particles, polymeric particles may have 
some advantages for drug delivery as they can be synthesised from 
biodegradable polymers. Biodegradable polymeric particles have been proven 
to exhibit increased blood circulation time and reduced liver accumulation in 
mice [226]. Kumar et al. [227] reported the synthesis of NO-releasing 
PEGylated NPs from different PEG-based block copolymers. The block 
copolymers were mixed with the NONOate adducts (PABA/NO or Double JS-
K) and subjected to a rapid micromixing, precipitation, and block-copolymer-
directed encapsulation process (Flash NanoPrecipitation). The size of the 
resultant NPs was 195-240 nm depending on the combination of block 
copolymer and NONOate adduct, and it increased to 290-440 nm after 1-20 h 
due to slow ripening of the NPs. The soluble PEG blocks in the amphiphilic 
block copolymers provide steric barrier to protect and stabilise the 
encapsulated NONOates from glutathione deactivation, which was 
characterised by much longer half-life of PEG-protected NPs in glutathione 
solution (40 min-5 h) than that of the free NONOates (4.5-15 min).  
Another NO-releasing polymeric microparticles reported by Yoo et al. 
[228] were made from PLGA and dethylenetriamine (DETA) NONOate. 
DETA NONOate was mixed with the PLGA solution and entrapped by the 
microparticles during their formation. The NO-releasing PLGA microparticles 
(19-83 µm) could entrap up to ~73 % of the total DETA NONOate added with 
the loading content up to ~3.7 mg. DETA NONOate was stabilised in the 
microparticles characterised by longer decomposition time (2-6 h) of the 
microparticles than that of the intact DETA NONOate (20 min). 
 Chapter 2 Literature Review 
- 48 - 
Recently, a new type of NO-releasing NPs was developed by Friedman 
et al. [229] based on biocompatible hydrogel/glass composites. The NO-
releasing composite NPs were produced from the sol-gel process of a mixture 
containing TMOS, PEG, chitosan, glucose and sodium nitrite (NaNO2), 
followed by lyophilisation or heat treatment and grinding. The composite NPs 
liberated NO via a different mechanism, in which NO is generated from the 
thermal reduction of added NaNO2 by glucose once exposed to moisture. The 
glassy matrices provided necessary condition for thermal reduction, while 
hydrogels retained the generated NO within the dry composite NPs. The 
release of NO was found regulated by the extent of hydration of the composite 
NPs. The composite NPs had an average size of 10 nm, and could release NO 
for over 1 month with sustained NO concentration more than 800 nM. Later 
studies showed that the NO-releasing composite NPs could effectively exert 
antimicrobial activity and accelerate wound healing process [230]. The 
circulation of these NPs also induced vasodilation and increased 
microvascular perfusion [231]. 
2.4.6 Future Directions of NO-Releasing Materials  
As a vital role involved in numerous physiological and 
pathophysiological processes, the therapeutic potential of NO to treat 
pathological processes such as CVD and bacterial infection have been well 
evidenced [232, 233]. Despite the extensive applications of organic nitrates 
and inhaled NO in clinic, more researches are focusing on the localised 
delivery of NO due to the concerns of drug tolerance, difficulty in handling 
NO gas and the high reactivity and dose-dependent effects of NO. Prolonged 
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NO release is also desirable to prevent late restenosis and promote vascular 
recovery in a long term. In the development of NO-releasing materials, 
physical incorporation of NO donors as additives in a host material is the most 
straightforward approach. The NO release properties can be tuned by choosing 
appropriate types of NO donor and host material or controlling the amount of 
the dopant. However, there is a risk of NO donor or decomposition by-product 
leaching from the host material. For NO donors such as NONOates, the 
decomposition by-products are toxic and may cause serious problems. With 
this concern, covalently modifying the host material with NO-releasing 
functional groups may be a better approach.  
Although most of the NO-releasing materials have been developed in 
membrane or gel form over the past two decades, the interests in developing 
NO-releasing particles are increasing. The NO-releasing particles can exhibit 
some controlling effects on the NO liberation by themselves. Meanwhile, they 
can also be incorporated into a variety of materials for enhanced release 
control. As the effects of NO are tissue-specific and concentration-dependent, 
the NO release properties of the material may be easily tuned by varying the 
amount of NO-releasing particles incorporated in order to meet the 
requirements for specific application. 
For the applications of NO-releasing materials, so far, most of the NO-
releasing materials have been applied in topical applications such as wound 
dressings and vasodilation patches. These applications usually address a 
specific problem with a certain property of NO. However, the inherent 
advantages of NO-releasing materials lie in their ability to combat numerous 
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issues ranging from infection and thrombosis to the foreign body response and 
neointimal hyperplasia. As mentioned in Section 2.4.3, NO deficiency affects 
virtually every point in the restenosis development. This implies that the 
development of NO-releasing stents and vascular grafts for PCI and CABG 
procedures may address several components in post-surgery restenosis, and 
provide great therapeutic benefits. Both NO-releasing polymeric membranes 
and hydrogels have been studied as the materials for vascular grafts or 
functional coatings for the devices. However, as a promising approach for NO 
delivery, NO-releasing particles have seldom been applied in the construction 
or modification of vascular grafts or stents. Therefore, applying NO-releasing 
particles in those devices can be a future research direction for NO-releasing 
material development. To construct composite devices with NO-releasing 
particles, several factors may need to be considered including the NO-
releasing particle dosage, the appropriate techniques to integrate the particles 
with the other materials and the biocompatibility, biodegradability, mechanical 
compliance and surface bioactivity of the device. Besides, the ease of storage 
and handling is also an important factor to be considered. With all these 
considerations, the constructed NO-releasing materials or devices may be 
more promising for the therapeutic applications of NO. 
2.5 Materials and Fabrication Techniques 
The choice of appropriate materials and processing techniques is the 
key in determining the properties of a medical device. Synthetic polymers 
have been widely used in biomedical applications due to their modifiable 
properties and well established synthesis methods [234]. As biosafety is 
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essential for biomedical devices, all the materials used to construct the 
proposed controlled release system are carefully chosen and with good 
biocompatibility. In this section, the relevant materials and fabrication 
techniques used in this study will be reviewed.  
2.5.1 Materials  
2.5.1.1 Gelatin-Siloxane Nanoparticles 
Gelatin-siloxane nanoparticles (GS NPs) are a new type of bioactive 
NPs synthesised from a two-step sol-gel process [235]. The GS hybrids were 
originally designed to introduce the inorganic siloxane (Si-O-Si) groups to 
natural polymers like gelatin to form hybrids with better bioactivity and 
biodegradability [236]. Upon follow-up processing or chemical reactions, GS 
hybrids can be made into porous scaffolds [237, 238], nanofibres [239, 240] 
and NPs [235, 241] for various applications such as bone tissue engineering 
and gene therapy. 
GS NPs are produced by forming a crosslinked network of siloxane 
from the co-condensation of GS hybrids and 3-aminopropyl-trimethoxysilane 
(APTMS). The reaction is initiated by the immediate pH change of the sol 
from acidic to basic solution upon the addition of APTMS [235]. GS NPs are 
with well-controlled size in nanoscale and have positive charges on the surface. 
They have been studied as a novel non-viral vector for gene delivery and 
expression [235, 242]. GS NPs can attract and encapsulate the electronegative 
DNA or oligopeptides through electrostatic interaction, preventing them from 
degradation by lysosome. In vitro study of GS NPs has shown not only 
satisfactory cytocompatibility, but also the capability to effectively penetrate 
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into cells and break lysosome to release DNA or drugs [235, 243]. Compared 
with other nanoscale silica and organosilicate used for drug and gene delivery 
[33, 244, 245], GS NPs are free from organic solvent and surfactant templates, 
which may cause harm to cells. Furthermore, various functional groups can be 
immobilised on the surface of GS NPs. Because of the amino groups in the 
chemical structure, GS NPs can be thiolated to have thiol (-SH) groups on the 
surface [235, 243]. Theoretically, materials with –SH groups can undergo S-
nitrosation to become a carrier of NO [141]. Therefore, GS NPs may be a 
good candidate material for controlled release of NO. 
2.5.1.2 Poly(vinyl alcohol) (PVA) 
Poly(vinyl alcohol) (PVA) is a linear synthetic polymer with a 
relatively simple chemical structure (Figure 2-4). It is synthesised from the 
polymerisation of vinyl acetate to poly(vinyl acetate) followed by partial or 
full hydrolysis. The molecular weight and degree of hydroxylation determine 
the physical and chemical properties of PVA. PVA is water soluble, and the 
solubility decreases with increasing degree of hydroxylation and 
polymerisation [246]. When dissolved in water, PVA can turn to gel form and 
possess gel properties. The melting temperature of PVA is 180-240 °C 
depending on the degree of hydroxylation, and its decomposition temperature 
is 30-40 °C below the melting temperature [247]. Therefore, PVA materials 
are usually prepared via dissolution in solvent instead of melting. 
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Figure 2-4 Molecular structure PVA 
The excellent biocompatibility of PVA has been well recognised with 
the US Food and Drug Administration (FDA) approval for clinical use. 
Though PVA is not biodegradable, it can be absorbed into blood circulation 
and eliminated from body mainly from renal glomeruli and hepatic bile ducts 
[248]. PVA with low molecular weight can also be excreted more rapidly 
through the kidney into the urine [249]. 
PVA is one of the most important polymers for industrial applications. 
They have been used as adhesives, textile fibres, paper coating agents, 
emulsion stabilisers [250]. PVA has also been used in many medical 
applications such as soft contact lenses, artificial cartilage, and non-adhesive 
membranes [251, 252]. In addition, PVA hydrogels provide three-dimensional 
(3D) porous network that allows the absorption of small solute molecules and 
their diffusion to the surrounding environment. Therefore, PVA hydrogels 
have also been studied as promising materials for controlled drug delivery 
[253, 254]. 
Due to the inferior mechanical strength, PVA hydrogels are often 
crosslinked chemically or physically to enhance the mechanical properties 
[255]. Chemical crosslinking can be introduced by using ultraviolet (UV) or 
gamma irradiation in the presence of sensitisers or photoinitiators such as 
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dialdehydes (glutaraldehyde or glyoxal) [256], sodium benzoate [257], and 
Irgacure2959 [258]. However, there is a risk of toxic residue release, which 
may alter the biological activity or degrade the biologically active agent 
incorporated [259]. Chemical crosslinking can also increase the molar mass of 
PVA, which results in prolonged excretion process and accumulation of PVA 
inside body [260]. These concerns can be eliminated by introducing physical 
crosslinking with freezing-thawing (F/T) method, which is free of chemical 
agents and does not increase the molar mass of PVA [261]. The details about 
F/T method will be introduced in Section 2.5.2.1. 
2.5.1.3 Poly(ε-caprolactone) (PCL) 
Poly (ε-caprolactone) (PCL) is a semi-crystalline linear aliphatic 
polyester (Figure 2-5). It is synthesised mainly from catalysed ring-opening 
polymerisation (ROP) of ε-caprolactone or catalysed polycondensation of 6-
hydroxyhexanoic acid [262]. PCL exists in a rubbery state due to the low glass 
transition temperature (Tg, -60 °C). It has a high thermal stability characterised 
by a decomposition temperature of 350 °C. Because of the low melting 
temperature (59-64 °C), PCL can be processed easily at a slightly heated 
temperature without significant molecular weight loss [263]. In addition, being 
soluble in many organic solvents and compatible with a wide range of other 
materials, it enables the use of PCL in many applications. 
O
O n  
Figure 2-5 Molecular structure PCL 
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The mechanical properties of PCL depend on the molecular weight of 
PCL and the fabrication technique. It was reported that heat-compressed PCL 
films with intermediate molecular weight (Mw = 44,000) have a tensile 
strength of 16 MPa, tensile modulus of 400 MPa and elongation at break at 
80-1000 % [264]. Compared to other aliphatic polyesters with similar 
molecular weight, PCL has much weaker mechanical strength. This can be 
explained by the difference in Tg: PCL is in the rubbery state at room 
temperature whereas most aliphatic polyesters are in the glassy state. Because 
of these mechanical properties, PCL may be more useful in the applications 
for soft tissues, and additional measures may be required to enhance the 
mechanical strength for hard tissue applications. 
Previous studies have also shown that PCL is biodegradable via the 
hydrolysis of its aliphatic ester linkages [265]. In vivo study showed that when 
exposed to tissue fluids, PCL was first broken down into ε-hydroxy-caproic 
acid (C6H12O6), and then metabolised into carbon dioxide and water [266]. In 
vitro and in vivo studies have proven the good biocompatibility of PCL as the 
polymer and its degradation products are non-toxic and do not induce a 
deleterious inflammatory response of local tissues [267, 268]. The degradation 
rate depends on both the molecular weight and the morphological property of 
the material. Compared with other polyester, PCL has a much slower 
degradation rate (>24 months) due to its high crystallinity [269], which makes 
it suitable for long-term applications. 
Because of the good biocompatibility, PCL has the FDA approval for 
medical use. It has been used in a number of biomedical applications such as 
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drug delivery in wound healing [270] and scaffolds for vascular and bone 
tissue engineering [267, 271, 272]. PCL films can be fabricated by various 
methods including solvent cast [273], biaxial stretching [272], and 
electrospinning [274]. The resultant properties of PCL films, especially the 
mechanical properties, differ based on the fabrication method. Therefore, the 
selection of appropriate fabrication technique of PCL is required to fulfil the 
specific requirements from the target application. 
2.5.2 Fabrication Techniques 
2.5.2.1 Freezing-Thawing of PVA 
Freezing-thawing (F/T) technique is a physical crosslinking method for 
the gelation and solidification of some polymers, in particularly for PVA [259, 
275]. It was first developed by Peppas in 1975 [276]. Upon repeated freezing 
and thawing, PVA solutions can turn into highly elastic thermoreversible 
hydrogels. This sol-gel transition phenomenon of PVA has been explained 
with three basic mechanisms involving hydrogen bonding, polymer crystallite 
formation, or liquid-liquid phase separation process [277]. Hydrogen bonding, 
which is a directional intermolecular interaction, causes the formation of a 
physical crosslink (tie point) between two molecular chains in the gel (Figure 
2-6a). Some molecular chains entangle or associate with other chains in the 
network, and form small regions with ordered layered structure (Figure 2-6b). 
This leads to the formation of microcrystallites scattered in the disordered 
amorphous polymer matrix [278]. Another theory explains the phenomenon as 
a liquid-liquid phase separation into polymer-rich and polymer-poor regions 
by spinodal decomposition [279]. It is believed that the refinement of ice 
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crystals resulting from repeated freezing rejects PVA from the ice crystals, 
which forms the polymer-rich phase. This theory was evidenced by the 
increased pore size and more distinct skeleton of the gel with increasing 
freezing cycles [280, 281]. It has been suggested that these three mechanisms 
are not completely separated from each other, and each plays an 
interdependent role in the gel formation [280]. 
 
Figure 2-6 Formation of 3D network structure in freeze-thawed PVA 
hydrogels due to (a) hydrogen bonding, and (b) microcrystallite formation 
[277] 
The freeze-thawed PVA (FT-PVA) hydrogels are stable at room 
temperature and retain their original shape. The hydrogel properties depend on 
the molecular weight of the uncrosslinked PVA, the aqueous solution 
concentration, the temperatures and time length for each F/T cycle, and the 
number of F/T cycles [277]. The mechanical strength of FT-PVA hydrogels 
increases with increased number of F/T cycles [255]. Since F/T method 
introduces physical crosslinking without using any crosslinking agents, the 
concerns of increased PVA molar mass and toxic residue leaching with 
chemical crosslinking can be eliminated. FT-PVA hydrogels have been 
studied for different biomedical applications such as soft tissue replacement, 
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vascular and cartilage tissue engineering, and drug delivery [253, 255, 282, 
283]. FT-PVA hydrogels can be produced to resemble the properties of natural 
tissues including the water content, mechanical strength and elasticity [284]. 
By controlling the stress applied during the F/T process, anisotropic PVA 
hydrogel conduit can be produced to mimic the properties of anisotropic 
tissues such as aorta [283]. In addition, FT-PVA hydrogels can be used for 
localised controlled release of drugs and bioactive molecules. Drug donors in 
various forms such as soluble powder and particles can be incorporated into 
FT-PVA hydrogels, and the release properties can be tuned by varying the 
variables in F/T process [212, 285-287]. 
2.5.2.2 Biaxial Stretching of Polymer Films 
Biaxial stretching (BS) is a technique to fabricate semicrystalline 
polymer films used for a range of applications [288]. In BS process, polymer 
films are subjected to the stretching along two axes that are perpendicular to 
each other. The stretching can be carried out either sequentially or 
simultaneously, with or without heating [289, 290]. In this study, simultaneous 
biaxial stretching (SBS) technique will be applied, which takes place in the 
partly molten state of the polymer (Figure 2-7). Compared to sequential BS, 
SBS allows the production of uniform and highly oriented films at high speed 
while minimizing the energy and breaks occurring during deformation [291]. 
Polymer films used for SBS can be prepared via various fabrication methods 
such as extrusion, heated compression, solvent casting and spinning casting 
[289, 290]. The temperature, deformation rate and the drawing ratio for SBS 
process affect the polymer crystallisation process and the resulting film 
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morphology and properties. The heat-setting below the crystalline melting 
point under biaxial tension also imposes post-solidification alterations to the 
stretched films [292]. It has been proven that the physical properties of the 
stretched polymer films can be improved in both the longitudinal and lateral 
directions [289]. 
SBS has been used with a number of biocompatible semicrystalline 
polymers such as PCL [293-295], polypropylene (PP) [290] and poly(lactic 
acid) (PLA) [296] to produce thin films for biomedical applications. It has 
been shown that mechanical properties and thermal stability of the polymer 
films can be improved to varying degrees after SBS [289, 296]. As for PCL, 
success fabrication of ultra-thin PCL films (~1 µm in thickness) via SBS of 
spin cast films was reported [289]. SBS of PCL films prepared via different 
methods produced thin films with similar fibrillar networks in their 
morphologies, which is due to the chain orientation induced by stretching 
[289]. In vitro studies have also revealed the supportive effects of biaxial-
stretched PCL film on cell growth [294]. All these results suggest that SBS is 
a promising technique to fabricate thin films for applications in different areas 
of membrane tissue engineering.  
  
Figure 2-7 Schematic of simultaneous biaxial stretching of polymer films 
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2.5.2.3 Electrospinning 
Electrospinning is a well-recognised technique for the fabrication of 
polymer fibres with diameters ranging from several micrometres to a few 
hundred nanometres [297-299]. In electrospinning process (Figure 2-8), a 
polymer solution ejected from the spinneret is subjected to an intense electric 
field between the spinneret tip and the grounded collector. With increased 
intensity of the electric field, the solution at the spinneret tip elongates to form 
a conical shape known as the Taylor cone [300]. When the electric field 
reaches a critical value, the repulsive electrostatic force overcomes the surface 
tension force of the solution, and a charged jet of the solution is ejected from 
the tip of the Taylor cone. The charged jet evaporates as it travels in air to 
become a fibre, which is deposited randomly on the ground collector [298]. 
 
Figure 2-8 Schematic of the electrospinning setup [301] 
Electrospinning is controlled by several parameters: (1) process 
variables including electric field intensity, tip-to-collector distance, spinneret 
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dimension, collector type and solution feed rate; (2) solution properties 
including viscosity, conductivity and surface tension; and (3) ambient 
conditions including temperature, humidity and air velocity in the 
electrospinning chamber [297, 298]. By varying these parameters, the 
geometries and structural properties of the fibre matrices can be tuned 
effectively [302]. 
Electrospinning technique has been applied with more than 200 types 
of synthetic and natural materials for various biomedical applications such as 
vascular tissue engineering and drug delivery [274, 302-305]. The electrospun 
fibrous structure is a 3D matrix with high porosity and spatial 
interconnectivity, which enables the transportation of nutrients and wastes and 
the cell communication [274]. The electrospun fibrous matrix also has a large 
specific surface area, which benefits the drug delivery application with an 
efficient delivery of loaded drugs or bioactive molecules to the surrounding 
[304]. In addition, electrospun nanofibrous scaffolds can mimic the native 
ECM to facilitate cell attachment and proliferation [306]. Tissues with 
anisotropic structures and architectures such as tendons and blood vessels may 
also be mimicked by assemblies of electrospun aligned nanofibres [307, 308].  
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Chapter 3  
Synthesis of Nitric-Oxide-Releasing S-Nitrosothiol-
Modified Gelatin-Siloxane Nanoparticles 
 
3.1 Introduction 
Nitric oxide (NO) is an endogenous messenger molecule that can be 
found in almost all tissues of the body and throughout the central nervous 
system [133]. In the cardiovascular system, NO is continuously produced by 
intact endothelial cells (ECs). It functions as a vital mediator in the regulation 
of vascular tone, inhibition of platelet and leukocyte responses, regulation of 
vascular smooth muscle cell (vSMC) mitogenesis and proliferation as well as 
maintenance of endothelial integrity [144, 309]. On the other hand, 
dysfunction in endogenous NO production results in several pathologies [232, 
310]. NO deficiency resulting from the endothelial damage imposed by 
surgical procedures such as angioplasty and coronary artery bypass surgery 
has been shown to affect the development of post-surgery restenosis 
significantly, which is an occlusive vascular response to arterial injury and 
inflammation characterised by lumen narrowing [75, 161]. The lack of 
vasodilation and inhibition of platelet activation and vSMC proliferation due 
to NO deficiency promotes the key processes in restenosis development 
including negative remodelling, thrombus formation and neointimal 
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hyperplasia. In view of these, supplement of NO may be a promising 
therapeutic strategy to control and prevent post-surgery restenosis. 
Due to the high reactivity and concentration-dependent behaviour of 
NO, the research of exogenous NO delivery has been focused on the 
development of NO donors that can store and release NO in a controlled and 
sustained manner [173, 177, 180]. As reviewed in Section 2.4.5, many 
different systems have been developed for NO release including polymer 
membranes, hydrogels and nanoparticles (NPs). In these systems, NO-
releasing NPs are of particular interest as they not only exhibit some 
controlling effects on NO liberation, but also can be incorporated into a 
variety of materials for enhanced release control. Different types of NPs such 
as gold, silica and iron oxide NPs have been studied as carriers for NO [224, 
311, 312]. 
Besides incorporating NO donors as additives in/on the nanomatrices 
via absorption, adsorption or encapsulation, another main approach for NO-
releasing nanoparticle development is to immobilise NO-generating functional 
groups on the nanomatrices via covalent modification [313]. The most 
commonly applied covalent modifications are S-nitrosation or 
diazeniumdiolation of primary or secondary amines in the NP structure, which 
converts NPs into S-nitrosothiol (RSNO) or diazeniumdiolate (NONOate) 
adducts that are capable of generating NO. Compared to NONOates adducts, 
RSNO adducts have advantages on the cytotoxicity issue as RSNO is a type of 
chemical naturally existing in tissues and blood [147]. The synthesis of RSNO 
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can also be easily achieved by treating thiols with a variety of nitrosating 
agents at atmospheric pressure.  
In this work, a novel NO-releasing NP has been developed via RSNO 
functionalisation of inorganic gelatin-siloxane NPs. These NPs can act as large 
storage reservoirs of NO with a sustainable release of NO for 7 days. Their 
excellent cytocompatibility and effective regulation of vSMC and EC 
proliferation have also been demonstrated for potential cardiovascular 
application. 
3.2 Materials and Methods 
3.2.1 Materials 
Gelatin, 3-glycidoxypropyl-trimethoxysilane (GPTMS), 3-
aminopropyl-trimethoxysilane (APTMS), 2-Iminothiolane hydrochloride 
(Traut’s reagent), sodium nitrite (NaNO2), 5,5'-dithiobis-(2-nitrobenzoic acid) 
(Ellman’s reagent), phosphate buffer saline (PBS, 1x), penicillin-streptomycin 
(PS), fluorescein-isothiocyanate-labelled dextran (FITC-dextran, MW 40,000), 
Triton-X 100, bovine serum albumin (BSA) and 4',6-diamidino-2-
phenylindole (DAPI) were purchased from Sigma-Aldrich (Singapore). 
Nitrate/nitrite colorimetric assay kit was purchased from Cayman Chemical 
Company (USA). Dulbecco's modified eagle medium (DMEM) and fetal 
bovine serum (FBS) were purchased from Life Technologies (Singapore). 
AlamarBlue® was purchased from Life Technologies (Singapore). Cell 
Proliferation Reagent (WST-1) was purchased from Roche Diagnostics Asia 
Pacific (Singapore). L929 mouse fibroblasts (FBs, ATCC® CCL-1™) were 
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purchased from ATCC (Manassas, VA, USA). Human aortic smooth muscle 
cells (AoSMCs, CC-2571), smooth muscle cell growth medium (SmGM-2) 
and endothelial growth medium (EGM) were obtained from Lonza 
(Singapore). Human umbilical vein endothelial cells (HUVECs) were received 
as a gift from Mr. Wang Zuyong (National University of Singapore). Tissue 
culture plates (TCPs) and flasks, and low-adhesion TCPs were purchased from 
Nunc (Singapore) and Corning (Singapore), respectively. All reagents were of 
analytical grade and used as-received. Deionised (DI) water was de-gassed 
before use. 
3.2.2 Preparation of Gelatin-Siloxane Nanoparticles (GS NPs) 
GS NPs were synthesised using a sol-gel method as described in the 
previous study (Scheme 3-1) [235]. Briefly, gelatin was dissolved in 1 mM 
hydrochloride (HCl) to make a 0.75 % (w/v) gelatin solution. Appropriate 
amount of GPTMS was added to the gelatin solution, followed by the addition 
of APTMS after stirring for 30 min at 60 °C. The composition of the precursor 
sols studied was shown in Table 3-1. The mixture was allowed to react at 
60 °C for 12 h with continuous stirring. The resultant GS NPs were collected 
by centrifugation for 15 min at 10,000 rpm and 20 °C (Beckman Coulter, 
Singapore), and washed with DI water thrice. The amount of amino groups (-
NH2) on GS NPs were quantified using Acid Orange 7 (AO7) assay (see 
Section 3.2.5.3). 
3.2.3 Preparation of RSNO-Modified GS NPs (GS-NO NPs) 
The synthesis steps for GS-NO NPs were shown in Scheme 3-1. GS 
NPs were suspended in 50 mM potassium phosphate buffer (PPB, pH 8.0) to 
 Chapter 3 Synthesis of GS-NO NPs 
- 66 - 
get a 7 mg/mL suspension. Traut’s reagent was added to the GS NP 
suspension with a weight ratio of GS NP/Traut’s reagent = 8:1. The mixture 
was incubated overnight at 25 °C with continuous stirring. The resultant 
thiolated GS NPs (GS-SH NPs) were collected by centrifugation and washed 
thrice. The degree of thiolation of GS NPs was determined by Ellman’s 
reaction (see Section 3.2.5.4) [314]. GS-SH NPs were re-dispersed in 10 mM 
HCl and then reacted with NaNO2 of an equimolar amount as that of the thiol 
groups at 37 °C for 2 h to form RSNO-modified GS NPs (GS-NO NPs). GS-
NO NPs were collected by centrifugation for 15 min at 20 °C, 10,000 rpm, and 
washed with DI water thrice. GS-NO NPs were stored as concentrated 
suspension in DI water at -20 °C under light-shielded conditions [223]. 
 
Scheme 3-1 Schematic illustration of the synthesis of GS-NO NPs 
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3.2.4 Morphological Characterisation 
3.2.4.1 Dynamic Light Scattering (DLS) 
The size and surface charge of GS, GS-SH and GS-NO NPs in DI 
water were determined using DLS (Nano-ZS Zetasizer, Malvern Instruments, 
UK), equipped with a 4.0 mW internal laser. The detection was carried out at a 
scattering angle of 90 ° at 25 °C. The effective particle diameter was 
calculated from the auto-correlation function using the Malvern Zetasizer 
software assuming a log normal distribution. 
3.2.4.2 Field Emission Scanning Electron Microscopy (FESEM) 
The surface morphologies of GS NPs and GS-NO NPs were examined 
by FESEM (S-4300, Hitachi, Japan). Prior to the examination, samples were 
sputter-coated with gold at 10 mA for 30 s. Images were taken at an 
accelerating voltage of 15 kV. 
3.2.5 Composition Analysis 
3.2.5.1 Fourier Transform Infrared Spectroscopy (FTIR) 
The molecular structure of GS, GS-SH and GS-NO NPs were 
characterised by FTIR (Spectrum® One FT-IR Spectrometer, Perkin-Elmer, 
USA). The spectra were recorded over a range of 400-4000 cm-1 at a 
resolution of 1 cm-1. A background spectrum without any sample was 
subtracted from all the spectra. 
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3.2.5.2 Ultraviolet-Visible (UV-Vis) Spectrophotometry 
The effectiveness of RSNO modification on GS NPs was verified by 
UV-Vis spectrophotometry (Shimadzu UV-2450, Shimadzu Asia Pacific Pte 
Ltd, Singapore). The UV-Vis spectra of GS and GS-NO NPs were recorded 
over a range of 200-800 nm at 25 °C. DI water and GS NP suspension of 
equivalent concentration were used as the reference for GS NP and GS-NO 
NP, respectively.  
3.2.5.3 Acid Orange 7 (AO7) Assay 
The total amount of amino groups (-NH2) on GS NPs were quantified 
using Acid Orange 7 (AO7) assay according to [315] with some variations. 
Briefly, 6 mM AO7 solution was prepared by dissolving AO7 in pH 3.0 water 
(diluted HCl). 5 mg GS NPs were suspended in 1 mL AO7 solution for 24 h at 
25 °C under continuous shaking. The dye-bound GS NPs were collected by 
centrifugation and washed with pH 3.0 water thrice to remove unbound AO7. 
Then the GS NPs were suspended in 1 mL pH 12.0 water (diluted sodium 
hydroxide or NaOH) for 15 min at 25 °C to desorb the bound dye. The 
suspension was centrifuged, and the absorbance of the supernatant at 492 nm 
was measured using a spectrophotometric plate reader (FLUOstar Optima, 
BMG Labtech Japan Ltd, Japan). The amount of bound AO7 and thus, the 
quantity of amino groups was calculated using a standard curve of AO7 at pH 
12.0 with a linear range from 0 to 0.24 mM. 
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3.2.5.4 Ellman’s Reaction 
The degree of thiolation of GS NPs was determined by Ellman’s 
reaction [314]. Briefly, 10 mM Ellman’s reagent was prepared by dissolving 
the reagent in 50 mM PPB. 50 µL Ellman’s reagent was added to 0.5 mg GS-
SH NPs suspended in 2 mL PPB. After reacting for 2 h at 25 °C, the 
suspension was centrifuged, and the absorbance of the supernatant at 420 nm 
was measured using a spectrophotometric plate reader. The amount of thiol 
groups on GS-SH NPs was calculated using a standard curve of L-cysteine (0-
1.5 mM) reacted with Ellman’s reagent. 
3.2.6 Release Kinetics of NO from GS-NO NPs 
The NO release profile from GS-NO NPs was determined in vitro 
under physiological conditions in the dark. GS-NO NPs were suspended in 
PBS solution (pH 7.4) and kept at 37 °C in water bath. At different time point, 
GS-NO NPs were centrifuged down and the supernatant was replaced by the 
same volume of fresh PBS solution. The supernatant collected was frozen at -
20 °C. The production of NO by the GS-NO NPs was quantified by measuring 
the total amount of oxidation products of NO, sodium nitrite (NaNO2) and 
sodium nitrate (NaNO3), using a nitrate/nitrite colorimetric assay kit based on 
the Griess assay [316]. The absorbance of the supernatant at the wavelength of 
540 nm was measured using a spectrophotometric plate reader. Cumulative 
volume of NO release was calculated from the standard curve, and the 
quantity of NO released was expressed in terms of the total amount of NaNO3 
and NaNO2 in the supernatant. 
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Because NO was loaded on GS NPs through the formation of S-N 
bond, the resulted GS-NO NPs belongs to RSNOs. Therefore, the NO release 
mechanism of GS-NO NPs is assumed through thermal decomposition [210] 
according to 
2	RSNO	 → RS െ SR ൅ 2	NO	 ↑ 																									Eq. 3.1 
Based on the experimental data, a 1st-order exponential model was 
assumed for the kinetic curve of NO released versus time [206] according to 
the equation: 
ሾNOሿ௧ ൌ ሾNOሿ௙ െ ሾNOሿ௙݁ି௞௧																														Eq. 3.2 
where  ሾNOሿ୲ is the NO concentration at time t 
                        ሾNOሿ୤ is the final NO concentration 
                        k is the 1st -order rate constant (h-1) 
 
The initial rate (ܫோ ) of thermal NO release from GS-NO NPs was 
obtained by linear regression from the slopes of the initial section (less than 
10 % of the reaction) of the kinetic curves, according to 
ܫோ ൌ ∆ሾNOሿ∆ݐ 																																																	Eq. 3.3 
where   ∆ሾNOሿ is the change in NO concentration 
            ∆ݐ is the corresponding time interval 
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3.2.7 Cell Culture 
FBs were cultured in D10 medium (DMEM + 10 % FBS + 1 % PS) on 
tissue culture flask (25 ml). AoSMCs were cultured in SmGM-2 medium. 
HUVECs were culture in EGM10 (EGM + 10 % FBS). Cells were cultivated 
in an incubator at 37 °C with 5 % carbon dioxide (CO2), and the culture 
medium was changed every 3 days. Both AoSMCs and HUVECs used were 
within Passage-6. 
3.2.8 AlamarBlue® Assay 
The cytotoxicity of GS and GS-NO NPs was evaluated using 
AlamarBlue® assay [317]. Briefly, FBs were seeded on 24-well TCPs at a 
density of 5,000 cells/well. The culture medium was replaced by 1 mL GS- or 
GS-NO-containing culture medium of designated concentrations (100-600 
µg/mL) 12 h after seeding. After culture for pre-determined periods (1 and 7 
days), cells were washed with PBS and incubated with AlamarBlue® reagent 
(10 % in D10 medium) for 4 h at 37 °C. The absorbance of reacted solution 
was measured at 570 nm with the reference at 600 nm using a 
spectrophotometric plate reader. The cell viability in the tested concentration 
range of the NPs was determined by the following equation: 
Cell	viability	% ൌ Absorbance	of	test	groupAbsorbance	of	control	group ൈ 100	%							Eq. 3.4 
The FBs cultured with D10 medium were used as the control group. 
Three samples were used, and the absorbance for each sample was determined 
thrice. 
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3.2.9 Confocal Laser Scanning Microscopy (CLSM) 
The cellular proliferation of AoSMCs in response to GS-NO NPs was 
evaluated by counting the cell number using cell nucleus staining. The cellular 
uptake of GS-NO NPs by AoSMCs was investigated using FITC-labelled GS-
NO NPs. Cells were immediately examined using CLSM (FV1000, Olympus, 
Japan). 
3.2.9.1 Fluorescent DAPI Cell Nucleus Staining 
AoSMCs were seeded on 24-well TCPs at a density of 15,000 
cells/well. The culture medium was replaced by 1 mL GS-NO-containing 
culture medium of designated concentrations (100 and 600 µg/mL) after 
seeding for 24 h. After culturing for pre-determined periods (1, 3 and 7 days), 
cells were washed twice with PBS to remove the dead cells. AoSMCs were 
fixed using PFA (3.7 % in PBS) for 15 min, followed by permeabilisation 
using Triton-X (0.1 % in PBS) for 10 min and blocking using BSA solution (2 % 
in PBS) for 30 min. After washing thrice with PBS, cells were incubated with 
DAPI (0.1 % in PBS) for 5 min to visualise the nuclei. The total cell number 
was calculated based on the average cell number determined from the CLSM-
captured images using the built-in function of ImageJ software (USA). Three 
samples and four random regions of each sample were analysed. AoSMCs 
cultured with SmGM-2 medium were used as the control group in this work. 
3.2.9.2 In Vitro Cellular Uptake of GS-NO NPs 
FITC-labelled GS and GS-NO NPs were prepared by incubating 1.5 
mg NPs in 1 mL FITC-dextran solution (0.5 mg/mL in PBS) for 30 min. 
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AoSMCs were seeded on the coverglass in 12-well low-adhesion TCPs for 
overnight, followed by incubation in FITC-labelled-NP-containing culture 
medium (100 μg/ml) for 2 h. The cells were then washed twice with PBS and 
fixed with PFA solution (3.7 % in PBS) for 15 min. Images were captured by 
CLSM to visualise the distribution of GS and GS-NO NPs. 
3.2.10 WST-1 Assay 
The cellular proliferation of HUVECs in response to GS-NO NPs was 
evaluated using WST-1 assay [318]. HUVECs were seeded on 240-well TCPs 
at a density of 180,000 cells/well. The culture medium was replaced by 1 mL 
GS-NO-containing culture medium of designated concentrations (100, 300 
and 600 µg/mL) after seeding for 24 h. After culture for pre-determined 
periods (1, 3 and 7 days), cells were washed with PBS and incubated with 
WST-1 reagent (10 % in EGM10 medium) for 1 h at 37 °C. The absorbance of 
reacted solution was measured at 440 nm with the reference at 610 nm using a 
spectrophotometric plate reader. HUVECs cultured with EGM10 medium 
were used as the control group. Three samples were used, and the absorbance 
for each sample was determined thrice. 
3.2.11 Data Analysis 
Results were presented as mean ± standard deviation (SD) of the mean. 
Data analysis was performed on Prism 5 software. Statistical significance was 
determined by a two-tailed, unpaired student t-test. A value of p <0.05 was 
considered to be statistically significant. 
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3.3 Results 
3.3.1 Synthesis of GS-NO NPs 
Scheme 3-1 illustrates the synthetic strategy of GS-NO NPs. In acidic 
gelatin solution, GPTMS was grafted to gelatin via the cleavage of the C-O 
bond in the epoxy ring and subsequent attacking of the amino group on the 
side chain of gelatin [235, 236]. The methoxy silane groups (Si-OCH3) of 
GPTMS were simultaneously hydrolysed to form silanol groups (Si-OH). 
Upon the addition of APTMS, the reaction environment was changed from 
acidic to basic (pH 8.0-9.0), which resulted in the condensation of the 
hydrolysed molecules of GPTMS and APTMS. GS NPs were formed as a 
network of siloxane from this co-condensation. The resultant GS NPs was 
thiolated via the reaction between the amino groups and Traut’s reagent to 
form thiol groups. Finally, a nitroso group was attached to the sulphur atom 
via the condensation reaction of anionic nitrite and thiol groups [319], and 
yielded GS-NO NPs.  
3.3.2 Morphologies of GS and GS-NO NPs 
The size and surface charge of the as-synthesised GS and GS-NO NPs 
were summarised in Table 3-1. The size and surface charge of GS NPs could 
be controlled by tuning the composition of the sol-gel process. As the molar 
ratio of GPTMS/ATPMS = 2, the lower weight ratio (70 g/mol) of 
gelatin/GPTMS resulted in smaller NPs (245 ± 4 nm) whereas the higher ratio 
(200 g/mol) resulted in slightly larger NPs (292 ± 8 nm). Higher molar ratio of 
GPTMS/ATPMS (3 mol/mol) yielded NPs with similar size as those 
synthesised with lower molar ratio of GPTMS/ATPMS (2 mol/mol). For all 
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the compositions, the resultant NPs were monodispersed with the 
polydispersity index (PDI) smaller than 0.2. However, the surface charge 
exhibited by GS1 and GS2 were much lower than that of GS3, indicating 
lower stability and higher tendency for aggregation in the dispersion [320]. 
Therefore, the composition for GS3 was used to synthesise GS-NO NPs. In the 
rest of this thesis, GS NPs denote the NPs synthesised with composition GS3. 
Figure 3-1 depicts the size and surface charge distribution of GS and 
GS-NO NPs measured with the DLS method. The dimensions of GS and GS-
NO NPs were in the range of 130-800 nm, and the average diameter was 
approximately 300 nm. The size and size distribution of the NPs did not have 
obvious changes after modification (Figure 3-1a). Meanwhile, the surface 
charge slightly decreased after modification with a broader distribution range 
(Figure 3-1b). 
The FESEM images of GS and GS-NO NPs are shown in Figure 3-2. 
The GS and GS-NO NPs generally had spherical contours with granular 
surface. The average diameter of GS and GS-NO NPs measured from the 
images (n = 125) were 206 ± 36 and 217 ± 38 nm, respectively. These sizes 
were much smaller than those obtained from DLS measurement, which could 
be attributed to the hydrodynamic interaction of the NPs with water molecules 
[321].  
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Table 3-1 Composition and characteristics of GS and GS-NO NPs measured 
by DLS 
 





(mol/mol) Size (nm) PDI 
GS1 70 2 245 ± 4 0.125 15.23 ± 0.40 
GS2 200 3 299 ± 2 0.136 10.10 ± 0.35 
GS3 200 2 292 ± 8 0.067 41.07 ± 1.91 
GS-NO 200 2 299 ± 3 0.130 39.18 ± 0.99 
 
 
Figure 3-1 DLS measurements of the size (a) and surface charge (b) 
distribution of GS and GS-NO NPs 
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Figure 3-2 Representative image of GS (a) and GS-NO (b) NPs (scale bar = 1 
µm) 
3.3.3 Chemical Structure of GS-NO NPs 
The chemical structure of GS NP and the conjugation of the functional 
groups after each modification were confirmed by FTIR and UV-Vis 
spectroscopy. As shown in Figure 3-3a, the FTIR spectrum of GS NPs showed 
the absorption peaks of C-H stretching at 2938 and 2874 cm-1, while the two 
peaks at 1464 and 1458 cm-1 corresponded to the asymmetrical bending of 
CH3 and CH2, respectively. The presence of amine group were indicated by 
the N-H bending peaks at 1656 and 1556 cm-1, and the N-H out-of-plane 
bending peak at 696 cm-1 [322]. The N-H stretching band in the range of 3500-
3300 cm−1 was shown in a broader band from 3700-3000 cm-1 in combination 
with the stretching band of O-H. The characteristic absorption peaks of Si-O 
were shown at 1119 and 1038 cm-1 [323]. Other characteristic absorption 
peaks such as Si-C and C-O were also observed in the FTIR spectra of GS NP 
at 1201 and 1420 cm-1. For GS-SH NPs (Figure 3-3b) after thiolation reaction, 
the presence of the thiol group was confirmed by the absorption peak of 
disulphide bond (S-S) at 555 cm-1. For GS-NO NPs (Figure 3-3c), the 
appearance of the symmetric stretching peak of NO2 at 1385 cm-1 was 
 Chapter 3 Synthesis of GS-NO NPs 
- 78 - 
indicative of the successful reaction of GS-SH with NaNO2. However, the 
absorption peaks of S-NO was invisible due to the quick oxidation of NO. 
The presence of S-NO group in GS-NO was further confirmed by UV-
Vis spectroscopy (Figure 3-4). With reference to H2O, GS NPs (Figure 3-4a) 
did not show any characteristic peak in the range of 250-700 nm. Compared to 
GS NPs, GS-NO NPs (Figure 3-4b) showed absorption peaks at 340 and 537 
nm, corresponding to the maximum absorbance of S-NO in the UV and visible 
ranges, respectively. These have been assigned to the π → π* and nN → π* 
electronic transitions of the S-NO bond, respectively [209, 210]. Therefore, 
the successful RSNO modification of GS NP can be verified. 
The amount of relevant functional groups was quantified after each 
step of synthesis. The amount of -NH2 groups on GS NP surface was 
quantified to be 0.698 ± 0.126 mmol/g using AO7 assay. After modification 
with a 3-fold molar excess of Traut’s reagent, the amount of immobilised -SH 
groups was determined to be 0.160 ± 0.035 mmol/g using Ellman’s reaction. 
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Figure 3-3 FTIR spectra of (a) GS NPs, (b) GS-SH NPs and (c) GS-NO NPs  
 
Figure 3-4 UV-Vis spectra of (a) GS NPs and (b) GS-NO NPs 
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3.3.4 NO Release from GS-NO NPs 
The active NO molecules were rapidly oxidised to nitrite and/or nitrate 
by oxygen [324]. Therefore, the NO release characteristics of GS-NO NPs 
were evaluated in vitro by suspending GS-NO NPs in PBS at 37 °C and 
measuring the total amount of nitrite and nitrate contents in the suspension at 
different time points. By using the NO assay kit, the nitrates were reduced to 
nitrites first, and the nitrites were quantified via the chromogenic diazo 
reaction with Griess reagents [316], based on which the amount of NO release 
was determined. The NO release profiles of GS-NO NPs are shown in Figure 
3-5. The NO release from GS-NO NPs increased sharply during the first 2 h 
and then gradually levelled off. A gradual aggregation of GS-NO NPs was 
also observed during the study period. The NO release half-life was 
approximately 2 h, and the sustained release continued for 7 days before the 
concentration increase became undetectable. The total NO released from GS-
NO NPs over 7 days was 0.120 ± 0.006 µmol/mg.  
The cumulative NO release profile of GS-NO NPs was fitted to the 1st-
order exponential model (Eq. 3.2). As shown in Table 3-2, the 1st-order rate 
constant k for GS-NO NPs was calculated to be 0.06 ± 0.008 h-1. The initial 
rate IR for GS-NO NPs was calculated as the slope of the linear portion at the 
beginning of the release profile according to Eq. 3.3, which was 0.03 ± 0.001 
mol/(L·h).  
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Figure 3-5 NO release profiles from GS-NO NPs under physiological 
conditions (pH 7.4, 37 °C) in the dark for 7 days (n = 3) 
Table 3-2 1st-order rate constants (k) and initial rates (IR) of NO release from 
GS-NO NPs at 37 °C in the dark and from S-nitrosoglutathione aqueous 
solution 
 k (h-1) IR (mol/(L·h)) 
GS-NO 0.06 ± 0.008 0.03 ± 0.001 
S-nitrosoglutathione* 0.77 ± 0.016 0.01 ± 0.009 
* Values were adapted from [206] 
 
 
3.3.5 Cytotoxicity of GS-NO NPs 
To evaluate the cytotoxicity of GS-NO NPs, in vitro cytotoxicity test 
was conducted against L929 FBs. AlamarBlue® assay was used to evaluate the 
cell viability after exposure to the NP suspension for 1 and 7 days. The cell 
viability for GS and GS-NO NPs were expressed as the percentage of cell 
viability of the control group according to Eq. 3.4. As shown in Figure 3-6a, 
no obvious toxicity was observed after 1 day for either GS or GS-NO groups 
at concentrations up to 600 µg/mL. After 7 days (Figure 3-6b), no significant 
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toxicity was observed for either GS or GS-NO groups within the tested 
concentration range. Both GS and GS-NO groups showed a general increasing 
trend in cell viability with increased concentration of NPs. These results 
indicated that GS-NO NPs had negligible cytotoxicity within the tested 
concentration range up to 600 µg/mL. 
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Figure 3-6 Cytotoxicity of GS and GS-NO NPs against L929 FBs as 
measured using AlamarBlue® assay after (a) 1 day and (b) 7 days. Data were 
expressed as the percentage of control (assigned 100 %), where control 
represents cells cultured in the absence of NPs (n = 3) 
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3.3.6 AoSMC Cellular Responses to GS-NO NPs 
The proliferative response of AoSMCs to GS-NO NPs was examined 
by culturing the cells with GS-NO NPs at different concentrations and 
counting the cell number at different time points. As shown in Figure 3-7, the 
cell numbers of the GS-NO groups after 1 day were comparable to that of the 
control group, which was cultured with medium alone. After 3 days, cell 
cultured with 600 µg/mL GS-NO NPs showed approximately 19 % (p <0.01) 
decrease in cell number as compared to the control group. On day 7, the 
decrease in cell number for 600 µg/mL GS-NO NPs became more significant, 
reaching 40 % (p <0.001) of the cell number for the control group. There was 
also a significant difference (p <0.001) in cell number between 100 and 600 
µg/mL GS-NO groups on day 7. For 100 µg/mL GS-NO NPs, the cell number 
increased slowly over 7 days (p <0.05), while the cell number for 600 µg/mL 
GS-NO NPs kept decreasing. These results indicated that GS-NO NPs had an 
inhibitive effect on AoSMC proliferation, and the effect was in a 
concentration-dependent manner. 
The cellular uptake of GS and GS-NO NPs were examined by 
incubating AoSMCs with FITC-labelled NPs. As shown in Figure 3-8, both 
FITC-labelled GS and GS-NO NPs could be internalised into AoSMCs after 
culturing for 2 h. NP adhesion on the cell surface (red arrows) was also 
observed. 
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Figure 3-7 Proliferation of AoSMCs cultured with GS-NO NPs of various 
concentrations for 7 days. Data were expressed as the cell number countered 
from the CLSM images (n = 3; *** p <0.001; ** p <0.01; * p <0.05) 
 
Figure 3-8 Cellular uptake of (a) GS and (b) GS-NO NPs in AoSMCs after 2-
h cell culture with the FITC-labelled NPs (Red arrows: the NPs adhered on the 
cell membrane) 
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3.3.7 HUVEC Cellular Responses to GS-NO NPs 
The proliferative response of HUVECs to GS-NO NPs was 
investigated by culturing the cells with GS-NO NPs at different concentrations. 
WST-1 assay was used to examine the cell proliferation at different time 
points. The cell viability was expressed as the percentage of the control group, 
which was cultured with culture medium alone. As shown in Figure 3-9, the 
cell viability for GS-NO groups was 40-60 % of the control after culture for 1 
day. After 7 days, the cell viability of the group cultured with 100 µg/mL GS-
NO NPs significantly increased to approximately 190 % (p <0.05) of the 
control. The group cultured with 300 µg/mL GS-NO NPs had a slightly 
increase in cell viability to 78 % of the control whereas the one cultured with 
600 µg/mL GS-NO NPs remained a cell viability at 45 % of the control. The 
cell proliferation of HUVECs showed obvious dependence on the GS-NO NP 
concentration in the culture medium. Lower concentration of GS-NO NPs at 
100 µg/mL showed promotive effect on cell proliferation. The promotive 
effect diminished with increasing GS-NO concentration, and the cell 
proliferation ceased when cultured with 600 µg/mL GS-NO NPs. 
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Figure 3-9 Proliferation of HUVECs cultured with GS-NO NPs of various 
concentrations for 7 days. Data were expressed as the percentage of control 
(assigned 100 %), where control represents cells cultured in the absence of 
GS-NO NPs (n = 3; * p <0.05) 
3.4 Discussion 
In this work, a novel NO-releasing NP has been developed via RSNO 
functionalisation of inorganic gelatin-siloxane NPs. With an optimised reagent 
ratio, the synthesised GS-NO NPs were monodispersed with well controlled 
size and excellent aqueous stability. The size measured with DLS was larger 
than that determined from the FESEM images due to the presence of 
hydrodynamic interactions. It has been shown that DLS measurements were 
more accurate for soft materials like proteins whereas the size of dense 
materials was usually overestimated [321, 325]. The actual size of GS-NO 
NPs was approximately 200 nm in diameter, which was in the optimal size 
range for cellular uptake (100-200 nm) reported in literature [326]. The 
successful modification of GS NPs were confirmed by both instrumental 
characterisation and chemical assays. As FTIR characterisation could only 
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prove the successful thiolation and S-nitrosation indirectly with the 
characteristic peaks of S-S and NO2, UV-Vis spectroscopy characterisation 
was carried out to confirm the presence of S-NO group in GS-NO NPs with 
the characteristic peaks at 336 and 545 nm [327]. The relevant functional 
groups such as -NH2 and -SH were also quantified to determine the 
effectiveness of the reaction. Though a 3-fold molar excess of Traut’s reagent 
was used to ensure effective thiolation, the degree of thiolation of -NH2 groups 
determined by Ellman’s assay was 23 %. This was probably due to the intra- 
and/or inter-molecular S-S bond formation [328]. 
In vitro study of NO release from GS-NO NPs revealed that GS-NO 
NPs could spontaneously release NO under physiological conditions in the 
dark for 7 days. As a RSNO adduct, GS-NO NPs liberated NO from the 
thermal or photochemical decomposition via a homolytic cleavage of the S-
NO bond [188]. The decomposition reaction could be greatly accelerated by 
the presence of transition metal ions (Cu2+) [189]. To simplify the 
decomposition mechanism, the NO release study in this work was carried out 
in the dark, and DI water was used for PBS preparation to eliminate the 
presence of Cu2+. The overall decomposition followed Eq. 3.1, which could be 
divided into 2 reactions shown as Eqs. 3.5 and 3.6. The formation of S-S bond 
in Eq. 3.6 could happen on the same NP and in between different NPs, 
resulting in the aggregation of NPs observed during the NO release study.  
GS െ SNO	 → GS െ S∗ ൅ NO∗																																				Eq. 3.5 
GS െ S∗ ൅ GS െ S∗ → GS െ S െ S െ GS																											Eq. 3.6 
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By fitting the cumulative NO release profile of GS-NO NPs to the 1st-
order exponential model, the 1st-order rate constant and initial release rate for 
GS-NO NPs were determined to be 0.06 ± 0.008 h-1 and 0.03 ± 0.001 
mol/(L·h), respectively. Compared to another common NO-generating 
chemical S-nitrosoglutathione (Table 3-2), GS-NO NPs had a 3-fold higher 
initial NO-releasing rate in aqueous solution, while the 1st-order rate constant 
was approximately 13-fold smaller. These indicated that GS-NO NPs could 
release a large amount of NO in the beginning, and exhibited a stabilising 
effect throughout the decomposition period. The total amount of NO released 
from GS-NO NPs was 0.120 ± 0.006 µmol/mg. This capacity for NO was 
comparable or higher as compared to a few reported RSNO-modified 
polymers [209, 213] (Table 3-3). Though the total amount of NO released 
from GS-NO NPs was lower than some recently developed RSNO-modified 
NO-releasing NPs [310, 312], the NO release profile from GS-NO NPs was in 
accordance with those reported NO-releasing NPs. In addition, GS-NO NPs 
showed satisfactory NO-releasing properties with a combined consideration of 
the NO capacity and release period. 
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GS-NO NPs PBS/37 ~0.12 µmol/mg ~2 168 
S-nitrosoPC5-




µmol/mm2 ~7.5 48 
NO-releasing PLGA 
NPs [228] PBS/37 
~0.34 
µmol/mg ~1.2 6 
Iron oxide NPs [310] PBS/37 ~0.66 µmol/mg ~3.7 6.7 
NO-Releasing Silica 
NPs [311] PBS/37 
0.6 
µmol/mg ~3.5 30 
Fe3O4/Silica(−SNO) 
NPs [312] PBS/37 
1.34 
µmol/mg 16.9 50 
 
 
For materials to be useful as potential therapeutics, cytocompatibility is 
an essential requirement. A well-accepted method to determine the material 
cytocompatibility is to place the material in direct contact with FBs [329]. 
This method has also been applied to determine the cytotoxicity of NO-
releasing materials [213, 222, 330]. In this work, the cytotoxicity of GS and 
GS-NO NPs were evaluated within the concentration range of 100-600 μg/mL 
against L929 FBs. After culture for 1 day, no significant cytotoxicity was 
observed within the tested concentration range for GS or GS-NO NPs. After 
culturing for 7 days, GS and GS-NO groups of higher concentrations (500 and 
600 μg/mL) even showed a stronger cellular metabolic activity than the 
control group. This might be attributed to the silicon composition in the NP, 
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which has an enhancement effect on cell proliferation [331]. However, this 
increasing trend was in contrary with those reported previously that peptide- 
or DNA-modified GS NPs showed significant cytotoxicity against HeLa cells 
beyond a concentration of 300 μg/mL [235, 243]. This might be explained by 
the differences in the cell source tested and the substrate immobilised on the 
NP surface. Taken together the cytotoxicity evaluation results, it could be 
concluded that GS-NO NPs exhibited negligible cytotoxicity with the tested 
concentrations up to 600 μg/mL. 
As a potential therapeutic agent for post-surgery restenosis, one of the 
most important functions of NO is its inhibitory effect on vSMCs. In this work, 
GS-NO NPs were evaluated for their effects on AoSMC proliferation. It has 
been shown that GS-NO NPs inhibited AoSMC proliferation in a 
concentration-dependent manner. When cultured with 100 μg/mL GS-NO NPs, 
the cell number had significant increase over 7 days (p <0.05). However, the 
proliferation rate was slower than that of the control group, indicating an 
inhibitive effect of released NO on AoSMC proliferation. In contrast, cell 
culture with 600 μg/mL GS-NO NPs resulted in continuous decrease in the 
cell number of AoSMCs, implying the occurrence of AoSMC apoptosis. These 
findings were in consistent with those reported by Yu et al. [332] that 
exogenous NO donors induced vSMC apoptosis in a concentration- and time-
dependent manner. As NO reacted rapidly with oxygenated heme proteins to 
produce peroxynitrite, excessively high levels of NO could cause 
accumulation of peroxynitrite, which led to the release of cytochrome c from 
mitochondria, activation of caspases, and initiation of cell apoptosis [333]. It 
has also been demonstrated that the burst release of NO to high concentrations 
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(l M) would result in the reaction with superoxide to form a large quantity of 
reactive nitrogen species (RNS) that were more cytotoxic than NO [334]. In 
addition, high levels of RNS could cause depletion of reductive species such 
as glutathione, leading to programmed cell death [335]. This concentration-
dependent regulation of vSMC proliferation and apoptosis indicated the 
importance of controlled and sustained release of NO from NO-releasing 
materials. As cells dying by apoptosis could release basic fibroblast growth 
factor that elicited proliferation of vSMCs [336], vSMC apoptosis induced by 
excessive NO should be avoided. Therefore, low concentrations of GS-NO 
NPs at about 100 μg/mL were more useful to control the vSMC proliferation. 
It has been previously reported by Wang et al. [235] that peptide-
modified GS NPs could penetrate the cell membranes of HeLa cells via 
endocytosis. In this work, similar cellular uptake of GS-NO NPs was observed 
after culture with GS-NO NPs for 2 h. This might be an advantage of GS-NO 
NPs as NO donors since it provided another possible route to deliver NO to 
vSMCs before NO was released from the NP, avoiding undesirable loss of NO 
to the environment. Besides vSMCs, ECs might also benefit from the 
endocytosis of GS-NO NPs as it has been reported by Nishikawa et al. [337] 
that polysiloxane NPs could be endocytosed via caveolae in human aortic ECs, 
and enhanced the NO production from ECs by activating the endothelial nitric 
oxide synthase. 
While GS-NO NPs exhibited concentration-dependent inhibition of 
AoSMC proliferation, they also showed concentration-dependent regulation of 
HUVEC proliferation. Lower concentration of GS-NO NPs at 100 µg/mL 
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resulted in significant cell proliferation, and this promotive effect was 
weakened with increasing concentration. The cell proliferation appeared to 
cease when cultured with 600 µg/mL GS-NO NPs. These observations were in 
accordance with those reported by Brookes et al. [153] that low NO 
concentrations (10 nM to 1 μM) resulted in anti-apoptotic effects of ECs 
whereas high concentrations induce cell death. The NO-mediated protection 
from EC apoptosis was through the reduction of caspase 3-like protease 
activity and hence the inhibition of lipopolysaccharide-induced apoptosis 
[159]. This might also explain the decreased cell viability observed for all GS-
NO groups at day 1 as compared to the control as the NO release rate was high 
in the first 24 h (Figure 3-9), resulting in excessively high levels of NO to 
induce apoptosis. Considering together the cellular responses of AoSMCs and 
HUVECs, 100 µg/mL was a reasonable dose for GS-NO NPs to control the 
vSMC proliferation and promote EC proliferation. 
It has been suggested that an ideal NO-releasing material should not 
only be cost-effective and easy to apply, but also be capable for a sustained 
release over a therapeutically meaningful time period [229]. There were 
several properties of GS-NO NPs revealed in this work implying their 
considerable therapeutic promise for restenosis. The synthesis of GS-NO NPs 
was simple and straightforward without requiring the use of either complex 
NO-releasing chemicals or external loading of gaseous NO. Besides the 
excellent cytocompatibility, the NO release from GS-NO NPS could sustain 
over 7 days to prevent vSMC over-proliferation and promote EC growth. It 
has also been proven that NO flux could help to inhibit platelet adhesion and 
thrombus formation [338], which were important pathophysiological processes 
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involved in restenosis development. Due to the versatile chemistry of S-NO 
groups, it was possible to modulate the NO release rate of GS-NO NPs by 
means such as exposure to visible light. In addition, the cellular uptake of GS-
NO NPs within a short time enabled another possible route for NO delivery 
besides the free diffusion of released NO into cells (Scheme 3-2). As in the 
form of NPs, GS-NO NPs could also be easily applied locally or incorporated 
into other materials for enhanced release control, which further broadened the 
range of potential applications for GS-NO NPs. 
 
Scheme 3-2 Possible routes for NO delivery to target cells from GS-NO NPs. 
Route 1 represents the free diffusion of released NO from GS-NO NPs into 
target cells, and Route 2 represents the NO release from GS-NO NPs after 
they enter the target cells via endocytosis 
3.5 Summary 
In this work, a novel NO-releasing inorganic gelatin-siloxane NP, GS-
NO NP, has been developed as a new NO delivery vehicle via RSNO 
functionalisation. Results showed that GS-NO NPs could be synthesised from 
a simple and organic-solvent-free process. They were with a well-controlled 
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size of approximately 200 nm, and exhibited excellent aqueous stability. The 
NO release from GS-NO NPs could sustain for over 7 days for a total amount 
of 0.120 ± 0.006 µmol/mg NPs following a 1st-order exponential profile. 
While GS-NO NPs showed negligible cytotoxicity against FBs, they were able 
to regulate AoSMC and HUVEC proliferation in a concentration-dependent 
manner. A dose at 100 µg/mL of GS-NO NPs could slow down the AoSMC 
proliferation and promote the growth of HUVECs significantly. In addition, 
GS-NO NPs exhibited the ability to permeate the cell membrane within a short 
time, implying another possible route for NO delivery to target cells. These 
results demonstrated that GS-NO NPs could have potential in cardiovascular 
applications such as post-surgery restenosis prevention. Their capability to 
release NO in a controlled and sustainable manner might effectively inhibit the 
key processes such as vSMC over-proliferation involved in restenosis 
development.
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Chapter 4  
Properties of Physically Crosslinked Poly(vinyl 




Hydrogels have been extensively developed and applied in 
pharmaceutical and biomedical fields as controlled release materials for drugs 
and protein delivery, scaffolds that provides sufficient structural integrity in 
tissue engineering, and adhesives or barriers between tissue and material 
surfaces [339]. Poly(vinyl alcohol) (PVA) is one of the most important 
synthetic polymers used in many biomedical applications due to its excellent 
chemical stability, easy compactibility, high elasticity and good 
biocompatibility [340]. It has been studied as the material for soft contact 
lenses, artificial cartilage, and non-adhesive membranes [251, 252]. It has also 
been considered as a promising material for controlled release system due to 
its three-dimensional (3D) porous network structure [24, 25]. 
Despite the inherent inferior mechanical strength, the mechanical 
properties and water absorbability of PVA can be flexibly altered through 
physical or chemical crosslinking to meet the requirements of specific 
applications [255]. Chemical crosslinking of PVA is usually introduced via 
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ultraviolet (UV) or gamma irradiation in the presence of sensitisers or 
photoinitiators such as glutaraldehyde and acetaldehyde [341-343]. Physical 
crosslinking can be introduced using freezing-thawing (F/T) method, which 
involves repeated freezing and thawing processes. As reviewed in Section 
2.5.2.1, the mechanism of physical crosslinking introduced via F/T technique 
include the formation of intermolecular hydrogen bonding and polymer 
crystallites as well as the liquid-liquid phase separation of PVA from the 
solvent [278]. The properties of resultant crosslinked PVA hydrogels depend 
on the molecular weight of the uncrosslinked PVA, the solution concentration, 
and several parameters of the F/T process [277]. Compared to chemical 
crosslinking, F/T method has advantages such as no involvement of chemical 
agents, and no increase in the molar mass of PVA [261]. 
Freeze-thawed PVA (FT-PVA) hydrogels have been studied for 
different biomedical applications due to their biocompatibility and tailorable 
properties [255, 282]. As they can resemble the properties of natural tissues 
such as water content and elasticity, they have been used to develop soft tissue 
replacement devices such as cartilages and blood vessels [251, 283]. There has 
also been increasing interest in using FT-PVA hydrogels for localised drug 
delivery as their release behaviours can be tuned by varying the process 
parameters [285, 286]. Besides soluble drugs, drug-releasing nanoparticles 
(NPs) have also been incorporated into FT-PVA hydrogels [287, 344]. As for 
the controlled release of nitric oxide (NO), NO-releasing FT-PVA hydrogel 
has been reported by incorporating S-nitrosoglutathione (GSNO) as the 
additive into the hydrogel [212].  
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In Chapter 3, a novel NO-releasing gelatin-siloxane NP (GS-NO NP) 
has been developed for sustained release of NO. To make use of it for 
localised NO release in cardiovascular disease treatment, it is necessary to 
incorporate it into a host matrix. However, how the addition of NP affects the 
properties of the host material remains unclear. In this work, the potential of 
FT-PVA hydrogels as the host material for GS-NO NPs is studied, focusing on 
its property changes with NP addition. Gelatin-siloxane NPs (GS NPs) are 
used instead of GS-NO NPs as their physical properties are similar. It has been 
shown that the properties of GS NP-doped FT-PVA (FT-PVA/GS) hydrogels 
will not be compromised with GS NP addition in certain concentration range 
as compared to those of FT-PVA hydrogels. The feasibility of tuning the 
properties of FT-PVA/GS hydrogels is also demonstrated. 
4.2 Materials and Methods 
4.2.1 Materials 
PVA (MW = 145,000, >98 % hydrolysis) was purchased from Merck 
Schuchardt OHG. Petri dishes were bought from Nunc (Singapore). Other 
materials used were obtained as described in Section 3.2.1. 
4.2.2 Preparation of GS NPs 
The synthesis of GS NPs followed the description in Section 3.2.2. 
4.2.3 Preparation of FT-PVA/GS Hydrogels 
As shown in Scheme 4-1, 10 wt. % PVA aqueous solution was 
prepared by dissolving PVA in deionised (DI) water in 80 °C water bath for 3 
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h. After PVA solution was cooled down to 25 °C, GS NPs were added to PVA 
aqueous solution to make PVA/GS mixtures of various GS NP concentrations 
(25, 75 and 125 µg/ml). The PVA/GS mixtures were cast onto petri dishes, 
and subjected to different cycles (N = 1, 2 and 4) of freezing (-20 °C for 21 h) 
and thawing (25 °C for 3 h), to form hydrogel films of varying GS NP 
concentrations (FT-PVA/25GS, FT-PVA/75GS and FT-PVA/125GS) [345]. 
Freeze-thawed pure PVA hydrogels (FT-PVA) were used as controls. 
 
Scheme 4-1 Schematic illustration of the preparation of FT-PVA/GS 
hydrogels (Representative product: FT-PVA/125GS specimen subjected to 4 
F/T cycles) 
4.2.4 Swelling Test 
The hydrogel samples were cut into square shape (1 × 1 × 0.1 cm3). 
The samples was pre-weighed using an electronic mass balance (AB265-S 
Mettler Toldeo, Singapore), and then immersed in phosphate buffered saline 
solution (PBS, 1x) at 37 °C. At specific time points, the samples were taken 
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out and weighed after wiping the surface gently. The degree of swelling was 
calculated according to 
Degree	of	swelling	ሺDSሻ	% ൌ ௧ܹ െ ௜ܹ
௜ܹ
ൈ 100%																									Eq. 4.1 
where ௜ܹ and ௧ܹ are the initial weight and the weight at time t for the 
hydrogel samples, respectively [346]. The test was conducted for a total of 48 
h, and three samples were used for each group. 
4.2.5 Mechanical Properties 
The mechanical properties of FT-PVA and FT-PVA/GS hydrogels 
were examined via tensile and compressive tests conducted using a 
mechanical testing system (5500 MicroTester, Instron, USA) at 25 °C and 80 % 
humidity. Mechanical properties were determined from the stress-strain curve, 
where the strain under stress was defined as the percentage change in length 
relative to the initial length of the specimen. 
4.2.5.1 Tensile Test 
Hydrogel samples were cut into rectangular shapes (1 × 5 cm2), and 
their thickness was measured using a Digimatic Micrometer (APB-1D, 
Mitutoyo Corporation, Japan) at 4 random positions. Tensile test was 
conducted by the mechanical testing system with a load cell of 100 N, and a 
crosshead speed at 10 mm/min until failure. The tensile modulus was 
determined as the secant elastic modulus at 40 % strain by dividing the 
corresponding stress by the strain. The determination of yield stress and strain 
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was as shown in Scheme 4-2. The ultimate stress and strain were taken as the 
failure stress and strain. Four samples were used for each group. 
4.2.5.2 Compression Test 
Hydrogel samples were cut into square shapes (2 × 2 cm2), and their 
thickness was measured using the Digimatic Micrometer at 2 random positions. 
Compression test was conducted by the mechanical testing system with a load 
cell of 1 kN, and a compression rate of 0.5 mm/min until a load of 800 N was 
reached. The compressive modulus was determined as the tangent modulus at 
40 % strain. The compressive yield strength and strain were determined using 
the method shown in Scheme 4-2. Four samples were used for each group. 
 
Scheme 4-2 Schematic illustration of how to determine the yield stress and 
strain. The point chosen was vertically corresponded to the intersection point 
of the tangent lines of the initial and the rear linear portions of the stress-strain 
curve 
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4.2.6 Differential Scanning Caloriometry (DSC) 
DSC study was carried out using a Differential Scanning Calorimeter 
(Model 2910, TA Instruments, Singapore). 10 mg of air-dried sample placed 
in an aluminium pan was heated at a rate of 10 °C/min from 25 to 270 °C, and 
the temperature was held at 270 °C for 1 min before cooling down to 25 °C at 
a rate of 10 °C/min. Ambient air was used as the purge gas. The heat required 
to melt the sample (∆H) was determined by integrating the area under the 
melting peak. The degree of crystallinity was determined by dividing ∆H by 
the heat required for melting a 100 % crystalline PVA sample, which was 
138.6 J/g [347]. 
4.2.7 Field Emission Scanning Electron Microscopy (FESEM) 
The structure of the hydrogels experienced 2 and 4 F/T cycles were 
examined via FESEM (S-4300, Hitachi, Japan) following the description in 
Section 3.2.4.2. Prior to the examination, the hydrated hydrogel samples were 
freeze-dried, ruptured in liquid nitrogen, and sputter-coated with gold at 20 
mA for 30 s. 
4.2.8 Statistical Analysis 
Results were presented as mean ± standard deviation (SD) of the mean. 
Data analysis was performed on Prism 5 software. Statistical significance was 
determined by a two-tailed, unpaired student t-test. A value of p <0.05 was 
considered to be statistically significant. 
 Chapter 4 Freeze-thawed PVA with GS NPs 
- 103 - 
4.3 Results 
4.3.1 Swelling Behaviour of FT-PVA/GS Hydrogels 
The effects of NP addition on the swelling behaviour of FT-PVA 
hydrogels were studied in vitro. The DS was determined according to Eq. 4.1. 
Figure 4-1 illustrates the dynamic swelling behaviour of FT-PVA hydrogels 
subjected to different F/T cycles. All the FT-PVA hydrogels showed 
increasing DS in the first few hours. Once they reached the maximum DS after 
6-10 h, all the FT-PVA samples experienced continuous decrease in the DS 
until the end of the test. The time taken to reach the maximum DS decreased 
from approximately 10 (1 or 2 F/T cycles, Figures 4-1a and b) to 6 h (4 F/T 
cycles, Figure 4-1c) with increasing F/T cycles applied. For the same time 
point, there was a significant decrease in the DS with increasing F/T cycles 
applied (p <0.001).  
 
Figure 4-1 Dynamic swelling of FT-PVA hydrogels subjected to (a) 1 F/T 
cycle, (b) 2 F/T cycles and (c) 4 F/T cycles in PBS at 37 °C for a total of 48 h 
(n = 3) 
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The dynamic swelling behaviours of FT-PVA and FT-PVA/GS 
hydrogels subjected to different F/T cycles are shown in Figure 4-2. With 1 
F/T cycle applied (Figure 4-2a), the DS decreased with the addition of GS NPs 
as compared to that of the FT-PVA (p <0.01 for FT-PVA/25GS and FT-
PVA/75GS; p >0.05 for FT-PVA/125GS). However, the DS for FT-PVA/GS 
hydrogels increased with increasing concentration of GS NPs in the hydrogels, 
which could also be observed in Figures 4-2b and c. With 2 F/T cycles applied 
(Figure 4-2b), only FT-PVA/25GS showed significantly decreased DS (p 
<0.001) as compared to FT-PVA whilst FT-PVA/75GS and FT-PVA/125GS 
showed similar (FT-PVA/75GS) or higher (FT-PVA/125GS, p <0.05) DS as 
compared to FT-PVA. Similar swelling behaviours were also observed for 4 
F/T cycles (Figure 4-2c) except that the DS of FT-PVA/25GS became 
comparable to that of FT-PVA (p >0.05). 
There was a general trend observed in Figures 4-2a-c that the time 
taken to reach the maximum degree of swelling decreased from 6-10 h for FT-
PVA to 2-4 h for FT-PVA/GS hydrogels. For FT-PVA/GS hydrogels, the time 
required for the maximum degree of swelling decreased from approximately 4 
(1 and 2 F/T cycles) to 3 h (4 F/T cycles) with increased F/T cycles applied. 
Similar as that observed in Figure 4-1 for FT-PVA, a decrease in the DS with 
increasing F/T cycles applied was also observed across Figures 4-2a-c for FT-
PVA/GS hydrogels with the same NP concentration. 
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Figure 4-2 Dynamic swelling of FT-PVA and FT-PVA/GS hydrogels 
subjected to (a) 1 F/T cycle, (b) 2 F/T cycles and (c) 4 F/T cycles in PBS at 
37 °C for a total of 48 h (n = 3) 
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4.3.2 Mechanical Properties of FT-PVA/GS Hydrogels 
4.3.2.1 Tensile Properties 
The tensile properties of FT-PVA/GS hydrogels were determined from 
tensile test, and compared to those of FT-PVA hydrogels, to find out the 
effects of NP addition. Figure 4-3 shows the tensile stress-strain curves for 
FT-PVA and FT-PVA/125GS hydrogels subjected to different F/T cycles. 
Compared with the stress-strain curve of human coronary artery [348], FT-
PVA hydrogels showed similar curve pattern especially in the elastic 
deformation region and when more F/T cycles were applied (Figure 4-3a 
inset). The curves for both FT-PVA and FT-PVA/125GS hydrogels followed a 
typical stress-strain curve pattern for viscoelastic polymers. At the same 
tensile strain, the strength of the FT-PVA hydrogels was improved with 
increasing F/T cycles applied (Figure 4-3a). The same trend was also observed 
for FT-PVA/125GS hydrogels (Figure 4-3b). As the initial cross section of the 
stress-strain curves (0-40 % strain) approximately followed a linear 
relationship, the tensile modulus was determined as the secant elastic modulus 
at 40 % strain. 
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Figure 4-3 Representative tensile stress-strain curves for (a) FT-PVA and 
human coronary artery [348] (inset) and (b) FT-PVA/125GS hydrogels 
subjected to various F/T cycles  
Figure 4-4 represents the tensile modulus of FT-PVA and FT-PVA/GS 
hydrogels at 40 % strain. All the FT-PVA/GS hydrogels exhibited an 
increasing trend in tensile modulus with increasing F/T cycles applied. 
Moderate addition of GS NPs (FT-PVA/25GS and FT-PVA/75GS) resulted in 
higher tensile modulus than that of the FT-PVA subjected to the same F/T 
cycles (1.1-4.1 x increase, p <0.05). However, further increase of GS NP 
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concentration (FT-PVA/125GS) led to higher tensile modulus than that of FT-
PVA only when 1 F/T cycle was applied (0.8 x increase, p <0.01), and the 
modulus became lower than that of FT-PVA with 2 and 4 F/T cycles applied. 
 
Figure 4-4 Tensile modulus of FT-PVA and FT-PVA/GS hydrogels subjected 
to different F/T cycles. The tensile modulus was determined as the secant 
modulus at 40 % strain on the stress-strain curve. * represents the significant 
difference as compared to the tensile modulus of FT-PVA subjected to the 
same F/T cycles (n = 4; *** p <0.001; ** p <0.01; * p <0.05) 
The yield stress and strain of FT-PVA and FT-PVA/GS hydrogels 
were determine and presented in Figure 4-5a and b, respectively. Generally, 
FT-PVA and FT-PVA/GS samples exhibited higher yield stress and lower 
yield strain with more F/T cycles applied. FT-PVA/25GS showed significantly 
higher yield stress (0.6-1.5 x increase, p <0.01) as compared to FT-PVA. 
However, the increase in yield stress as compared to FT-PVA became smaller 
with increasing NP concentration and F/T cycles applied. FT-PVA/125GS 
exhibited significantly lower (p <0.05) yield stress as compared to FT-PVA 
subjected to the same F/T cycles. As shown in Figure 4-5b, the yield strain of 
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FT-PVA/GS hydrogels was generally lower than that of FT-PVA samples 
subjected to the same F/T cycles.  
Similar changes as those for the yield stress were observed for the 
ultimate stress (Figure 4-5c) except that the ultimate stress of FT-PVA became 
comparable with that of FT-PVA/25GS when subjected to 4 F/T cycles. The 
ultimate strain for FT-PVA/GS samples was generally lower than that of FT-
PVA (Figure 4-5d), and the difference became significant for samples 
subjected to 4 F/T cycles (p <0.05). 
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Figure 4-5 Tensile properties of FT-PVA and FT-PVA/GS hydrogels 
subjected to different F/T cycles: (a) yield stress, (b) yield strain, (c) ultimate 
stress and (d) ultimate strain. The ultimate stress and strain were determined as 
the stress and strain at fracture. * represents the significant difference as 
compared to the value of FT-PVA subjected to the same F/T cycles (n = 4; 
*** p <0.001; ** p <0.01; * p <0.05) 
4.3.2.2 Compressive Properties 
The compressive properties of FT-PVA/GS hydrogels were also 
determined and compared to those of FT-PVA hydrogels. Figure 4-6 presents 
the compressive stress-strain curves for FT-PVA and FT-PVA/125GS 
hydrogels subjected to different F/T cycles. The stress-strain curves for both 
FT-PVA and FT-PVA/125GS hydrogels followed a typical curve pattern for 
viscoelastic polymers. For FT-PVA hydrogels (Figure 4-6a), the compressive 
strength was improved with increasing F/T cycles applied at a fixed strain. 
The same trend was also observed for FT-PVA/125GS (Figure 4-6b). 
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Figure 4-6 Representative compressive stress-strain curves for (a) FT-PVA 
and (b) FT-PVA/125GS hydrogels subjected to various F/T cycles 
Figure 4-7 illustrates the compressive tangent modulus at 40 % strain 
for FT-PVA and FT-PVA/GS hydrogels subjected to different F/T cycles. 
There was a general trend for all the groups that the compressive tangent 
modulus increased with increasing F/T cycles applied. With 1 or 2 F/T cycles 
applied, FT-PVA/75GS showed significantly higher compressive modulus 
 Chapter 4 Freeze-thawed PVA with GS NPs 
- 113 - 
than FT-PVA subjected to the same F/T cycles (0.6-2.1 x increase, p <0.05) 
while FT-PVA/125GS showed the lowest compressive modulus. However, the 
increase in compressive modulus for FT-PVA/25GS and FT-PVA/75GS 
became smaller with more F/T cycles. After 4 F/T cycles, the compressive 
modulus of FT-PVA/25GS and FT-PVA/75GS became significantly lower 
than that of FT-PVA while that of FT-PVA/125GS was comparable. 
 
Figure 4-7 Compressive modulus of FT-PVA and FT-PVA/GS hydrogels 
subjected to different F/T cycles. The compressive modulus was determined as 
the tangent modulus at 40 % strain on the stress-strain curve. * represents the 
significant difference as compared to the compressive modulus of FT-PVA 
subjected to the same F/T cycles (n = 4; ** p <0.01; * p <0.05) 
The compressive yield stress and strain of FT-PVA and FT-PVA/GS 
hydrogels subjected to different F/T cycles were shown in Figure 4-8. All the 
groups followed an increasing trend in yield stress, and a decreasing trend in 
yield strain with increasing F/T cycles applied. While FT-PVA/75GS had 
comparable yield stress to FT-PVA regardless the F/T cycles (Figure 4-8a), 
FT-PVA/25GS showed significantly lower yield stress as compared to FT-
 Chapter 4 Freeze-thawed PVA with GS NPs 
- 114 - 
PVA when subjected to 4 F/T cycle (p <0.05). For FT-PVA/125GS, the yield 
stress was significantly lower than that of FT-PVA for 1 and 2 F/T cycles (p 
<0.05) whereas the value became comparable with 4 F/T cycles applied. With 
1 or 2 F/T cycles applied, FT-PVA exhibited higher yield strain as compared 
to FT-PVA/GS hydrogels (Figure 4-8b). However, FT-PVA/GS hydrogels had 
smaller decrease in yield strain with increasing F/T cycles applied, and 
exhibited higher yield strain than FT-PVA after 4 F/T cycles. 
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Figure 4-8 Compressive properties of FT-PVA and FT-PVA/GS hydrogels 
subjected to different F/T cycles: (a) compressive yield stress and (b) 
compressive yield strain. * represents the significant difference as compared to 
the value of FT-PVA subjected to the same F/T cycles (n = 4; *** p <0.001; 
** p <0.01; * p <0.05) 
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4.3.3 Crystallinity of FT-PVA/GS Hydrogels 
The crystallinity of FT-PVA and FT-PVA/GS hydrogels were 
determined from DSC test and shown in Table 4-1. For all the groups, the 
crystallinity increased with increasing F/T cycles applied. For FT-PVA/GS 
hydrogels, the crystallinity showed a decreasing trend with increasing GS NP 
concentration. With 1 or 2 F/T cycles applied, FT-PVA/25GS and FT-
PVA/75GS showed comparable crystallinity as compared to FT-PVA (p >0.05) 
whereas FT-PVA had significantly higher crystallinity with 4 F/T cycles 
applied (p <0.05). FT-PVA/125GS showed significant decrease in crystallinity 
(p <0.05) as compared to FT-PVA with more than 1 F/T cycle applied.  
Table 4-1 Crystallinity of FT-PVA and FT-PVA/GS hydrogels experienced 
different F/T cycles 
Number of F/T 
cycles 






1 33.2 ± 0.7 34.2 ± 0.6 34.0 ± 1.1 29.9 ± 1.0 
2 37.5 ± 0.6 36.0 ± 0.5 35.8 ± 0.8 30.8 ± 0.7 
4 43.9 ± 0.9 37.5 ± 0.6 37.1 ± 0.9 33.2 ± 1.1 
 
 
4.3.4 Structural Properties of FT-PVA/GS Hydrogels 
The effects of NP addition on the structural properties of FT-PVA/GS 
were studied by examining the fracture cross-sections of FT-PVA and FT-
PVA/GS hydrogels with 2 and 4 F/T cycles applied. As shown in Figure 4-9, 
all the groups showed generally a transformation from well-defined matrix 
with oval-shaped pores to irregular-shaped structure, with slightly larger pores 
with increasing F/T cycles applied. The PVA rich regions also became denser 
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with more F/T cycles. With the same F/T cycles applied, the pore size of FT-
PVA/GS hydrogels was generally smaller than that of FT-PVA, and the 
polymer-rich phase of FT-PVA/GS hydrogels was thicker. FT-PVA/25GS and 
FT-PVA/75GS had similar morphologies as FT-PVA whereas FT-
PVA/125GS showed obvious difference that the porous structure was much 
more nonuniform.  
 Chapter 4 Freeze-thawed PVA with GS NPs 
- 118 - 
 
Figure 4-9 FESEM images of the fractured cross-sections of FT-PVA and FT-
PVA/GS hydrogels subjected to 2 and 4 F/T cycles (scale bar = 10μm) 
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4.4 Discussion 
With the intention of using FT-PVA hydrogel as the host material for 
GS-NO NPs, the effects of NP addition to the hydrogel properties were 
investigated in this work. The properties of FT-PVA/GS hydrogels with 
different NP concentrations and F/T cycles applied were compared to those of 
FT-PVA hydrogels. For hydrogels, the DS was one of the most important 
parameters for evaluating the performance of hydrogels [349]. In this work, 
the swelling test using a gravimetric method revealed that both FT-PVA and 
FT-PVA/GS hydrogels exhibited lower DS with more F/T cycles applied. This 
observation was reasonable as the swelling characteristics of a network 
polymer depended upon the extent of crosslinking [346]. Increasing F/T cycles 
resulted in more crosslinking in the polymer so that there were fewer rubbery 
or partially rubbery contents available for solvent molecule penetration and 
polymer chain relaxation. With GS NP addition, the DS of FT-PVA/GS 
hydrogels subjected to 1 F/T cycle decreased as compared to that of FT-PVA 
hydrogels. This might be attributed to that that GS NPs acted as the 
crosslinking centres for the dangling chains, leading to higher crosslinking 
density than pure FT-PVA. This also helped to explain the shorter time taken 
to reach the maximum DS for FT-PVA/GS hydrogels. However, the addition 
of GS NPs also reduced the polymer mobility, disrupted the formation of 
intermolecular hydrogen bonding in the PVA matrix, and impeded the 
formation of crystalline domains, which together led to increased proportion 
of amorphous polymer that could be swollen with water [350, 351]. This 
explained the increase in DS with increasing GS NP concentration for FT-
PVA/GS hydrogels. As the formation of crystalline domains and hydrogen 
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bonding among PVA chains were much easier for FT-PVA hydrogels, the 
decrease in DS for FT-PVA with increasing F/T cycles applied was faster than 
FT-PVA/GS hydrogels. Therefore, comparable DS was observed for FT-PVA 
and FT-PVA/GS hydrogels with 4 F/T cycles applied. Once the maximum DS 
was reached, both FT-PVA and FT-PVA/GS samples exhibited de-swelling 
behaviour with decreasing DS until the end of the test. This might be 
attributed to the additional crystallisation during swelling at long times [259]. 
Moderate thermal treatment at 37 °C might also promote the growth of 
crystalline regions [352]. Taken together the swelling test results, the addition 
of GS NPs could promote the formation of physical crosslinking and hence, 
reduce the DS of FT-PVA/GS hydrogels and the time taken to reach the 
maximum DS. The most effective concentration tested in this work was 25 
µg/mL. However, these effects of GS NP addition became weaker with 
increasing GS NP concentration and/or increasing F/T cycles applied. 
For materials used for medical devices, the mechanical properties need 
to fulfil the requirement for specific application to guarantee the performance. 
In this work, the effects of GS NP addition on both the tensile and 
compressive properties of FT-PVA/GS hydrogels were studied. The 
mechanical test results proved that the addition of GS NPs would not affect 
the viscoelastic behaviours of FT-PVA/GS hydrogels. Both FT-PVA and FT-
PVA/GS hydrogels exhibited higher stiffness and tensile strength and lower 
strain with more F/T cycles applied due to the higher degree of crosslinking. 
This observation was consistent with the findings reported by Ricciardi et al. 
[353] that increasing F/T cycles applied led to the increase in mechanical 
properties due to more formation of physical crosslinking and closer bonding 
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of the polymers. The formation of crystallites with increasing F/T cycles 
applied also allowed the mechanical load to be distributed along the 3D 
structure [259]. For FT-PVA/GS hydrogels, the stiffness and strength 
decreased with increasing GS NP concentration. This might be attributed to 
the obstructive effects of GS NPs on the polymer chain mobility, and the 
subsequent crosslinking and crystalline formation among polymer chains. This 
change of mechanical properties as a function of NP concentration was 
inconsistent with the previous finding reported by Huang et al. [354] that the 
mechanical properties of a FT-PVA-based nanocomposites was improved with 
increasing addition of nano-sized clay platelets. This different finding was 
probably because the concentrations of the nano-sized clay platelets used in 
their study were much lower than those used in our study. As a result, the high 
density of crosslinking brought by the addition of nano-platelets was dominant 
in affecting the overall mechanical properties. Our tensile test results 
suggested that FT-PVA/GS hydrogels could have improved or comparable 
tensile properties to FT-PVA with moderation addition of GS NPs (25 or 75 
µg/mL). Further addition of GS NP with more F/T cycles applied would 
compromise the mechanical properties. 
Beside the tensile properties, the compressive properties of FT-
PVA/GS hydrogel were also evaluated as FT-PVA hydrogels have been 
widely studied as the scaffold material for applications such as artificial 
cartilages that are usually subjected to compressive forces [355]. Similar as 
observed for the tensile properties, the addition of GS NPs did not affect the 
viscoelastic behaviours of FT-PVA/GS hydrogels in their compressive 
properties. With increasing F/T cycles applied, FT-PVA/GS hydrogels showed 
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increased stiffness and compressive strength and decreased strain due to the 
formation of crosslinking. When subjected to 1 and 2 F/T cycles, FT-
PVA/75GS hydrogels exhibited higher stiffness than FT-PVA as a result of 
the balance in the promotion of crosslinking formation and obstruction of 
crystalline formation by the presence of GS NPs. However, the crosslinking 
among polymer chains and crystalline formation were easier for FT-PVA with 
increasing F/T cycles applied due to high polymer chain mobility. This 
explained the faster increase in the stiffness and compressive strength of FT-
PVA with increasing F/T cycles applied as compared to FT-PVA/GS 
hydrogels, and the highest stiffness exhibited by FT-PVA with 4 F/T cycles 
applied. The faster increase in the stiffness and compressive strength observed 
for FT-PVA/125 as compared to FT-PVA/25GS and FT-PVA/75GS might be 
explained that besides the crosslinking formation, high concentration of rigid 
GS NP might bear more compressive stress transferred from the PVA matrix 
[354]. From the compression test results, it could be concluded that moderate 
addition of GS NPs (25 or 75 µg/mL) could result in comparable or even 
enhanced compressive properties as compared to FT-PVA with 1 or 2 F/T 
cycles applied whereas high concentration of GS NPs in FT-PVA/GS required 
more F/T cycles to achieve similar properties as those of FT-PVA. 
For a polymer material, its crystallinity is one of the fundamental 
properties that affect many of the polymer properties such as the mechanical 
properties. In this work, the crystallinity of FT-PVA and FT-PVA/GS 
hydrogels were determined and compared in order to help explain the changes 
in their swelling behaviours and mechanical properties. For both FT-PVA and 
FT-PVA/GS hydrogels, the crystallinity increased with increasing F/T cycles 
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applied. This was in accordance with the finding previously reported by 
Simoes et al. [212] that increasing F/T cycles applied led to increased 
crystallinity of FT-PVA hydrogels due to the formation of crystallites in the 
structure. With increasing F/T cycles applied, the crystallinity of FT-PVA 
became higher than that of FT-PVA/GS hydrogels. This could be explained 
that the presence of GS NPs would cause the adsorption of PVA molecules 
onto GS NP surfaces, the tying of PVA chains due to crosslinking, and the 
disruption of hydrogen bonding among PVA chains, resulting in the inhibition 
of the polymer chain movement [356, 357]. The reduced polymer mobility 
prevented chain folding and crystallite formation, and contributed to the 
decrease in crystallinity of FT-PVA/GS hydrogels. This interference from GS 
NPs to the crystallite formation in PVA became stronger with increasing GS 
NP concentration. As a result, FT-PVA/125GS exhibited the lowest 
crystallinity. It has been suggested that the mechanical properties and water 
resistance of PVA hydrogels increased with increasing crystallinity [358]. 
Therefore, the low crystallinity of FT-PVA/125GS hydrogels could help to 
explain its highest DS and inferior tensile properties as compared to the other 
FT-PVA/GS groups with lower GS NP concentrations. However, the 
crystallinity was not the only factor in determining the mechanical properties 
of FT-PVA/GS hydrogel. Other factors such as the crosslinking induced by the 
presence of GS NPs and stress transfer from PVA matrix to rigid GS NPs 
should also be considered together when explaining their properties. 
The fractured cross-sections of FT-PVA and FT-PVA/GS hydrogels 
subjected to different F/T cycles were compared to study the direct effects of 
GS NP addition on the structure of the hydrogel. For both FT-PVA and FT-
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PVA/GS, the increase in pore size and the densification of polymer-rich 
regions with increasing F/T cycles applied were also observed previously in 
FT-PVA hydrogels [212]. These changes were probably attributed to the 
liquid-liquid phase separation induced by F/T cycles [278]. During successive 
F/T cycles, the growing ice crystals formed preferentially in the pores during 
the freezing process, and concentrated the polymer solution in regions 
between the ice crystals [359]. Upon thawing, the ice crystals melted, leaving 
pores of increased size. For FT-PVA hydrogels, the primary crystallites 
formed after the first F/T cycle acted as the crosslinking centres for dangling 
chains and the nuclei for the growth of secondary crystallite. The addition of 
GS NPs could provide more crosslinking centres and nuclei for crystallite 
growth at the beginning, resulting in smaller space for ice crystal formation. 
As a result, the pore size of FT-PVA/GS hydrogels was generally smaller and 
their polymer-rich phase was thicker than that of FT-PVA. On the other hand, 
the presence of GS NPs in high concentration might induce more random 
crosslinking in PVA matrix in the first F/T cycle, resulting in the formation of 
irregular-shaped pores and hence, the heterogeneity of the porous structure as 
observed for FT-PVA/125GS hydrogels. The non-uniform porous structure of 
FT-PVA/125GS might also be a factor in affecting the mechanical strength 
due to the nonuniform stress distribution.  
Considering together all the experimental findings in this work, the 
properties of FT-PVA hydrogels depended on several factors including the 
degree of crosslinking, the degree of crystallite formation, and the structure of 
the matrix. One way to enhance the overall properties of FT-PVA hydrogels 
was to apply more F/T cycles, which would result in more crosslinking and 
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crystallite formation. The addition of GS NP could provide more crosslinking 
centres for PVA molecules and more nuclei for crystallite formation, resulting 
in improved swelling and mechanical properties of FT-PVA/GS as compared 
to those of FT-PVA especially after 1 or 2 F/T cycles. However, the presence 
of GS NPs also reduced the mobility of PVA chains, inhibiting the 
intermolecular hydrogen bonding in PVA matrix and impeding the formation 
of crystalline domains. This impact became stronger with increasing GS NP 
concentration and/or increasing F/T cycles applied. Therefore, the overall 
effect of GS NP addition on the properties of FT-PVA hydrogels depended on 
the concentration of GS NP in the matrix, and the number of F/T cycles 
applied. As seen from the results, moderate addition of GS NPs (25 or 75 
µg/mL) could improve some properties of FT-PVA such as swelling 
behaviour and tensile strength, especially when 1 or 2 F/T cycles were applied. 
Meanwhile, with moderate GS NP addition, the other properties tested for FT-
PVA/GS could also be maintained comparable to those for pure FT-PVA 
hydrogels. The addition of GS NPs in higher concentration (125 µg/mL) 
would compromise the mechanical properties of FT-PVA hydrogels to some 
extent. However, some of the mechanical properties such as compressive 
strength might be compensated by applying more F/T cycles.  
The original intention of this study was to explore the potential of FT-
PVA hydrogels as the host material for the NO-releasing GS-NO NPs. Since 
GS-NO NPs had very similar properties as GS NPs, it was expected that the 
addition of GS-NO NPs would have similar effects on the properties of FT-
PVA hydrogels. Depending on the requirements for specific target 
applications, the properties of GS-NO NP-doped FT-PVA hydrogels could be 
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tuned by varying the doping of GS-NO NPs and the number of F/T cycles 
applied. 
4.5 Summary 
In this work, the potential of FT-PVA hydrogels as the host material 
for GS-NO NPs has been investigated, focusing on its property changes with 
NP addition. GS NPs were used instead of GS-NO NPs due to their similar 
properties. Results showed that with the presence of GS NPs, FT-PVA/GS 
hydrogels could have a lower degree of swelling and shorter time to reach the 
maximum swelling as compared to pure FT-PVA. FT-PVA/GS hydrogels 
could also exhibit higher stiffness and improved tensile and compressive 
strength. In addition, FT-PVA/GS hydrogels could achieve comparable 
crystallinity and structural properties as FT-PVA. The properties of FT-
PVA/GS hydrogels improved with increasing F/T cycles applied. However, 
the enhancing effects of GS NP on the hydrogel properties weakened with 
increasing GS NP concentration and/or increasing F/T cycles applied. Among 
the tested concentrations, moderate addition of GS NPs at 25 or 75 µg/mL 
could improve some of the properties of FT-PVA hydrogels without 
compromising the others especially when 1 or 2 F/T cycles were applied. It 
was expected that GS-NO NP-doped FT-PVA would show similar properties 
as those observed for FT-PVA/GS hydrogels. These results demonstrated that 
FT-PVA hydrogels might be suitable as the host material for GS-NO NPs 
dosed at moderate concentrations so that their hydrogel properties could be 
maintained or even improved. The properties of GS-NO NP-doped FT-PVA 
hydrogels might also be tuned by varying the doping amount of GS-NO NPs, 
 Chapter 4 Freeze-thawed PVA with GS NPs 
- 127 - 
and the number of F/T cycles applied to meet the requirements for specific 
applications. 
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Chapter 5  
Development of a Composite Controlled Release 
System of Nitric Oxide 
 
5.1 Introduction 
Nitric oxide (NO) has been considered with great potential as a 
therapeutic agent for many pathological conditions such as angina, 
hypertension, and post-surgery restenosis. Currently, clinical routes to deliver 
NO include inhalation [360], parenteral injection [361] and oral/sublingual 
administration [165]. However, there are also limitations with these 
approaches. Inhalation of NO requires complex equipment to handle the NO 
gas. Parenteral delivery may involve multiple injections to achieve therapeutic 
effects, raising the level of discomfort for the patients. For oral delivery, the 
bioactivity of the NO-generating drugs may be destroyed by the metabolism in 
the digestive system. In addition, prolonged administration of NO-generating 
drugs such as organic nitrates is often associated with the development of drug 
tolerance [191]. Therefore, localised delivery of NO in a sustained manner has 
become the focus in the development of NO-releasing materials.  
Due to the intrinsic short half-life of NO, different delivery platforms 
have been developed in a form of membranes, gels and nanoparticles (NPs) as 
reviewed in Section 2.4.5. Among these NO delivery platforms, NO-releasing 
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NPs have been of increasing interest, and tested in a variety of animal models 
and in human clinical trials with favourable results [362]. Depending on the 
target application, NO-releasing NPs can be produced with unique properties 
such as paramagnetism [310]. It is also possible to incorporate NO-releasing 
NPs into other host material to make the host material possess NO-releasing 
properties, or to achieve better controlled release property [36].  
For the prevention of post-surgery restenosis, there have been many 
reports on the development of NO-releasing polymeric coatings on currently 
in-use stents and vascular grafts [363-365]. Alternatively, NO-releasing 
polymeric membranes have also been developed as the material for synthetic 
vascular grafts [366]. However, very few studies have demonstrated the 
application of NO-releasing NPs in the modification of synthetic vascular 
grafts. In Chapter 4, it has been demonstrated the potential of using freeze-
thawed poly(vinyl alcohol) (FT-PVA) hydrogel as the host material for the 
NO-releasing S-nitrosothiol-modified gelatine-siloxane nanoparticle (GS-NO 
NP) without compromising the hydrogel properties. However, to be used as 
the material for synthetic vascular grafts, the mechanical strength of FT-PVA 
hydrogels determined in Chapter 4 is far away less than that required for a 
vascular graft [126]. There may also be a risk of blood leaking from FT-PVA 
hydrogels due to their porous structure.  
Poly(ε-caprolactone) (PCL) films have been investigated extensively as 
scaffolds for vascular tissue engineering (VTE) applications due to their 
excellent biocompatibility and unique prolonged biodegradation rates [367, 
368]. PCL films fabricated via simultaneous biaxial stretching (SBS) method 
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have been reported with high mechanical strength [289]. In this work, a 
composite system for controlled release of NO (PCL/PVA/GS-NO) has been 
developed by assembling GS-NO NP-incorporated PVA hydrogel and biaxial 
stretched PCL (µPCL) film using freezing-thawing (F/T) and electrospinning 
techniques. The integrated PCL/PVA/GS-NO composite system can possess 
not only more controlled NO release property as compared to freely suspended 
GS-NO NPs, but also improved mechanical properties as compared to single 
FT-PVA hydrogel release system. Its potential to be used as a material for 
synthetic vascular graft construction is also demonstrated. 
5.2 Materials and Methods 
5.2.1 Materials 
PCL (MW = 80,000), sodium hydroxide (NaOH), and dichloromethane 
(DCM) were purchased from Sigma-Aldrich (Singapore). Methanol was 
purchased from Merck (Singapore). Human aortic smooth muscle cells 
(AoSMCs, CC-2571), smooth muscle cell growth medium (SmGM-2) were 
obtained from Lonza (Singapore). Other materials used were obtained as 
described in Sections 3.2.1 and 4.2.1. 
5.2.2 Preparation of µPCL Films 
µPCL films were prepared according to the method previously 
reported by Tiaw et al. [289]. Briefly, PCL pellets were fed into a 2-roll mill, 
which was heated to 80 °C with a rolling speed of 1 rpm. The molten PCL was 
collected from the surface of the rolls to form solid mass. The PCL solid mass 
was then melt-pressed at 80 °C, 300 MPa with a home-made heat press 
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machine. The melt-pressed PCL films were cut into square shape (6 × 6 cm2), 
pre-heated to 58 °C in a temperature-controlled chamber, and subjected to 
SBS to acquire µPCL films. The µPCL films were cooled down and soaked in 
3 M NaOH aqueous solution for 20 h. The treated µPCL films were washed 
with deionised (DI) water thrice, and air-dried at 25 °C. 
5.2.3 Preparation of µPCL Films with Electrospun PCL Fibres (cPCL) 
PCL pellets were dissolved in DCM and methanol (7:3) to obtain a 12 
wt. % solution. The electrospinning setup consisted of a 10 ml syringe 
mounted on a syringe pump (KD Scientific, USA) with a blunt-ended 21 
Gauge syringe needle, a high voltage supplier (CZE 1000R, Spellman High 
Voltage Electronics Corporation, USA), and a ground aluminium plate 
collector. NaOH-treated µPCL films were stuck onto the ground aluminium 
plate to collect PCL fibres. The electrospinning process was carried out with 
an electric field of 15 kV, a tip-to-collector distance of 15 cm, and a solution 
feed rate of 3 mL/h for 1 h. The resultant cPCL films were vacuum-dried at 
25 °C to remove all solvents prior to use. 
5.2.4 Preparation of GS-NO NPs 
The synthesis of GS-NO NPs followed the description in Section 3.2.3. 
5.2.5 Preparation of PCL/PVA/GS-NO Composites 
The preparation steps for PCL/PVA/GS-NO composites were shown in 
Scheme 5-1. The preparation of PVA/GS-NO mixtures of various GS-NO NP 
concentrations (5 and 10 mg/ml) followed the description in Section 4.2.3, 
using 10 wt. % PVA aqueous solution. 0.5 ml PVA/GS-NO mixture was 
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uniformly cast on the fibrous side of the cPCL films (8 × 1 cm2). The 
composite was subjected to vacuum for 2 min followed by 2 cycles of freezing 
(-20 °C for 2.5 h) and thawing (25 °C for 0.5 h), to form the composite 
systems of varying GS-NO NP concentrations (PCL/PVA/5GS-NO and 
PCL/PVA/10GS-NO). The composites with pure PVA hydrogel layer 
(PCL/PVA) were used as controls. 
 
Scheme 5-1 Schematic illustration of the preparation of PCL/PVA/GS-NO 
composites (Representative product: PCL/PVA/5GS-NO specimen) 
5.2.6 Differential Scanning Caloriometry (DSC) 
DSC study was carried out using a Differential Scanning Calorimeter 
(Model 2910, TA Instruments, Singapore), and followed the description in 
Section 4.2.6. 
5.2.7 Water Contact Angle (WCA) 
The change of surface hydrophilicity after each step of the assembly 
was evaluated by WCA measurement using a video contact angle system 
(VCA2000, Advanced Surface Technologies, USA). A drop of 3 μL DI water 
was dispensed from the syringe and transferred onto the sample surface. The 
2 F/T cycles
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WCA was measured 10 s after the drop dispersion for full drop development. 
Three samples were used for each group. 
5.2.8 Morphological Characterisation 
5.2.8.1 Field Emission Scanning Electron Microscopy (FESEM) 
The morphology of µPCL, cPCL, PCL/PVA and PCL/PVA/GS-NO 
composites was examined via FESEM (S-4300, Hitachi, Japan). Prior to the 
examination, cPCL and freeze-dried PCL/PVA/GS-NO samples were ruptured 
in liquid nitrogen, and all the samples were sputter-coated with gold at 20 mA 
for 30 s. Images were taken at an accelerating voltage of 7 kV. 
5.2.8.2 Confocal Laser Scanning Microscopy (CLSM) 
The distribution of GS-NO NPs within the PCL/PVA/GS-NO 
composite system was evaluated by using FITC-labelled GS-NO NPs in the 
preparation of PCL/PVA/10GS-NO composites. FITC-labelled GS-NO NPs 
were prepared according to the description in Section 3.2.9.2. The distribution 
of FITC-labelled GS-NO NPs was visualised using CLSM (FV1000, Olympus, 
Japan). 
5.2.9 Swelling Test 
The swelling behaviour of the PCL/PVA/GS-NO composite was 
studied via the swelling test. The sample preparation and test procedure 
followed the description in Section 4.2.4. The degree of swelling (DS) was 
determined according to  
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Degree	of	swelling	ሺDSሻ% ൌ ௚ܹ௧ െ ௚ܹ௜
௚ܹ௜
ൈ 100%																		۳ܙ.	5-1 
where ௚ܹ௜ and ௚ܹ௧ are the initial weight and the weight at time t for 
the hydrogel portion of the composites, respectively. PCL/PVA composites 
were used as controls, and three samples were used for each group. 
5.2.10 Tensile Test 
The mechanical properties of µPCL, cPCL and PCL/PVA/GS-NO 
composites were examined via tensile test conducted using a mechanical 
testing system (5500 MicroTester, Instron, USA) at 25 °C and 80 % humidity. 
The mechanical properties were determined from the stress-strain curve, 
where the strain under stress was defined as the percentage change in length 
relative to the initial length of the specimen. The sample preparation and 
tensile test parameters followed the description in Section 4.2.5.1. The 
Young’s Modulus was determined as the slope of the initial linear part of the 
stress-strain curve. The yield stress and strain were determined with an offset-
strain of 0.005. Ultimate stress and strain were taken as the values at sample 
failure. Four samples were used for each group. 
5.2.11 Release Kinetics of NO from PCL/PVA/GS-NO Composites 
The NO release profile from PCL/PVA/5GS-NO composites was 
determined in vitro following the description in Section 3.2.6. 
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5.2.12 Statistical Analysis 
Results were presented as mean ± standard deviation (SD) of the mean. 
Data analysis was performed on Prism 5 software. Statistical significance was 
determined by a two-tailed, unpaired student t-test. A value of p <0.05 was 
considered to be statistically significant. 
5.3 Results 
5.3.1 Assembly of PCL/PVA/GS-NO Composites 
PCL/PVA/GS-NO composites were produced by assembling three 
components: µPCL film, electrospun PCL fibrous matrix and GS-NO NP-
containing PVA hydrogel. The assembly was carried out via physical 
processes. Electrospun PCL fibres adhered to the surface of NaOH-treated 
µPCL due to the residue solvent in the fibres and consequent local dissolution 
of µPCL, forming joints between PCL fibres and µPCL [369]. The PCL 
fibrous matrix formed by randomly electrospun PCL fibres via van der Waals 
forces and crosslinking between fibres by residue solvent [370]. The capture 
of the PVA/GS-NO hydrogel layer in the PCL fibrous matrix was through van 
der Waals forces, the physical crosslinking of PVA within the matrix induced 
by F/T cycles, and intra- and inter-molecular hydrogen bonding [371].  
Figure 5-1 shows the DSC curves for each individual material before 
assembly and the composites formed after assembly. NaOH-treated µPCL 
(Figure 5-1a) and electrospun PCL fibres (Figure 5-1b) exhibited slightly 
different melting peaks and melting temperatures due to the different 
processing techniques used for PCL. By assembling them together, the 
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resultant cPCL (Figure 5-1c) exhibited a melting peak shifted to the middle of 
those for NaOH-treated µPCL and electrospun PCL fibres, and a melting 
temperature (61.5 °C) in-between the values of those two individual materials. 
Pure FT-PVA subjected to 2 F/T cycles (Figure 5-1d) exhibited a single 
melting peak at around 228.5 °C. After the integration of cPCL, PVA and GS-
NO NPs, the resultant PCL/PVA/5GS-NO (Figure 5-1e) showed two melting 
peaks around 61.5 and 229.5 °C, corresponding to that of cPCL and FT-PVA, 
respectively. The widths of both peaks were similar as that observed for each 
individual material, implying no interference between materials in their 
composition. The addition of GS-NO NPs did not show obvious influence in 
the melting behaviour of cPCL, but resulted in a slight increase of the melting 
temperature of FT-PVA portion in the composite. 
 
Figure 5-1 Representative DSC curve for (a) NaOH-treated µPCL, (b) 
electrospun PCL fibres, (c) cPCL, (d) FT-PVA subjected to 2 F/T cycles and 
(e) PCL/PVA/5GS-NO subjected to 2 F/T cycles 
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5.3.2 Surface Hydrophilicity of PCL/PVA/GS-NO Composites 
The change in the material surface hydrophilicity after each step of the 
assembly was determined via WCA measurement. As shown in Figure 5-2, 
NaOH-treated µPCL films showed a WCA of 60.5 ± 4.1 °, which significantly 
increased to 133.5 ± 1.0 ° (p <0.001) after a layer of electrospun PCL fibres 
was deposited on the film. Once a layer of PVA was applied to the PCL 
fibrous matrix and subjected to 2 F/T cycles, the WCA decreased significantly 
to 34.5 ± 4.5 ° (p <0.001). Compared with PCL/PVA composites, the addition 
of GS-NO NPs in PVA matrix led to a significant increase in WCA, and the 
increase became larger with increasing GS-NO NP concentration.  
 
Figure 5-2 Change in the material surface hydrophilicity after each step of the 
assembly (n = 3; *** p <0.001; * p <0.05) 
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5.3.3 Morphological Properties of PCL/PVA/GS-NO Composites 
During the development of PCL/PVA/GS-NO composites, the 
morphological and structural changes of the materials were examined via 
FESEM, to determine the effects of the modification or processing carried out 
in each step of the assembly. In the preparation of μPCL films, the surface 
roughness of μPCL films with NaOH treatment for 20 h (Figure 5-3b) 
increased obviously as compared to the original surface (Figure 5-3a) due to 
the hydrolysis reaction. As shown in Figure 5-3c and d, smooth PCL fibres 
were produced from the electrospinning process, and deposited randomly on 
the surface of µPCL to form the fibrous matrix. The average thickness of the 
fibrous matrix formed after electrospinning for 1 h was measured from 
FESEM images to be 68.8 ± 2.6 µm (n = 20). The effect of 2-min vacuum 
treatment after applying the PVA solution on the fibrous side of the cPCL was 
evaluated by comparing Figure 5-3e and f. Without vacuum treatment, PVA 
solution only diffused into part of the PCL fibrous matrix as a clear edge of 
the PVA layer was observed in Figure 5-3e (red arrows). In contrast, complete 
diffusion of PVA throughout the PCL fibrous matrix was observed after 
vacuum treatment for 2 min (Figure 5-3f), and an integrated matrix of PVA 
and PCL fibres formed upon 2 F/T cycles. 
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Figure 5-3 FESEM images of (a) µPCL, (b) NaOH-treated µPCL, (c) 
electrospun PCL fibres on cPCL, (d) cPCL, (e) PCL/PVA without vacuum 
treatment and (f) PCL/PVA with vacuum treatment. (Red arrows: the edge of 
the PVA layer penetrated into PCL fibrous matrix; scale bar = 50 µm) 
The morphologies of integrated PCL/PVA/GS-NO composites with 
different GS-NO NP concentrations were examined and shown in Figure 5-4a-
d. Dense PVA/GS-NO layer integrated with PCL fibrous matrix was observed 
(Figure 5-4a and c), which was jointed to the µPCL membrane via the fibrous 
layer. Magnified images of the PVA/GS-NO layer (Figure 5-4b and d) showed 
the distribution of GS-NO NPs within the PVA matrix around the edges of the 
pores (red arrows). GS-NO NP distribution within the hydrated composites 
was examined by using FITC-labelled GS-NO NPs. As shown in Figure 5-4e, 
GS-NO NPs were distributed uniformly within the hydrogel layer of the 
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PCL/PVA/10GS-NO composite. The distribution of electrospun PCL fibres 
(white arrows in Figure 5-4e) could also be observed in the hydrated hydrogel 
layer, indicating the integration of PVA and PCL fibrous matrix.  
 
Figure 5-4 Morphology of PCL/PVA/GS-NO composites with different GS-
NO NP concentrations: (a, b) FESEM images of the cross-sections of 
PCL/PVA/5GS-NO, (c, d) FESEM images of the cross-sections of 
PCL/PVA/10GS-NO and (e) CLSM image of the cross-section of hydrated 
PCL/PVA/5GS-NO (Red arrows: GS-NO NPs; white arrows: electrospun PCL 
fibres; scale bar = 100 μm for a and c, 10 μm for b and d, and 500 μm for e) 
  
µPCL
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5.3.4 Swelling Behaviour of PCL/PVA/GS-NO Composites 
The dynamic swelling behaviour of PCL/PVA/GS-NO composites was 
studied in vitro. The DS was determined according to Eq. 5.1 accounting only 
the weight change in the hydrogel portion of the composite. Figure 5-5 
illustrates the dynamic swelling behaviour of PCL/PVA and PCL/PVA/GS-
NO composites subjected to 2 F/T cycles. PCL/PVA/GS-NO composites 
showed similar swelling behaviour as PCL/PVA composites. Both PCL/PVA 
and PCL/PVA/GS-NO composites reached the maximum degree of swelling 
after 1 h, and the DS decreased continuously until the end of the test. 
PCL/PVA/10GS-NO composites had slightly higher DS (p >0.05) than 
PCL/PVA/5GS-NO.  
 
Figure 5-5 Dynamic swelling of (a) PCL/PVA, (b) PCL/PVA/5GS-NO and (c) 
PCL/PVA/10GS-NO composites subjected to 2 F/T cycles in PBS at 37 °C for 
a total of 48 h (n = 3) 
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5.3.5 Mechanical Properties of PCL/PVA/GS-NO Composites 
The tensile properties of the composite after each step of the assembly 
and the resultant PCL/PVA and PCL/PVA-GS-NO composites were 
determined from tensile test and compared. The composites showed stable 
bonding between the µPCL film and the integrated fibre and hydrogel layer as 
no detachment between layers was observed throughout the test. Figure 5-6 
shows the representative tensile stress-strain curves for the components in the 
composite and the integrated PCL/PVA and PCL/PVA-GS-NO composites. 
Generally, all the curves followed a stress-strain curve pattern for elastomer 
with an initial elastic deformation zone and following plastic deformation zone. 
NaOH-treated µPCL films (Figure 5-6a) showed obviously stronger 
mechanical properties as compared to the others. The stress-strain curve of 
cPCL (Figure 5-6c) exhibited a combined shape of those for NaOH-treated 
µPCL and electrospun PCL fibres (Figure 5-6b). With the assembly of the 
hydrogel layer, the integrated composites (Figure 5-6d-f) showed further 
decreased mechanical strength as compared to that of cPCL.  
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Figure 5-6 Representative tensile stress-strain curves for (a) NaOH-treated 
µPCL, (b) electrospun PCL fibres, (c) cPCL, (d) PCL/PVA, (e) 
PCL/PVA/5GS-NO and (f) PCL/PVA/10GS-NO 
Table 5-1 summarises the mechanical properties of the components 
and integrated composites determined from the stress-strain curves. With a 
layer of electrospun PCL fibres (approximately 70 µm thick), cPCL showed 
decreased mechanical properties as compared to NaOH-treated µPCL in 
Young’s Modulus (0.8 x decrease, p <0.001), yield stress (0.8 x decrease, p 
<0.001) and ultimate stress (0.8 x decrease, p <0.01), but increased yield strain 
(0.2 x increase, p <0.05; Table 5-1). Once the hydrogel layer was assembled to 
cPCL, the mechanical properties of the resultant PVA/PCL or PCL/PVA/GS-
NO composites decreased as compared to cPCL in Young’s Modulus (0.5-0.6 
x decrease, p <0.05), yield stress (0.5-0.7 x decrease, p <0.05) and ultimate 
stress (0.6-0.7 x decrease, p <0.05; Table 5-1). PCL/PVA/GS-NO composites 
also had a significant decrease in yield strain (0.3-0.6 x decrease, p <0.05) as 
compared to cPCL. Comparing the PCL/PVA and PCL/PVA/GS-NO 
composites, the addition of GS-NO NPs at 5 mg/mL resulted in an increase in 
 Chapter 5 PCL/PVA/GS-NO Composites 
- 144 - 
Young’s Modulus (0.4 x increase, p <0.01), yield stress (0.6 x, p <0.05) and a 
decrease in ultimate strain (0.2 x decrease, p <0.01; Table 5-1) as compared to 
PCL/PVA. The addition of GS-NO at 10 mg/mL led to similar mechanical 
properties as compared to PCL/PVA except a decrease in yield strain (0.5 x 
decrease, p <0.01; Table 5-1). For PCL/PVA/GS-NO composites, 
PCL/PVA/5GS-NO showed stronger mechanical properties than 
PCL/PVA/10GS-NO in Young’s Modulus (1.4 x, p <0.005) and yield stress 
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Yield stress  
(MPa) 








NaOH-treated µPCL 16.9 ± 2.1 118.1 ± 9.4 2.1 ± 0.2 2.0 ± 0.1 20.0 ± 0.5 234.2 ± 9.9 -- 
Electrospun PCL fibresª 112.7 ± 9.5 11.4 ± 2.2 0.4 ± 0.1 3.9 ± 0.5 3.1 ± 0.4 155.6 ± 6.8 -- 
cPCL 86.3 ± 11.0 23.3 ± 2.0 0.4 ± 0.1 2.4 ± 0.2 3.3 ± 0.4 244.8 ± 21.2 -- 
FT-PVA/GSb 1154 ± 103 0.1 ± 0.0 0.04 ± 0.0 36.5 ± 2.1 0.4 ± 0.1 202.5 ± 37.5 -- 
PCL/PVA 217.7 ± 13.0 8.7 ± 0.7 0.1 ± 0.0 2.1 ± 0.1 1.1 ± 0.2 226.5 ± 29.5 -- 
PCL/PVA/5GS-NO 198.3 ± 17.6 12.4 ± 0.9 0.2 ± 0.0 1.7 ± 0.3 1.3 ± 0.2 166.0 ± 21.0 99.9 ± 2.8 
PCL/PVA/10GS-NO 206.3 ± 23.0 8.5 ± 1.1 0.1 ± 0.0 1.0 ± 0.2 1.0 ± 0.2 228.4 ± 16.1 48.3 ± 3.1 
ª Films of electrospun PCL fibres were prepared by electrospinning for 1.5 h with ground aluminium plate collector 
b Values were taken as those for FT-PVA/GS with 0.025 mg/mL GS NPs subjected to 2 F/T cycles (21 h freezing and 3 h thawing) 
* Values were calculated assuming a vascular graft based on single film-layer with a radius of 2.3 mm
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5.3.6 NO Release from PCL/PVA/GS-NO Composites 
As NO molecules were rapidly oxidised to nitrite and/or nitrate by 
oxygen [324], the NO release from PCL/PVA/GS-NO composites were 
evaluated in vitro by immersing PCL/PVA/GS-NO in PBS at 37 °C, and 
measuring the total amount of nitrite and nitrate contents in the suspension at 
different time points. The NO release profiles for PCL/PVA/5GS-NO 
composites and GS-NO NPs are shown in Figure 5-7. By averaging the 
amount of NO released to the amount of GS-NO NPs incorporated in the 
composite, the total amount of NO released from PCL/PVA/5GS-NO 
composites was 1.20 µmol/mg, which was the same as determined for GS-NO 
NPs. PCL/PVA/5GS-NO composites (Figure 5-7a) showed a slower and 
prolonged NO release profile as compared to freely suspended GS-NO NPs 
(Figure 5-7b). The half-life of NO release increased from approximately 2 h 
(ݐ′଴.ହ) for GS-NO NPs to 16 h (ݐ଴.ହ) for PCL/PVA/5GS-NO composites. The 
NO release time was also extended from 7 to 40 days.  
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Figure 5-7 NO release profiles from (a) PCL/PVA/5GS-NO composites and 
(b) GS-NO NPs under physiological conditions (pH 7.4, 37 °C) in the dark. 
The cumulative NO release from PCL/PVA/5GS-NO composites is averaged 
to the amount of GS-NO NPs incorporated. ݐ଴.ହ and ݐ′଴.ହ denote the half-life of 
NO release from PCL/PVA/5GS-NO and GS-NO NPs, respectively (n = 3) 
5.4 Discussion 
In this work, a composite controlled release system of NO was 
developed by assembling incompatible polymeric film and hydrogel via 
physical processes. The resultant PCL/PVA/GS-NO composite was composed 
of three major components: the µPCL film in providing mechanical support, 
PVA hydrogel in providing controlled release properties, and GS-NO NPs 
capable of generating NO. The 3D porous electrospun PCL matrix was used to 
capture the PVA/GS-NO mixture, and bond them to the µPCL film. With the 
aid of vacuum treatment, PVA/GS-NO mixture could diffuse over the entire 
PCL fibrous matrix, and formed an integrated fibre-hydrogel layer with PCL 
fibres upon F/T cycles via interpenetrating crosslinking network. As all the 
methods used for the integration were physical processes, the composition for 
each individual component was intact, which was confirmed by DSC study as 
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the changes in material composition and structure could be reflected in the 
melting behaviour [372]. Obvious change in the material surface 
hydrophilicity after each step of the assembly was also revealed by WCA 
measurement, indicating the stacking of different material layers. The addition 
of GS-NO NPs in PVA led to an increase in WCA as compared to PCL/PVA, 
which could be attributed to the higher crosslinking density of PVA as the 
presence of GS-NO NPs provided more crosslinking centres [373]. However, 
similar swelling behaviours of PCL/PVA and PCL/PVA/GS-NO composites 
did not reflect the higher crosslinking density induced by the presence of GS-
NO NPs. This implied that the electrospun PCL matrix capturing the hydrogel 
might be dominant in controlling the swelling behaviour of the composites. 
µPCL films were applied in the design of the composite system to 
improve the integrity and mechanical properties of the composites. In this 
work, µPCL films were treated with NaOH for 20 h to increase the surface 
roughness. Both surface and bulk erosions of µPCL films took place due to the 
ester hydrolysis of PCL promoted by basic NaOH. Due to the semicrystalline 
nature of PCL, the amorphous portion of µPCL films reacted faster than the 
crystalline portions, revealing the crystallites on the film surface as observed 
in Figure 5-3b. It was observed during electrospinning that NaOH-treated 
µPCL films led to more electrospun PCL fibre deposition on the film surface 
with a uniform distribution as compared to non-treated µPCL. This could be 
explained that the revealed crystallites on the film surface provided more sites 
for the attachment of electrospun PCL fibres.  
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On the other hand, the hydrolysis of µPCL film also compensated the 
mechanical properties of the film, resulting in obvious lower mechanical 
strength of NaOH-treated µPCL as compared to the previously reported values 
for µPCL films [289]. With the integration of electrospun PCL fibres and PVA 
hydrogel, the mechanical properties further decreased due to the inferior 
properties of these two materials. In order to minimise the thermal 
decomposition of GS-NO NPs during the F/T cycles, 2 F/T cycles with shorter 
F/T time (2.5 h freezing and 0.5 h thawing) were applied as compared to that 
used in Chapter 4 (21 h freezing and 3 h thawing). This would result in poorer 
mechanical strength of the hydrogel as shorter F/T time limited the formation 
of ice crystals during freezing and the movement of polymer chain during 
thawing to form crosslinking and crystallite [277]. The thickness of the 
integrated fibre-hydrogel layer was approximately 10-fold of that of the 
NaOH-treated µPCL film. However, the integration of NaOH-treated µPCL 
film still led to significantly improved mechanical properties of 
PCL/PVA/GS-NO composites in Young’s Modulus (85-124 x), yield stress 
(2.5-5 x) and ultimate stress (2.5-3.1 x) as compared to the highest strength 
determined in Chapter 4 for FT-PVA/GS hydrogels subjected to 2 F/T cycles, 
which was even with less GS NP addition and longer F/T time. The ductility 
was not compromised as observed in the ultimate strains for PCL/PVA/GS-
NO and FT-PVA/GS (Table 5-1). In addition, the bonding between NaOH-
treated µPCL film and the fibre-hydrogel layer via PCL fibres remained stable 
as no detachment was observed during the tensile test until sample failure. 
This was in agreement with the previously reported strong attachment between 
electrospun PCL nanofibres and underlying PCL films [369]. These results 
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proved that NaOH-treated µPCL films could be well integrated to the NO-
releasing hydrogels via fibrous matrix, to enhance their mechanical properties.  
As a controlled release system of NO, the primary goal to achieve for 
PCL/PVA/GS-NO composite was slower and longer NO release than freely 
suspended GS-NO NPs. In vitro NO release study revealed that 
PCL/PVA/5GS-NO composites could release the same total amount of NO at 
a slower rate in the beginning for a much longer time than GS-NO NPs. The 
half-life of NO release was also extended from 2 to 16 h. This improved NO 
release property might be attributed to the protective effect of the integrated 
fibre-hydrogel matrix. Although it has been generally assumed that S-
nitrosothiols (RSNOs) decomposed by thermal homolytic cleavage of the S-N 
bond, it has not been tested effectively under physiologically relevant 
conditions [188, 374]. Other decomposition mechanisms of RSNOs such as 
photolytic [375] and transition metal ion-dependent breakdown [376] have 
been well established. The encapsulation of GS-NO NPs by the fibre-hydrogel 
matrix protected GS-NO NPs from the trace transition metal ions presenting in 
PBS, which could stimulate the catalytic breakdown of RSNOs. The scattering 
of GS-NO NPs in the fibre-hydrogel matrix also prevented local high 
concentration of GS-NO NPs as it has been shown RSNO dimerization 
between the decomposition product and authentic RSNO would accelerate the 
RSNO decomposition reaction. In addition, the intermolecular hydrogen 
interaction between GS-NO NPs, PCL and PVA might also help to stabilise 
the S-N bond [211]. Though the NO release from PCL/PVA/GS-NO was a 
reaction-diffusion process, it was difficult to use a theoretical model to 
describe the release behaviour due to the complex structure of the fibre-
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hydrogel matrix and complicated GS-NO NP decomposition mechanism 
affected by the fibre-hydrogel. Nonetheless, it was proven by the release study 
that the incorporation of GS-NO NPs into the fibre-hydrogel matrix could 
effectively improve the NO release property of GS-NO NPs. 
In order to evaluate the potential of PCL/PVA/GS-NO composite as 
materials for synthetic vascular graft construction, theoretical burst pressure 
was estimated for PCL/PVA/GS-NO composites according to Laplace’s Law 
(burst pressure = material yield stress × thickness/radius) [377] assuming a 
tubular artery graft with a radius of 2.3 mm. The theoretical burst pressure for 
the graft based on PCL/PVA/5GS-NO was approximately 100 mmHg whereas 
for PCL/PVA/10GS-NO, the value was only 48 mmHg (Table 5-1). Although 
the theoretical burst pressure for PCL/PVA/5GS-NO was much lower than the 
burst pressure of a human artery (~3000 mmHg), it was close to the systolic 
arterial pressure of healthy humans (~120 mmHg) [378]. It was possible to 
improve further the mechanical properties of PCL/PVA/GS-NO by measures 
such as shortening the time of NaOH treatment, increasing the thickness of 
µPCL films, and reducing the thickness of the fibre-hydrogel layer. It was 
reported recently that PCL films produced by uniaxial stretching showed much 
improved mechanical strength with strong stability against degradation in 
erosive environment [379]. With this type of PCL film, the mechanical 
properties of PCL/PVA/GS-NO composites might also be improved, to have 
adequate strength as required for vascular graft construction.  
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5.5 Summary 
In this work, a composite controlled release system of NO was 
developed by assembling different functional components with 
electrospinning and F/T techniques. PCL/PVA/GS-NO composites consisted 
of µPCL film in providing mechanical support, integrated fibre-hydrogel 
matrix in providing controlled release properties, and incorporated GS-NO 
NPs capable of generating NO. Electrospun PCL fibrous matrix bonded the 
hydrogel to µPCL film, and was integrated with the hydrogel upon F/T cycles. 
The physical integration improved the systematic performance of the 
composites without affecting the composition of each component. Compared 
to FT-PVA/GS hydrogels, PCL/PVA/GS-NO showed improved stiffness and 
mechanical strength with comparable ductility due to the presence of µPCL 
film. The NO release property was improved to a slower and more sustained 
manner than freely suspended GS-NO NPs, and the NO release could last for 
40 days. This prolonged NO release property was favoured in controlling post-
surgery restenotic events, implying the potential of PCL/PVA/GS-NO 
composites in the applications for restenosis prevention. Despite that the 
mechanical strength of the presented PCL/PVA/GS-NO composites was 
inadequate for synthetic vascular graft construction, the assembly of 
PCL/PVA/GS-NO suggested an engineering approach to modify the surface of 
PCL films for NO-releasing property, which could also be applied to other 
types of PCL films. This work also demonstrated an idea in the engineering 
design of medical devices, which was to assemble incompatible components 
with superior properties in different fields to achieve better systematic 
performance. 
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Chapter 6  
Conclusions 
 
As cardiovascular diseases have become the leading cause of mortality 
worldwide, synthetic vascular grafts are in increasing demand for the 
reconstructive bypass surgeries due to the limited supply of autologous grafts. 
However, current synthetic vascular grafts suffer a major problem of post-
surgery restenosis triggered by the loss of vascular endothelial layer. In the 
control of restenosis, nitric oxide (NO) has been considered with great 
therapeutic potential as it is a natural modulator of several contributors to 
restenosis development. Among various forms of materials developed for 
controlled NO release, NO-releasing nanoparticles (NPs) have gained 
increasing attention due to their intrinsic controlled release property and the 
ease of incorporation into other materials. However, very few studies have 
demonstrated the application of NO-releasing NPs in the improvement of 
medical devices such as synthetic vascular grafts. This project thus proposed a 
novel design of a composite controlled release system of NO via the 
integration of NO-releasing nanoparticle and components, in providing 
controlled release property and mechanical strength, which had the potential 
as an improved material for synthetic vascular graft construction to prevent 
post-surgery restenotic events. 
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In the first part of this report, a novel NO-releasing inorganic gelatin-
siloxane nanoparticle (GS-NO NP) was developed as a new NO delivery 
vehicle using a simple and organic-solvent-free process. Inorganic gelatin-
siloxane nanoparticles (GS NPs) were synthesised using sol-gel chemistry and 
functionalised via S-nitrosation to yield GS-NO NPs. The resultant GS-NO 
NPs were monodispersed spherical particles with a diameter of ~200 nm. The 
NO release from GS-NO NPs could sustain for 7 days following a 1st-order 
exponential profile, and reached a total amount of ~0.12 µmol/mg. The GS-
NO NPs showed excellent cytocompatibility against fibroblasts, and a 
concentration-dependent regulation of AoSMC and HUVEC proliferation. 
With GS-NO NPs at low concentration (100 µg/mL), the proliferation of 
AoSMCs could be slowed down whereas the growth of HUVECs were 
significantly promoted. GS-NO NPs also exhibited the ability to permeate the 
cell membrane within 2 h, implying another possible route for NO delivery to 
target cells.  
In the second part of this report, the property changes of physically 
crosslinked PVA hydrogels (FT-PVA) with GS NP addition were investigated 
to evaluate their potential as carriers for GS-NO NPs. Freezing-thawing (F/T) 
cycles were applied to introduce physical crosslinking in PVA. The addition of 
GS NPs in FT-PVA exhibited a combined effect of providing crosslinking 
centres to promote crosslinking, and reducing polymer chain mobility to limit 
the crystallite formation and inter/intra-molecular hydrogen bonding. 
Moderate addition of GS NPs (25 or 75 µg/mL) with 1 or 2 F/T cycles applied 
could limit the swelling behaviour of FT-PVA, improve both tensile and 
compressive properties in elastic modulus (1.1-4.1 x increase in tensile 
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modulus; 0.6-2.1 x increase in compressive modulus) and strength (0.6-1.5 x 
increase in tensile yield stress), and maintain the uniform structural of FT-
PVA. However, the enhancing effect of GS NP on the hydrogel properties 
weakened with increasing GS NP concentration and/or increasing F/T cycles 
applied. Higher concentration of GS NPs in FT-PVA (125 µg/mL) resulted in 
heterogeneity in hydrogel structure and reduced tensile strength. Similar 
concentration-dependant properties for GS-NO NP-doped FT-PVA were 
expected due to the similar properties of GS and GS-NO NPs. These findings 
suggested that FT-PVA hydrogels might be suitable for applications with GS-
NO NP addition at moderate concentrations so that their properties could be 
maintained or even improved. 
In the last part of this report, with GS-NO NP addition in high 
concentrations (up to 10 mg/mL), a biaxial stretched PCL film (µPCL) was 
added to FT/PVA hydrogels to enhance the mechanical property. The 
composite controlled release system of NO (PCL/PVA/GS-NO) was 
constructed by assembling GS-NO NPs, PVA and µPCL with electrospun 
PCL fibrous matrix and F/T techniques. The resultant PCL/PVA/GS-NO 
composites consisted of a µPCL base film and an integrated fibre-hydrogel 
layer with GS-NO NPs attached to the film. PCL/PVA/GS-NO composites 
had much improved mechanical properties as compared to FT-PVA/GS 
hydrogels in Young’s Modulus (85-124 x), yield stress (2.5-5 x) and ultimate 
stress (2.5-3.1 x) whilst maintaining its ductility. The NO release property was 
also improved whereby a slower and more sustained release was observed as 
compared to the freely suspended GS-NO NPs, such that the NO release could 
last for 40 days with a release half-life of 16 h. This prolonged NO release 
 Chapter 6 Conclusions 
- 156 - 
property was favourable in the application for restenosis prevention as it 
would be possible to prevent vSMC over-proliferation and promote EC growth 
for a longer period to achieve better control over the restenotic events. 
Although the mechanical strength of the presented PCL/PVA/GS-NO 
composites was inadequate for synthetic vascular graft construction, it was 
possible to improve the mechanical strength by adjusting the components or 
using stronger PCL films.  
This project explored the application of inorganic GS NPs as NO 
carriers via S-nitrosothiol modification. It also suggested an engineering 
approach to modify the surface of PCL films for NO-releasing property, which 
could also be applied to other types of PCL films. In addition, the 
development of PCL/PVA/GS-NO composites demonstrated an idea in the 
engineering design of medical devices, which was to assemble incompatible 
components with superior properties in different fields to achieve improved 
systematic performance. 
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Chapter 7  
Future Work 
 
This PhD project provided an engineering approach to construct a 
novel composite controlled release system of NO for potential cardiovascular 
tissue engineering application. The design was realised by developing a new 
NO-releasing nanoparticle, and applying suitable host materials to meet the 
requirements for controlled release property and mechanical compliance. 
However, there are several investigations that still need to be carried out to 
fully understand the functionality of each component and the integrated 
composite system. 
For the NO-releasing GS-NO NPs, the NO release kinetics was studied 
via experiments carried out in the dark at 37 ° C in PBS with neutral pH (7.4), 
to avoid photolytic decomposition of GS-NO NPs. The release profile was 
studied by assuming a thermal decomposition of S-nitrosothiols (RSNOs). It 
has been established that the decomposition of RSNOs also involves the 
transition metal ion-dependent breakdown [376], and the thermal 
decomposition is affected by the pH value of the environment [380]. Therefore, 
further investigations are necessary to study the NO release kinetics of GS-NO 
NPs at different temperatures, pH values and in different solutions such as DI 
water. These investigations will help to correlate the NO release property of 
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GS-NO NPs to the environmental factors, providing more controlling 
measures to achieve desirable NO release for specific applications. 
The study on the property changes of freeze-thawed PVA (FT-PVA) 
hydrogels with GS NP addition revealed the potential of FT-PVA as GS-NO 
NP carriers, especially for applications with moderate GS-NO NPs addition. 
However, there is a lack of understanding the retaining efficacy of FT-PVA to 
GS NPs. Further investigation of the retaining efficacy can be realised by 
using FITC- or AO7-labelled GS NPs in the preparation of FT-PVA/GS 
hydrogels, and detecting the FITC or AO7 content in the immersing solution. 
Flow chambers can also be applied to determine the retaining efficacy under 
dynamic conditions. The understanding of the retaining efficacy of FT-PVA 
will help to explain the NO release behaviour of GS-NO NP-doped FT-PVA 
hydrogels. 
Another systematic investigation required for GS-NO NP-doped FT-
PVA is the effect of F/T cycles on the NO release property. The thermal 
decomposition of GS-NO NPs may be affected by both the length of F/T time 
and the number of F/T cycles applied. The NO release profile should be 
determined for GS-NO NP-doped FT-PVA hydrogels subjected to varying 
number of F/T cycles with different F/T times. This study will help to 
determine the optimal processing parameters for GS-NO NP-doped FT-PVA 
hydrogels to have minimal loss of NO and appropriate NO release property. 
For the integrated PCL/PVA/GS-NO composites, in vitro cell culture on the 
hydrogel side of the composites should be conducted in the future to evaluate 
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their competency of supporting cell attachment and growth. The efficacy in 
restenosis prevention should be evaluated in terms of regulating vSMCs 
proliferation and inhibiting platelet adhesion to the surface [197]. As the 
presented PCL/PVA/GS-NO composites have inadequate mechanical strength 
for synthetic vascular graft construction, the mechanical compliance of 
PCL/PVA/GS-NO composites should be improved further by means of 
adjusting the thickness of µPCL film and fibre-hydrogel layer, shortening the 
NaOH treatment time, and/or applying more F/T cycles. Other types of PCL 
films with stronger mechanical properties (e.g. uniaxial stretched PCL films 
[379]) may also be applied instead of µPCL films to enhance the mechanical 
properties of the PCL/PVA/GS-NO composites. 
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